Targeting Endogenous Homeostatic Mechanisms For The Treatment Of Cocaine Use Disorder: Contribution Of Nr4a1 And Target Gene Expression by Carpenter, Marco
University of Pennsylvania 
ScholarlyCommons 
Publicly Accessible Penn Dissertations 
2021 
Targeting Endogenous Homeostatic Mechanisms For The 
Treatment Of Cocaine Use Disorder: Contribution Of Nr4a1 And 
Target Gene Expression 
Marco Carpenter 
University of Pennsylvania 
Follow this and additional works at: https://repository.upenn.edu/edissertations 
 Part of the Neuroscience and Neurobiology Commons 
Recommended Citation 
Carpenter, Marco, "Targeting Endogenous Homeostatic Mechanisms For The Treatment Of Cocaine Use 
Disorder: Contribution Of Nr4a1 And Target Gene Expression" (2021). Publicly Accessible Penn 
Dissertations. 4215. 
https://repository.upenn.edu/edissertations/4215 
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/4215 
For more information, please contact repository@pobox.upenn.edu. 
Targeting Endogenous Homeostatic Mechanisms For The Treatment Of Cocaine 
Use Disorder: Contribution Of Nr4a1 And Target Gene Expression 
Abstract 
Cocaine use disorder continues to be a worldwide public health problem and currently there are no 
approved medications for its treatment. Decades of research have identified a number of targets that 
have largely been ineffective in reducing relapse. Drug- and cue-associated memories are important 
components of relapse that remain relatively unexplored. Given that chromatin modifications confer long-
lasting changes in gene expression necessary for stable cellular phenotypes, histone modifications 
acquired during abstinence may cause individual genes to “remember” prior drug exposure. Additional 
research on the homeostatic mechanisms active during prolonged abstinence is required to develop 
novel pharmacotherapies that reduce context-dependent drug memories. In this dissertation, we address 
this gap in knowledge using our established cocaine self-administration model which induces long-lasting 
changes in gene expression and chromatin. First, we profiled gene expression at early and late abstinence 
across several different brain reward regions, including the nucleus accumbens (NAc), ventral tegmental 
area (VTA), and prefrontal cortex (PFC). We found that the transcription factor, nuclear receptor subfamily 
4 group A member 1 (Nr4a1), is activated during early abstinence but declines at late abstinence. Nr4a1 
target genes were differentially expressed at both early and late abstinence. Therefore, we asked if Nr4a1 
mediates transient and sustained changes in gene transcription via the enrichment of permissive and 
repressive histone modifications associated with Nr4a1 binding at target genes. Using clustered regularly 
interspaced short palindromic repeats (CRISPR) activation and inactivation (CRISPRa/i), we demonstrated 
that activation of Nr4a1 suppresses cocaine mediated behavior via epigenetic regulation of target genes. 
Next, we established the utility of Cytosporone B, a pharmacological activator of Nr4a1, in regulating 
Nr4a1 activation and reducing context-dependent cocaine memories. Finally, to identify the source of 
Nr4a1 expression, we isolated specific neuronal cell types in the NAc and analyzed gene expression and 
histone modification enrichment. Then, using cell-type specific CRISPRa we show that Nr4a1 activation in 
adenosine A2a receptor neurons suppresses context dependent cocaine memories. Together, research 
from this dissertation describes the role of cell-type specific Nr4a1 in persistent gene activation during 
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TREATMENT OF COCAINE USE DISORDER: CONTRIBUTION OF NR4A1 AND 
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 Cocaine use disorder continues to be a worldwide public health problem and 
currently there are no approved medications for its treatment. Decades of research have 
identified a number of targets that have largely been ineffective in reducing relapse. Drug- 
and cue-associated memories are important components of relapse that remain relatively 
unexplored. Given that chromatin modifications confer long-lasting changes in gene 
expression necessary for stable cellular phenotypes, histone modifications acquired 
during abstinence may cause individual genes to “remember” prior drug exposure. 
Additional research on the homeostatic mechanisms active during prolonged abstinence 
is required to develop novel pharmacotherapies that reduce context-dependent drug 
memories. In this dissertation, we address this gap in knowledge using our established 
cocaine self-administration model which induces long-lasting changes in gene expression 
and chromatin. First, we profiled gene expression at early and late abstinence across 
several different brain reward regions, including the nucleus accumbens (NAc), ventral 
tegmental area (VTA), and prefrontal cortex (PFC). We found that the transcription factor, 
nuclear receptor subfamily 4 group A member 1 (Nr4a1), is activated during early 
abstinence but declines at late abstinence. Nr4a1 target genes were differentially 
expressed at both early and late abstinence. Therefore, we asked if Nr4a1 mediates 
transient and sustained changes in gene transcription via the enrichment of permissive 
and repressive histone modifications associated with Nr4a1 binding at target genes. Using 






inactivation (CRISPRa/i), we demonstrated that activation of Nr4a1 suppresses cocaine 
mediated behavior via epigenetic regulation of target genes. Next, we established the 
utility of Cytosporone B, a pharmacological activator of Nr4a1, in regulating Nr4a1 
activation and reducing context-dependent cocaine memories. Finally, to identify the 
source of Nr4a1 expression, we isolated specific neuronal cell types in the NAc and 
analyzed gene expression and histone modification enrichment. Then, using cell-type 
specific CRISPRa we show that Nr4a1 activation in adenosine A2a receptor neurons 
suppresses context dependent cocaine memories. Together, research from this 
dissertation describes the role of cell-type specific Nr4a1 in persistent gene activation 
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Cocaine Use Disorders 
Worldwide, the number of deaths associated with cocaine abuse is increasing and 
cocaine abuse disorders contribute to substantial healthcare utilization (Lewer et al., 
2019). In the United States, death due to cocaine overdose accounted for 18% of all 
overdose deaths in 2016, second only to opioid-related drugs (Hedegaard et al., 2018). 
Three quarters of opiate drug overdoses were associated with concomitant use of other 
drugs, with cocaine ranked as the drug most frequently co-abused (Hedegaard et al., 
2018). Importantly, in some patient populations, such as non-Hispanic Black women and 
men, the cocaine death rate exceeds that of opioids (Shiels et al., 2018). Thus cocaine-
related deaths continue to rise with the few treatment options available. The most 
intractable hurdle in the treatment of cocaine use disorder is the inability to subdue drug 
cravings during abstinence. Decades of research have identified a number of targets that 
have largely been ineffective in reducing relapse. These data underscore the severity of 
cocaine abuse disorder as a public health problem, and the desperate need for novel 
therapeutic discoveries. Small molecule regulation of drug- and cue-associated memories 
remains relatively unexplored as a therapeutic target, yet cues have consistently been 
shown to be important component of relapse. This dissertation describes homeostatic 
gene expression pathways important in suppressing cocaine memories and maintaining 
abstinence following substance use, with a focus on Nr4a1 in NAc.  
The primary target of cocaine, the dopamine transporter (DAT), can be found 
throughout the dopaminergic circuitry, including nigrostriatal, mesolimbic and mesocortical 






inhibition of DAT and dopamine (DA) reuptake in the nucleus accumbens (NAc), a key 
brain reward region (Kaouane et al., 2012; M. Ritz et al., 1987; M. C. Ritz & George, 1997). 
Both pre-clinical and clinical data suggest that chronic cocaine use leads to 
neurodegeneration, coupled with reduced uptake of DA and dopamine type 2 (D2) 
receptor density (Gozzi et al., 2011; Majewska, 1996; Schoemaker et al., 1985; Volkow et 
al., 1997; Volkow et al., 1993). The primary cellular effector of DA in the striatum, gamma-
aminobutyric acid (GABA) MSNs, show profound changes in structure and function 
following loss of DA signaling (Diana, 2011; Meredith et al., 1995). Not surprisingly, long-
term cocaine abuse is associated with Parkinsonism, which is similarly characterized by 
the dysregulation of dopamine signaling (Domingo, 1997; Illés et al., 2019; Majewska, 
1996). Given that DA plays a central role in motivational states that drive behavior, 
dysregulation of the DA system may drive long-term neuroadaptations and persistent drug 
craving during abstinence.  
Cocaine Relapse in Humans 
Persistent drug memories are closely linked to the continuation of drug use and 
become progressively stronger during abstinence (Dunning et al., 2011; Moeller et al., 
2012; Parvaz et al., 2016). This neurophysiological mechanism includes intense craving 
elicited by cues or contexts previously associated with drugs (Bossert et al., 2013; Correia 
et al., 2020; Dunning et al., 2011; Moeller et al., 2012; Parvaz et al., 2016). Not all 
individuals respond to abstinence equally and there is considerable variability in the 
severity of dependence, route of administration, concurrent dependance on other drugs, 
treatment history, and many other disease symptoms (Coffey et al., 2000). Subjective, 
self-reported, accounts of craving lack reliability and cannot be modeled in pre-clinical 
mouse models. However, cue induced reactivity can be measured by 






the emotional intensity of a stimulus (Dunning et al., 2011; Moeller et al., 2012; Parvaz et 
al., 2016). Although subjective measures of cocaine craving substantially decrease after 
one month of abstinence, cue-induced brain excitability in individuals with cocaine use 
disorders follows an inverted U-shaped trajectory as a function of abstinence duration 
(Parvaz et al., 2016). Drug users show increasing reactivity to drug-cues for up to six 
months of abstinence, a time point which falls within the window of discharge from most 
treatment programs (Parvaz et al., 2016). It is promising that drug-induced reactivity 
returns to baseline by one year, indicating that drug memories are reversible (Parvaz et 
al., 2016). Importantly, cue induced reactivity can be modeled in animal models, providing 
a translationally relevant approach to study vulnerability to relapse during abstinence. 
Taken together, we hypothesize homeostatic mechanisms subdue drug craving during 
late abstinence, but similar mechanisms are suppressed during early abstinence, 
contributing to a high vulnerability to relapse.  
Available Treatment Modalities for Cocaine use disorder  
No medications have been approved for cocaine use disorders and psychosocial 
treatments are burdened by high dropout rates and short periods of abstinence 
(Kampman, 2019; Stitzer et al., 2010). The most effective psychosocial treatments, such 
as voucher-based reinforcement therapy, promote abstinence in patients via positive 
reinforcement (Kampman, 2019). Current medication classes under investigation include 
dopamine reuptake inhibitors and modulators of inhibitory synaptic transmission. Pre-
clinical studies provide evidence that modulators of inhibitory (GABA) and excitatory 
(glutamate) neurotransmission reduced cocaine seeking (Conrad et al., 2008; Cornish & 
Kalivas, 2000; Kalivas & Volkow, 2011; Schmidt & Pierce, 2010; Wolf, 2016). Several 
clinical trials have evaluated the efficacy of topiramate, a GABA agonist/glutamate 






2013). Whereas some clinical trials show efficacy in reducing cocaine intake and 
prolonging abstinence for short periods (Kampman, 2019; Karila et al., 2008), others find 
no differences between topiramate and placebo treated groups, indicating a temporary 
effect on cocaine dependence (Karila et al., 2008). These data call into question 
topiramate efficacy and highlight the need for more thorough preclinical data using animal 
models (Arenas et al., 2016; Echeverry-Alzate et al., 2014; Foll et al., 2008).  
Several genes coding for the dopaminergic system have been linked to cocaine 
dependence including genes for the DA receptors, D2 (Gelernter et al., 1999), D3 (Freimer 
et al., 1996), and D4 (Ballon et al., 2007), and DA transporter (DAT) (Cabana-Domínguez 
et al., 2019; Gelernter et al., 1994). However, genome wide association studies have 
reported conflicting data, likely due to the complex genetic nature of cocaine dependence 
(Hedegaard et al., 2018; Cabana-Domínguez et al., 2019). In addition, dopamine agonism 
is plagued by extremely low retention rates (Grabowski et al., 2001; Kampman, 2019). 
These failed clinical trials suggests that dopamine agonism may only be efficacious in 
particular sub populations but there is a lack of data to support this notion (Dackis et al., 
2005; Kampman, 2019; Kampman et al., 2013; Umbricht et al., 2014). These ambiguous 
results are indicative of the heterogeneity and persistence of cocaine use disorders. We 
suggest that more effective medications and dosing strategies will prioritize long-lasting 
pharmacological properties and persistent regulation of abstinence-induced 
neuroadaptations that promote a return to neuronal homeostasis.  
Preclinical Models of Cocaine Use Disorders 
 Despite decades of research on the neurobiological mechanism underlying 
cocaine use disorders, the translation of pre-clinical findings to treatment options remains 
poor. It is possible that traditional models of cocaine use disorders fail to model the human 






and intravenously (Edwards & Koob, 2013; Koob et al., 2004; Mello, 1996; Panlilio & 
Goldberg, 2007; Thomsen & Caine, 2007; Wise & Koob, 2014). This feature of self-
administration provides face validity and has been used to demonstrate important aspects 
of substance use disorders (Wise & Koob, 2014). Despite this progress, fundamental 
questions remain concerning factors that promote abstinence. Cue-associated relapse, a 
key symptom of substance use disorders, has been extensively used to model increased 
drug craving observed in humans (Koob et al., 2004; O’Brien et al., 1998; Parvaz et al., 
2016; R. Sinha, 2001). In this model, rodents are trained to self-administer cocaine and 
undergo a period of forced abstinence typically for 1, 3, and 6 months (Lu, Grimm, 
Dempsey, et al., 2004). Drug craving is then measured by the persistence of drug seeking 
in the absence of available drug at these distinct time points. However, long-lasting 
cocaine craving is not permanent and follows an inverted U-shaped curve (Conrad et al., 
2008; Wolf, 2016). Most of the work supporting the notion that long lasting changes are 
temporary have focused on synaptic proteins that occur at specific timepoints but do not 
consider how changes in early abstinence affect long lasting changes in gene expression 
in the absence of context- and/or drug-associated reexposure (Freeman et al., 2010; 
Walker et al., 2018).  For example, in rats, the stable elevation of glutamate receptors and 
spine density in NAc is found after 30 days, but not 1-day, of cocaine abstinence (Christian 
et al., 2017; Conrad et al., 2008; Wolf, 2016). Such changes in plasticity and behavior 
dissipate by 180 days, suggesting that homeostatic mechanisms reverse cocaine 
pathology (Wolf, 2016), and underscoring the need to identify additional factors mediating 
homeostasis during abstinence (Lu, Grimm, Hope, et al., 2004; Wolf, 2016). The results 
of myriad studies suggest that session duration (Terrier et al., 2016), dose (Terrier et al., 
2016), and food training (Halbout et al., 2014) underlie the failure of mice to develop 






incubation in mice (Halbout et al., 2014; Nugent et al., 2017) as a behavioral enhancement 
at 7-days that declines by 28-days (Nugent et al., 2017). One explanation for this species 
specificity is that the incentive properties of contextual memories in mice are less salient 
than in rats (Tirelli et al., 2003). Nonetheless several paradigms use these behavioral time 
points in mice (Terrier et al., 2016). In summary, self-administration models key aspects 
of substance use disorders observed in humans, but methodological and technical 
aspects warrant the use of additional paradigms to identify novel mechanisms promoting 
homeostasis following drug exposure.  
 The conditioned place preference paradigm is a preclinical model used to measure 
the rewarding aspects of drug exposure (Tirelli et al., 2003). The basic premise of this 
model involves the association of contextual cues and drug treatment. Specifically, two 
compartments are designed to have distinct contextual cues (e.g., white wall vs black wall; 
solid floor vs grated floor) and then experimental animals are conditioned with drug 
treatment in one compartment and saline treatment in the other. After conditioning, the 
amount of time spent in the drug conditioned compartment is measured as a percentage 
of total time spent across both compartments, as a measure of memory of drug reward 
context. Depending on the dose, drugs of abuse like cocaine increase the amount of time 
that animals spend in the drug paired compartment. In this context, levels of dopamine 
and downstream activation of GABAergic neurons are involved in the expression of 
cocaine CPP (Hnasko et al., 2007; L. Wang et al., 2014). Interestingly, in the absence of 
DAT, mice still develop cocaine CPP (Rocha et al., 1998; Sora et al., 1998), suggesting 
that multiple pathways beyond DA neurotransmission mediate cocaine reward (Hnasko et 
al., 2007; Tilley et al., 2009). Of importance, there are key differences between 
intraperitoneal (IP) and intravenous (IV) drug exposure paradigms, such as peak levels of 






al., 1999; Pan et al., 1990). Specifically, the concentration of cocaine in the brain increases 
following repeated IP administration but remains constant following repeated IV 
administration (Ma et al., 1999; Pan et al., 1990). Thus, in conjunction, IVSA and CPP can 
be used to model certain aspects of substance use disorders with careful consideration of 
potential caveats. 
 Though important findings have been discovered using these models, some 
aspects of substance use disorders have been overlooked: 1) Many individuals take drugs 
periodically or at one point in their lives but do not develop substance use disorders or are 
able to remain abstinent for long periods of time (Anthony et al., 1994). Thus, although 
drug taking may reinforce future drug seeking, additional factors predispose certain 
individuals to substance use disorders (Grimm et al., 2002; Lu et al., 2003; See et al., 
2001). 2) The majority of rodent self-administration paradigms measure the salience of 
cocaine reward against the absence of reward. Given this caveat, drug seeking observed 
in self-administration paradigms may reflect the absence of enrichment rather than 
uncontrolled drug use (Venniro et al., 2019). That is to say that drug taking does not equal 
a substance use disorder per se. This point is especially important when considering how 
non-drug rewarding stimuli encountered in the normal environment may attenuate drug 
seeking (Venniro et al., 2019). Newer models have been developed including volitional 
choice between drug use and non-drug social rewards (e.g., employment and family), 
drug-seeking despite consequences, and the ability of conditioned stimuli to evoke drug 
seeking following period of forced abstinence (Venniro et al., 2017, 2018, 2019). These 
paradigms may model more pertinent aspects of substance use disorders and the 
molecular underpinnings of these phenomena remain largely unexplored (Venniro et al., 






 The environmental factors that contribute to these behaviors is important for 
several reasons. First, environmentally induced epigenetic modifications are regulated by 
known mediators of cocaine relapse such as stress, previous drug exposure and 
persistent memories. In this way, epigenetic regulation of transcription may explain the 
diversity observed in the continuum of drug use to drug abuse. Second, treatment 
responses can be predicted by the epigenetic state observed across individuals. 
Importantly, this data could be used to identify and treat at risk individuals. 
Transcriptional Regulation of Neuronal Homeostasis During Abstinence  
 Transcriptional changes in brain reward areas progressively increase with 
repeated drug exposure and underlie persistent neuroadaptations in both humans and 
animal models (Albertson et al., 2004; Bannon et al., 2005; Freeman et al., 2008, 2010). 
Regulation by transcription factors, such as delta FBJ murine osteosarcoma viral 
oncogene homolog B  (Fosb), and cAMP response element binding protein (CREB), has 
been implicated in substance use disorders for decades (Carlezon et al., 1998; Nestler, 
2012; Robison & Nestler, 2011). Fosb and CREB recruit histone modifying enzymes at 
target genes and contribute to long-term transcriptional regulation in NAc (Robison & 
Nestler, 2011). In animal models, changes in the expression of Fosb and CREB alter 
synaptic function in a variety of drug-exposure contexts (Feng et al., 2014; Renthal et al., 
2009; Walker et al., 2018). More recently another transcription factor, Npas4, has been 
implicated in the NAc transcriptional response of chronically activated circuits important in 
long-term neuroadaptations (Lin et al., 2008; Spiegel et al., 2014; Taniguchi et al., 2012, 
2017). In this context, deacetylation of Npas4 enhancer elements attenuates cocaine and 
cue -induced gene expression and reward (Taniguchi et al., 2012, 2017). Despite decades 






studies do bolster fundamental understanding of transcription factors in the etiology of 
substance use disorders and highlight the novel role of druggable transcription factors in 
drug relapse. 
Beyond alterations in synaptic function, transcriptional regulation of 
neuroprotection is a relatively unexplored homeostatic mechanism (Carpenter et al., 2020; 
Huang et al., 2011; Turrigiano & Nelson, 2004). Several lines of evidence suggest 
cocaine-induced alterations in neuroprotection across several different brain regions 
including the NAc, PFC and VTA (Freeman et al., 2008, 2010; Walker et al., 2018). In 
addition to neuroadaptations occurring during drug exposure, those activated during 
abstinence mitigate cocaine induced changes related to overexcitation, oxidative stress 
and subsequent neuronal cell death (Kovacic, 2005; Poon et al., 2007). Following cocaine 
exposure, the removal of excess dopamine, mediated by monoamine oxidase, leads to 
the production of toxic reactive oxygen species (ROS) (Arai et al., 1991; Hermida-
Ameijeiras, 2004). Increased ROS causes damage to lipids, proteins, and DNA (Popa-
Wagner et al., 2013), but the functional relevance of ROS in the context of cocaine remains 
largely unexplored. In other disorders, such as Parkinson’s, ROS functions as molecular 
switch regulating complex transcriptional programs that mediate cell death related to the 
loss of dopamine producing neurons (Dias et al., 2013). Similarly, both contingent and 
non-contingent models of cocaine exposure increased dopamine metabolism and ROS 
production in the NAc (Bashkatova et al., 2006; Dietrich et al., 2005; Egilmez et al., 1995; 
Jang et al., 2015; Uys et al., 2011). Given this finding, the transcriptional response 
engendered may play a role in the reinforcing efficacy of cocaine (Jang et al., 2015). 
Cocaine induced ROS production is found primarily in NAc neurons, but not in astrocytes, 
microglia or oligodendrocytes, of rats self-administering cocaine (Jang et al., 2015). 






administration without effecting food intake (Jang et al., 2015). This reduction in cocaine 
seeking supports the proposition that targeting endogenous homeostatic mechanisms is 
a potential inroad to identify novel mediators of neuroprotection (Carpenter et al., 2020). 
Recently our lab identified, Nr4a1, a ligand-activated transcription factor that regulates 
fundamental biology important in neuroprotection, as a promising target in cocaine use 
disorders (Carpenter et al., 2020). 
Nr4a1 Family of Transcription Factors  
The orphan nuclear receptor, Nr4a1, is a member of the steroid-thyroid hormone-
retinoid receptor superfamily. It is in a family that includes NR4A1, NR4A2 and NR4A3 
(NR4A; Kurakula et al., 2014). These immediate early genes are induced by multiple 
cellular stressors. Despite the similarities of NR4A1, NR4A2 and NR4A3 and the overlap 
of their genomic recognition sites, they exhibit cell and tissue-specific functions (Kurakula 
et al., 2014). Nr4a1 functions in maintaining cellular homeostasis and is implicated in 
neurological function, as well as cardiovascular, metabolic, inflammatory diseases, and 
cancer (Kurakula et al., 2014; Safe et al., 2016). Specifically, Nr4a1 plays an integral role 
in neuronal homeostasis and neuroprotection in response to hyperexcitation via the 
regulation of downstream synaptic effectors (Carpenter et al., 2020; Y. Chen et al., 2014; 
Jeanneteau et al., 2018; Walker et al., 2018). We recently discovered that Nr4a1 activation 
represses behavioral phenotypes across cocaine abstinence via activation of downstream 
target genes (Carpenter et al., 2020). In response to stimuli, Nr4a1 is upregulated and 
shuttled to the nucleus where it binds nerve-growth-factor inducible gene B (NGFI-B)-
responsive elements (NRBE) at target gene promoters (Kurakula et al., 2014). Although 
endogenous ligands have recently been identified; numerous compounds that activate 
Nr4a1 have been characterized (Carpenter et al., 2020; Mohankumar et al., 2018; 






(Kurakula et al., 2014), enhance learning and memory (Chatterjee et al., 2020) and protect 
against Parkinson’s disease (De Miranda et al., 2013, 2015). Importantly, the novel class 
of Nr4a1 ligands, C-DIMs, induce beneficial responses in various disease contexts 
(Kurakula et al., 2014). As outlined below, Nr4a1 function is dependent on the tissue and 
cell type context being studied. 
LifeMap Discovery™, the Embryonic Development and Stem Cells Database, and 
the Allen Brain Atlas, report Nr4a1 mRNA expression in the majority of human brain 
regions, including hypothalamus, hippocampus, thalamus, cerebellum, amygdala, 
striatum, cerebral cortex and pons. Nr4a1 is highly expressed in dopaminergic and 
dopaminoceptive neurons, specifically the dorsal striatum, NAc, olfactory tubercle, and 
prefrontal and cingulate cortices (Zetterström et al., 1996). Outside the brain, Nr4a1 is 
detected at varying high levels in the adrenal cortex, lungs, prostate, ovaries, and testes 
(Su et al., 2004). In disease and normal conditions Nr4a1 is measured by standard 
techniques including western blot, ELISA, immunohistochemistry and qRT-PCR. Nr4a1 
activity is indirectly measured by gene reporter systems or directly by chromatin 
immunoprecipitation and co-immunoprecipitation assays. 
Nr4a1 and Epigenetic Regulation of Gene Expression 
 Activated Nr4a1 shuttles to the nucleus where it binds DNA and recruits co-
activators and repressors to regulate the transcription of target genes. Nr4a1 protein 
consists of several structural domains, including the highly conserved DNA binding and 
ligand binding domains, which are critical to understanding the function of Nr4a1 (Krust et 
al., 1986). Once Nr4a1 is bound, ligand binding acts as the molecular switch for 
transactivation. In the ligand unbound state, Nr4a1 recruits a corepressor complex, which 
includes specificity protein 1 (Sp1), paired amphipathic helix protein Sin3a (Sin3a), REST 






deacetylase 1 (Hdac1), to downstream target genes (Xindong Liu et al., 2019; Matheos & 
Wood, 2020; Palumbo-Zerr et al., 2015). In response to ligand binding, the Nr4a1 co-
repressor complex disassociates and a co-activator complex, including p300, a histone 
acetyl transferase (HAT), promotes the unwinding of DNA and epigenetic activation via 
p300-dependent acetylation of histone H3 at lysine 27 (H3K27Ac) (Carpenter et al., 2020; 
Duren et al., 2016; Xindong Liu et al., 2019; Matheos & Wood, 2020). In agreement, Nr4a1 
binding predominantly occurs in intergenic regions overlapping with H3K27ac enhancer 
distribution patterns (Duren et al., 2016; Xindong Liu et al., 2019). Alternative splicing of 
Nr4a1 represents an additional regulatory mechanism and level of complexity that effects 
the recruitment of cofactors (Michelhaugh et al., 2005). Surprisingly, there is little 
concordance in the literature of gene expression changes in response to Nr4a1 activation 
or suppression. Nr4a1 belongs to a group of transcription factors that show concentration 
dependent effects on target gene response (K. D. Johnson et al., 2006; M. M. Johnson, 
2011; Kamath et al., 2008; Pope & Bresnick, 2010). The discordance in Nr4a1 effects on 
gene expression suggests the direction of gene expression is highly dependent on ligand 
availability and co-factor recruitment, which is often cell-type specific (Mohankumar et al., 
2020; Safe et al., 2016). Thus, it will be important to understand tissue- and cell type-
specific activity important in epigenetic regulation of Nr4a1 target genes.  
Nr4a1 and Mitochondrial Function 
The expression profile of Nr4a1 in energy dependent tissues such as brain, 
skeletal muscle, adipose tissues, heart, and liver suggest a functional role in energy 
metabolism (Pearen & Muscat, 2010). Within these tissues, glucose, free fatty acids, 
cholesterol, and LDL all upregulate Nr4a1 expression (Pearen & Muscat, 2010). In 
response to these signals Nr4a1 regulates mitochondrial function and rewires 






2018; Pawlak et al., 2015; Pearen & Muscat, 2010). For example, Nr4a1 sequesters liver 
kinase B1 in the nucleus and prevents the phosphorylation of 5-monophosphate- (AMP-) 
activated protein kinase α, which inhibits the synthesis of fatty acids, cholesterol, and 
triglycerides (Jeon, 2016). In the nucleus, activation of Nr4a1 attenuates the expression 
of isocitrate dehydrogenase, a key enzyme in the citric acid cycle (Koenis et al., 2018; M. 
S. Reynolds et al., 2016), leading to intracellular accumulation of the metabolite, succinate 
(Koenis et al., 2018; M. S. Reynolds et al., 2016). Interestingly, in addition to a role in 
metabolism, succinate inhibits histone methyltransferases, increases global levels of 
H3K27me3, and regulates gene expression (Koenis et al., 2018; Martínez-Reyes & 
Chandel, 2020), marking a key connection between Nr4a1 cellular function and epigenetic 
regulation of gene expression. In summary, Nr4a1 modulates mitochondrial functions as 
a redox-sensing switch capable of both gene and metabolite regulation.  
Energy metabolism differs appreciably between brain and most other tissues. In 
tissues such as heart, 60% to 80% of the energy requirement is produced by fatty acid 
oxidation, but in brain the main energy source is glucose and there are appreciably lower 
levels of fatty acid oxidation (Attwell & Laughlin, 2001; Schönfeld & Reiser, 2013). This is 
surprising given that the energy content of glucose is about half of fatty acids. However, 
the high susceptibility of neurons to oxidative stress favors glucose utilization to prevent 
the generation of ROS (Attwell & Laughlin, 2001). Neuronal activity is metabolically 
demanding and utilizes ~85% to 95% of the energy requirement of the brain (Attwell & 
Laughlin, 2001). The accumulation of ROS, as a consequence of energy production, is 
mitigated by a number of biochemical reactions within the mitochondria. Hydrogen 
peroxide, the main product of dopamine metabolism, is highly permeable and can enter 
neighboring GABAergic neurons causing degeneration (Dias et al., 2013). Under normal 






maintenance of homeostatic neuroprotective functions (Y. Tang & Zucker, 1997). In 
response to prolonged neuronal activity, homeostatic mechanisms are unable to meet the 
required metabolic demand which induces pathological damage (Zorov et al., 2014). 
Dysregulation of metabolism is the hallmark of Huntington’s, Parkinson’s, and other 
neurodegenerative genetic disorders associated with progressive motor, cognitive, and 
emotional deficits. Recent evidence suggests Nr4a1 reduced mitochondrial demand by 
eliminating the number of synapses via a AMPK-dependent mechanism in response to 
overexcitation (Jeanneteau et al., 2018). In summary, neuronal susceptibility to over 
excitation can be mitigated by multiple Nr4a1-dependent pathways that reduce ROS 
production via adaptions in mitochondrial and synaptic function. 
 Drugs of abuse, including cocaine, effect an array of metabolomic parameters 
such as the inhibition of glycolysis, the TCA cycle, the citrate cycle and biogenic amine 
metabolism (Kaplan et al., 2013; Hongyu Li et al., 2014; Ning et al., 2018; Shima et al., 
2011; Zaitsu et al., 2014). Interestingly data indicate the energy supply needs are different 
in the drug acquisition and abstinence phases and therefore may play a role in drug 
craving and reward (Zheng et al., 2013). Although further research is needed to better 
understand the role of Nr4a1 in mitochondira, these findings suggest mitochondrial 
metabolism may regulate cocaine craving associated with relapse (Uys et al., 2011). 
Nr4a1 Function in the Context of Disease  
Cancer 
Nr4a1 agonists are a promising candidate for the treatment of number of disorders 
including cancer. In the context of cancer agonists of Nr4a1 induce apoptosis only in 
cancer tissue (Hedrick et al., 2017; Lee and Jin, et al., 2014) but not in non-malignant 
tissue at clinically relevant levels (J. Liu et al., 2010; Y. Zhan et al., 2008). In fact, Nr4a1 






et al., 2013, 2015; Egarnes et al., 2017; T. Y. Liu et al., 2017; Palumbo-Zerr et al., 2015; 
Rothe et al., 2017). The most studied in vitro model for Nr4a1 activation is cancer cell 
based cytotoxicity screening (Kurakula et al., 2014; Lee and Li et al., 2014; Mohankumar 
et al., 2018; Y. Zhan et al., 2008). However, gene activity reporter systems are more 
appropriate for high throughput assays. For example, genetic constructs containing the 
NRBE and the luciferase gene can be transfected in cells to measure Nr4a1 transcriptional 
activity (Syng-Ook Lee, Li, et al., 2014). These methods were used to identify the 
octaketide, Cytosporone B (Csn-B), a naturally occurring Nr4a1 agonist isolated from 
Dothiorella sp HTF3, an endophytic fungus. Csn-B has strong affinity for Nr4a1 (EC50 = 
.278 nm) and molecular modeling infers physical binding (Y. Zhan et al., 2008). In non-
malignant cells Csn-B regulates transactivational activity of Nr4a1 and acts as a 
checkpoint for normal repair processes (Egarnes et al., 2017; T. Y. Liu et al., 2017; 
Palumbo-Zerr et al., 2015; Rothe et al., 2017; Y. Zhan et al., 2008). Importantly, Csn-B 
does not exert any of these effects in Nr4a1-null cells, indicating a Nr4a1-dependent effect 
of Csn-B (Egarnes et al., 2017; T. Y. Liu et al., 2017; Palumbo-Zerr et al., 2015; Y. Zhan 
et al., 2008). Using rational drug design various derivatives of Csn-B have synthesized to 
induce autophagy and inhibit inflammation (G.-Q. Chen et al., 2019). 
Additional novel Nr4a1 agonists have been identified from derivatives of the natural 
anticarcinogenic compound 3,3’-bis (indolyl) methane (DIM). C-DIMs are analogs based 
on a metabolic product in the GI tract of the natural compound indole-3-carbinole (I3C) 
(Schwartz & Ginsberg, 2002; S. Wang et al., 2016). Through luciferase activation assays 
and BIAcore binding assays, it has been demonstrated that some C-DIMs bind NR4A1. 
Specifically, among an initial series of 14 p-substituted C-DIMs the p-hydroxyphenyl C-
DIM analog (DIM-C-pPhOH) bound with high affinity (Kd= 0.11μM) to NR4A1 (Lee et al., 






C-DIM/NR4A1 ligands or Nr4a1 overexpression results in both induced and repressed 
gene expression (Duren et al., 2016). Nr4a1 has traditionally been studied in cancer where 
the compounds act as inverse agonist and block Nr4a1-dependent pro-oncogenic 
responses (Lee et al., 2010; Lee and Jin, et al., 2014). In muscle cells, they act as agonists 
and enhanced GLUT4 and glucose uptake (C.-S. Wu et al., 2018). Although gene reporter 
systems have been helpful in identifying Nr4a1 ligands, luciferase assays do not provide 
detailed information on Nr4a1 function in the context of these ligands. Nr4a1-DNA binding 
can be determined through the use of ChIP assays which can be correlated with 
transcriptional activity.  
Nr4a1 and Memory  
 Pharmacological and genetic manipulation of Nr4a1 in mice has elucidated its role in 
transcriptional regulation associated with long-term memory storage and aging. In the 
mouse hippocampus, Nr4a1-3 expression is transiently increased during learning and 
memory via histone acetylation and activation of downstream target genes (Hawk et al., 
2012). Notably, Nr4a1-3 are downstream of CREB/CBP activation, which is a central 
regulator of learning and memory (Bridi et al., 2017; Kida & Serita, 2014; Volakakis et al., 
2010). Pharmacological and viral mediated activation of Nr4a2 enhances hippocampal 
synaptic plasticity and long-term memory (Bridi et al., 2017; Chatterjee et al., 2020; Hawk 
et al., 2012). Whereas, loss of Nr4a2 causes deficits in long-term potentiation, abnormal 
increases in spine density and impaired long-term memory (Bridi et al., 2017; Y. Chen et 
al., 2014; Hawk et al., 2012; Kwapis et al., 2019). These data are consistent with the 
findings that reduced expression of Nr4a1-3 is associated with age-related memory 
decline and aging in humans (Chu et al., 2002). This body of literature demonstrates that 
Nr4a1-3 are important regulators of transcription necessary for memory formation. 






Altered levels of NR4A1 and NR4A2 expression are associated with Parkinson’s 
disease (Montarolo et al., 2016), schizophrenia (Corley et al., 2016) and cocaine use 
disorder in humans (Bannon et al., 2002; Bannon et al., 2004), due to its function in CREB-
mediated neuroprotection and dopamine-related neuroadaptation (Lévesque & Rouillard, 
2007; Volakakis et al., 2010). Nr4a1 is highly expressed in striatal regions of dopaminergic 
output, such as the NAc, where it determines adaptive changes in dopamine levels 
(Lévesque & Rouillard, 2007) via activation of target genes including Cartpt (Shieh, 2003). 
Specifically, Nr4a1 and Cartpt shows dynamic changes in its gene expression patterns 
following cocaine exposure (Freeman et al., 2008; J. N. Jaworski et al., 2003; Zhao et al., 
2014). In the striatum, Nr4a1 expression is expressed in both excitatory dopamine 
receptor 1 (D1) expressing and inhibitory dopamine receptor 2 (D2) expressing 
GABAergic neurons (Savell et al., 2020). Within these sub populations, Nr4a1 mRNA 
levels are under the tonic inhibitory control by physiological dopamine levels (Campos-
Melo et al., 2013). For example, repeated Levodopa (L-Dopa) treatment increases Nr4a1 
mRNA levels in both D1 and D2 neurons (Gilbert et al., 2006). In contrast, D1 and D2 
combined agonism upregulated Nr4a1 expression in D1 expressing neurons, whereas, 
D2 antagonism upregulated Nr4a1 expression in D2 expressing neurons (Gilbert et al., 
2006). Of interest, Nr4a1-deficient mice show increased sensitivity to psychostimulants 
measured by amphetamine-induced locomotor activity and dopamine metabolism 
(Bourhis et al., 2009; Gilbert et al., 2006). 
Nr4a1 and Cocaine use disorders  
The specific genes underlying cocaine use disorder are largely unknown, and 
Nr4a1 has not been genetically linked to substance use disorders. However, NR4A1-3 
and downstream target gene, cocaine and amphetamine-regulated transcript peptide 






abusers (Albertson et al., 2004; Bannon et al., 2005; W.-X. Tang et al., 2003), 
underscoring the significance of Nr4a1 target genes in cocaine use disorders. In mouse 
models, Nr4a1 is upregulated at early abstinence and 10-days of abstinence but returns 
to baseline by late abstinence (Carpenter et al., 2020; Freeman et al., 2008, 2010). During 
cocaine abstinence, the brain undergoes an additional set of changes that stably alters 
reward circuitry, drug-craving and dependence via chromatin modifications (Freeman et 
al., 2008, 2010; Wolf, 2016). 
These mechanisms (Damez-Werno et al., 2012; Koo et al., 2015) may underlie our 
preliminary observation that some Nr4a1 target genes remain differentially expressed after 
28-days of cocaine abstinence despite only transient cocaine-activation of Nr4a1. 
Establishing the molecular basis for epigenetic drug memories will further our 
understanding of the chronic nature of drug abuse. 
Overview of Dissertation  
 Cocaine induced transcription during abstinence mediates neuroadaptations 
important in relapse, but a master regulator has not been identified. Several studies have 
profiled gene expression during abstinence but many of them fail to interrogate the 
relationship between early and late abstinence (Freeman et al., 2008, 2010; Walker et al., 
2018). In addition, a select few studies investigate abstinence alone, in the absence of 
cocaine, context, or cue re-exposure. This research represents a critical gap in our 
knowledge of the homeostatic mechanisms that repair the brain following cocaine 
exposure. The main goal of this dissertation was twofold: 1) to identify and validate an 
upstream mechanism whereby cocaine exposure induces patterns of homeostatic gene 
expression via the enrichment of histone modifications, and 2) to develop therapeutic 
approaches for novel targets important in the suppression of cocaine relapse. In Chapter 






histone modification enrichment associated with early and late abstinence. We also 
interrogate the role of Nr4a1 activation and confirm its role in suppressing cocaine 
mediated behaviors, with a focus on using CRISPR-mediated gene activation and 
inhibition. In Chapter 3, we build on the evidence that Nr4a1 suppresses cocaine mediated 
behavior and utilize pharmacological activators of Nr4a1 for the treatment of cocaine use 
disorder. In Chapter 4, we develop a method to isolate specific neuronal cell-types to 
further validate the role of Nr4a1 in epigenetic regulation of target genes. Finally, we 
conclude this dissertation in Chapter 5 with a general discussion of this work, its potential 







CHAPTER 2  
NR4A1 SUPPRESSES COCAINE-INDUCED BEHAVIOR VIA EPIGENETIC 
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Endogenous homeostatic mechanisms can restore normal neuronal function following 
cocaine-induced neuroadaptations. Such mechanisms can exploited to develop novel 
therapies for cocaine use disorder, but a molecular target has not yet been identified. Here 
we profiled mouse gene expression during early and late cocaine abstinence to identify 
putative regulators of neural homeostasis. Cocaine activated the transcription factor, 
Nr4a1, and its target gene, Cartpt, a key molecule involved in dopamine metabolism. 
Sustained activation of Cartpt at late abstinence was coupled with depletion of the 
repressive histone modification, H3K27me3, and enrichment of activating marks, 
H3K27ac and H3K4me3. Using CRISPR-mediated Nr4a1 activation, we demonstrated the 
direct causal role of Nr4a1 in sustained activation of Cartpt and in attenuation of cocaine-
evoked behavior. Our findings provide evidence that targeting abstinence-induced 







 A core feature of cocaine use disorders is the propensity for relapse due to the 
aggregation of neuroadaptations during abstinence (Shaham & Hope, 2005). In human 
drug users, relapse is triggered by drug-associated cues (O’Brien et al., 1998), stress (R. 
Sinha, 2001) and acute drug re-exposure (Jaffe et al., 1989). To combat relapse, 
endogenous homeostatic mechanisms may restore and even reverse normal function to 
reward-related brain areas (Huang et al., 2011; Keramati et al., 2017). Both preclinical 
(Wolf, 2016) and human (Parvaz et al., 2016) studies indicate that drug-induced synaptic 
plasticity and the associated drug memories are reversible. Mechanisms that mediate 
adaptive changes to reduced drug-seeking behavior include gene expression during 
cocaine abstinence (Robison & Nestler, 2011). Therefore, the identification of a molecular 
mechanism of sustained homeostatic transcription across cocaine abstinence has 
important therapeutic implications. Only a limited number of studies have profiled global 
gene expression both immediately following drug taking and after abstinence(Freeman et 
al., 2010; Walker et al., 2018).  
 Many brain regions are involved in the formation of drug-associated 
neuroadaptations, including the VTA, PFC and NAc (Walker et al., 2018). To identify a 
master regulator of homeostatic gene expression, we profiled global transcriptomic 
changes in the NAc, VTA, and PFC at early and late abstinence following cocaine self-
administration in mice. Using IVSA and RNA-seq, we identified a key role for the 
transcription factor, Nr4a1, in regulating homeostatic target gene expression and cocaine-
evoked behavior. Nr4a1  plays an integral role in neuronal homeostasis and 
neuroprotection in response to hyperexcitation via the regulation of downstream effectors 
contributing to synapse distribution and function (Y. Chen et al., 2014; Jeanneteau et al., 






to the nucleus where it binds nerve-growth-factor inducible gene B (NGFI-B)-responsive 
elements (NRBE) at target gene promoters (Kurakula et al., 2014). Importantly, Nr4a1 
regulates gene expression via recruitment of chromatin modifying enzymes, many of 
which are stable across abstinence (Hedrick et al., 2017; Kurakula et al., 2014).  
 Histone modifications persist at specific genomic loci during abstinence and play 
an important role in stable transcriptional regulation associated with drug seeking 
(Robison & Nestler, 2011). Given that chromatin modifications confer long-lasting changes 
in gene expression necessary for stable cellular phenotypes, histone modifications 
acquired during abstinence may cause individual genes to “remember” prior drug 
exposure. Indeed, Nr4a1 is transiently expressed  during learning and supports memory 
formation via histone acetylation and activation of downstream target genes in the 
hippocampus (Hawk et al., 2012). Loss of Nr4a1 activation causes deficits in long-term 
potentiation, abnormal increases in spine density and impaired long-term memory (Bridi 
et al., 2017; Y. Chen et al., 2014; Hawk et al., 2012). Beyond changes in memory, altered 
levels of Nr4a1 and Nr4a2 expression are associated with Parkinson’s disease (Montarolo 
et al., 2016), schizophrenia (Corley et al., 2016) and cocaine use disorder in humans 
(Bannon et al., 2002; Bannon et al., 2004), due to its function in CREB-mediated 
neuroprotection and dopamine-related neuroadaptation (Lévesque & Rouillard, 2007; 
Volakakis et al., 2010). Nr4a1 is highly expressed in striatal regions of dopaminergic 
output, such as the NAc, where it determines striatal dopamine levels (Lévesque & 
Rouillard, 2007) via activation of target genes including cocaine and amphetamine-
regulated transcript peptide (Cartpt) (Shieh, 2003). Nr4a1-deficient mice show increased 
sensitivity to psychostimulants measured by amphetamine-induced locomotor activity and 






consistent with prior studies that show cocaine-induced expression of Nr4a1 (Freeman et 
al., 2010; Walker et al., 2018; Werme et al., 2000). 
 We identified Nr4a1 and its target genes as potentially important mediators of 
homeostatic gene expression across abstinence using an unbiased transcriptomic 
approach. We prioritized Nr4a1 given its key roles long-term memory and neuroprotection. 
We discovered a mechanism whereby Nr4a1 stably activated target genes and changed 
histone modification enrichment important in neuronal homeostasis, including Cartpt. 
Importantly, activation of Nr4a1 reduced cocaine reinforced behavior. Herein, we 
established Nr4a1 as a key regulator of persistent gene transcription during cocaine 
abstinence and as a promising therapeutic target for cocaine use disorder. 
Methods  
Animals 
 Adult male and female, 8-week-old C57BL/6J mice (The Jackson Laboratory) were 
used in this study. Mice were housed on a 12-h light-dark cycle at constant temperature 
(23°C) with access to food and water ad libitum. Animals were habituated to experimenter 
handling for at least 1 week before experimentation. All animals were maintained 
according to National Institutes of Health guidelines in Association for Assessment and 
Accreditation of Laboratory Animal Care.  Ethical and experimental considerations were 
approved by the Institutional Animal Care and Use Committee of The University of 
Pennsylvania. 
Cocaine Intravenous Self-Administration 
 Mice were single housed and habituated to the researcher by daily handling 
sessions for 7 days prior to the start of SA training. Operant responding was defined as 
active if paired with the delivery of a reinforcer, and inactive if paired with no reinforcer or 






tone. All studies were conducted on a fixed-ratio 1 (FR1). The acquisition of the 
instrumental task (nose poke or wheel spin) was facilitated in naïve mice by 10 daily, 1-
hour training sessions for operant responding to receive a food pellet reinforcer (Bio-Serv, 
Product #F0071; 20 mg). Mice were introduced to the food pellets and food restricted for 
3 days prior to the start of the operant training.   
 Following food SA, mice were implanted with an indwelling catheter to the right 
external jugular vein under ketamine (80 mg/kg) and xylazine (12mg/kg) anesthesia, 
followed by 3 days of recovery, during which time they were monitored daily for distress. 
Mice were then assigned to self-administer either saline or cocaine (0.7 mg/kg/infusion) 
on an FR1 schedule during daily 2-hour sessions for 21 consecutive days. We defined 
acquisition as the first of three consecutive sessions during which mice consumed an 
average of 5 mg/kg cocaine, or about 10 infusions (5.6-8.4 mg/kg), infusions did not vary 
by more than 20%, and at least 80% of responses were on the active wheel. Mice were 
sacrificed 1- and 28-days after the last cocaine session, brains were removed and NAc, 
VTA and PFC was dissected using 2 mm aluminum Harris micro-punch (Sigma-Aldrich). 
Tissue was frozen on dry ice and stored at -80 for downstream analysis.  
 Cocaine-seeking experiments: Following 10 days of cocaine SA mice underwent 
1- day or 28 days of abstinence. On day 21 of abstinence, NAc was targeted by stereotaxic 
injection, as described below. For seeking tests, mice were subjected to a single 2-hr SA 
session, in which no reinforcer was given for active responses, but all cues were present. 
Mice were sacrificed immediately following the seeking session and brain region(s) 
collected for downstream analysis.  
Investigator Administered Cocaine  
 Mice were group housed and habituated to the researcher by daily handling 






in 0.9% saline (i.p., 20mg/kg) or 0.9% saline in clean cages and allowed to move freely 
for 30 minutes, before being returned to home cages. NAc tissue was collected 1- and 28 
days after the last injection.  
Conditioned place preference  
 Mice were placed in a two-sided conditioning chamber (Ugo Basile) for 20 min to 
assess innate pretest preferences. Mice were then conditioned for 2-days to associate 
cocaine with their non-preferred side. Mice were injected in the morning with cocaine and 
in the afternoon with saline (i.p., 5, 10 or 20 mg/kg), then restricted to their preferred 
chambers and non-preferred, respectively, for 30 min. On day 4, mice were placed in the 
chamber with free access to both sides for a 20 min post-test session to assess 
conditioned place preference. ANY-Maze (version 4.99) software was used to analyze 
time and total distance traveled. NAc tissue was collected 4 hours following the post-test 
session. Cocaine preference for all testing sessions was calculated as time spent in the 
cocaine-paired chamber minus time spent in the saline-paired chamber and is reported as 
a preference score (in seconds). Mice were defined as having acquired cocaine CPP when 
the average cocaine preference score of the cocaine-treated group was significantly 
higher than the preference score at baseline (Burgdorf et al., 2017). 
Intra-NAc Transfection  
 NAc was targeted bilaterally (Heller et al., 2014, 2016) using the following 
stereotaxic coordinates: +1.6 (anterior/posterior), +1.5 (medial/lateral), and −4.4 
(dorsal/ventral) at an angle of 10° from the midline (relative to Bregma). In-vivo 
transfection were conducted using the transfection reagent Jet-PEI (Polyplus 
transfection), prepared according to manufacturer’s instructions. 12.5 μl DNA plasmid (1.0 
μg/uL) was diluted in 12.5 μl of 10% sterile glucose and added to diluted Jet-PEI, mixed 






PEI/Plasmid solution was delivered NAc at a rate of 0.2 l per minute, followed by 5 min 
of rest. Following surgery, mice were allowed to recover for 4-7 days and closely monitored 
for distress 
Tissue collection, RNA extraction and qRT-PCR 
 For tissue collection, mice were euthanized by cervical dislocation and the brain 
was placed in ice-cold phosphate buffered saline with protease inhibitor cocktail (Roche 
cOmplete Protease inhibitor). 1 mm thick sections of prefrontal cortex, nucleus accumbens 
and ventral tegmental area, brain regions were prepared using a cold tissue matrix and 
regions were micro-dissected with a 2- or 1.2-mm diameter micro-punch (Harris) under a 
fluorescence stereoscope (Leica). For in-vivo transfection studies, transfected tissue was 
visually inspected for confirmation of NAc targeting and dissection. RNA was isolated 
using the RNeasy Mini Kit (Qiagen) according to the manufacturer instructions. Primer 
sequences can be found in Supplementary Table 1.  Data was analyzed by comparing Ct 
values of the experimental group to control using the ΔΔCt method. 
RNA-seq data analysis 
 RNA-seq reads were aligned against mouse reference genome (mm9, ensemble 
annotation) using STAR (Version 2.4.1d) (Dobin et al., 2013) with default parameters. 
Aligned reads were normalized using different methods including TMM (Robinson & 
Oshlack, 2010), TMM_CPM (Robinson & Oshlack, 2010), RPKM (Robinson et al., 2010), 
EDAseq_UQ (Risso et al., 2011), FullQuantile (Risso et al., 2011), Median, PoissonSeq 
(Witten & Johnstone, 2012), RUV (Risso et al., 2014) and PORT 
(https://github.com/itmat/Normalization). Differential gene expression analysis was 
conducted using different models: DEseq2-Wald (Love et al., 2014), EdgeR-Robust-LRT 






B.; Whitney, 1947) and Parametric t-test (T. K. Kim, 2015). Q-values are determined for 
each of the 45 combinations of normalization and differential gene expression analysis. 
Genes with a mean q value smaller than 0.25 were considered a target of differential 
expression for each combination. A gene is identified as differentially expressed gene if it 
is detected by the combination of 5 different methods. 
Venn Diagrams, volcano plot and heatmaps 
 R packages Venn diagram and heatmaps were used to generate Venn Diagram 
and heatmap figures. Volcano plots were produced using R package ggplot2. Gene 
expression level in the heatmap and volcano plots were calculated based on RPKM 
normalization using ‘rpkm’ function from edgeR package. Gene length was calculated 
based on the length information from ensemble GFF annotation file. Genes with multiple 
isoforms were collapsed and the length was calculated according to the longest collapsed 
isoform. 
Chromatin immunoprecipitation 
 ChIP was conducted on bilateral NAc 2 mm punches dissected as described above 
from 1 mouse, 24 h after the last drug treatment or abstinence (Xu & Heller, 2018). For in 
vivo CRISPR studies unilateral NAc 1.2 mm punches were pooled from 5-6 mice. 
Chromatin was sheared using a diogenode bioruptor XL at high sonication intensity. For 
histone modification enrichment, chromatin was sheered for 30 minutes (30 s on/30 s off) 
and fragment size was verified at 150–300 bps with an Agilent 2100 bioanalyzer. For 
Nr4a1 binding enrichment, chromatin was sheered for 22 minutes (30 s on/30 s off) 
fragment size was verified at 400-600 bps. Sheared chromatin was incubated overnight 
with the following antibodies previously bound to magnetic beads (Dynabeads M-280, Life 
Technologies): antibody to H3K4me3 (EMD Millipore 07-473), antibody to H3K27me3 






(Novus NB100-56745), IgG (Novus NBP2-24891). The Dynabeads were washed twice 
each with 1 ml of Low Salt Wash Buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 2 mM EDTA, 
1% TritonX-100, 0.1% SDS), High Salt Wash Buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 
2 mM EDTA, 1% TritonX-100, 0.1% SDS), and TE Buffer (10 mM Tris, pH 8.0, 1 mM 
EDTA). After reverse cross-linking and DNA purification (Qiagen Spin Column), primers 
were designed to amplify regions -100- +100 bps spanning the Nr4a1-binding motif within 
gene promoter regions. qChIP primer sequences are be found in Supplementary table 2.  
Neuro2a transfections 
 Neuro2a (N2a) cells (n=1 x 106 cells) [CCL-131, ATCC (manufacturer 
authentication available on-line)] were cultured and transfected with a total of 300 ng of 
plasmid DNA using Effectene reagent (Qiagen) (Heller et al., 2014). RNA was isolated 
using the RNeasy Mini Kit (Qiagen) according to the manufacturer instructions. qPCR and 
data analysis were conducted as described above. 
Engineered DNA-binding molecule ChIP (enChIP) 
 enChIP (Active Motif) was conducted according to the manufacturer’s instructions 
with the following modifications (Fujita et al., 2018). N2a cells (n=10 x 106 cells) were 
transfected (Effectene) with 1 μg of pAM_dCas9 (Active Motif) and 1 μg of sgRNA-231. 
Cells were fixed 48 hours post-transfection with 1% formaldehyde at 37 °C for 5 min. 
The chromatin fraction was extracted, fragmented by sonication and 150-300 bp 
fragments were confirmed with the Agilent Bioanalyzer. The sonicated chromatin was pre-
cleared with 15 μg of normal mouse IgG (Active Motif) conjugated to 150 μl of Dynabeads-
Protein G (Invitrogen) and subsequently incubated with 15 μg of AM-Tag polyclonal 
antibody (Active Motif 61677), previously conjugated to 150 μl of Dynabeads-Protein G. 
The Dynabeads were washed twice each with 1 ml of Low Salt Wash Buffer (20 mM Tris, 






(20 mM Tris, pH 8.0, 500 mM NaCl, 2 mM EDTA, 1% TritonX-100, 0.1% SDS), and TE 
Buffer (10 mM Tris, pH 8.0, 1 mM EDTA). The Dynabeads were suspended in 285 μl of 
TE and 12 μl of 5 M NaCl and incubated at 65 °C overnight for reverse crosslink. After 
RNase A treatment at 37 °C for 1 h, samples were treated with Proteinase K at 65 °C for 
2 h. Subsequently, DNA was reverse crosslinked and purified (Qiagen Spin Column). 
qChIP primers were designed to amplify regions between -100 and -350 bps spanning the 
sgRNA-231 targeting sequence within the Nr4a1 gene promoter and a location 1kb 
upstream. Primer sequences are found in Table 2. 
Immunohistochemistry 
 Mice were unilaterally transfected with dCas9-VP64 or transfection reagent alone 
(mock) and sacrificed at 1-day post transfection. Animals were then transcardially 
perfused with ice-cold DPBS, followed by ice-cold 4% paraformaldehyde (PFA). Brains 
were fixed overnight in 4% PFA at 4ºC, and then cryoprotected in 30% sucrose solution 
overnight at 4ºC. Coronal brain sections (45 µm) were collected using a sliding microtome 
(Leica, SM2010R), and serial sections were stored at -20ºC in 96-well plates containing 
anti-freeze solution (300 g sucrose, 300 ml ethylene glycol, 500 ml 0.1M PBS). Brain 
sections were washed in TBS with 0.05% TritonX-100 and then incubated in primary 
antibody solution (3.33% donkey serum and 0.05% TritonX-100 in TBS) with anti-Cas9 
(Catalog # 61578, Active Motif, 1:500) overnight at 4ºC. Brain sections were washed in 
TBS with 0.05% TritonX-100 and then incubated in secondary antibody solution (3.33% 
donkey serum and 0.05% TritonX-100 in TBS) with Alexa Fluor 555 (1:250) and DAPI 
nuclear stain (Roche, 1:1000) for 1-2 hr. at room temperature. Brain sections were washed 
in TBS with 0.05% TritonX-100 and then incubated in a second primary antibody solution 
with anti-NeuN, AlexFluor 488 conjugated (Catalog # MAB377X, Millipore, 1:500) 






were mounted with 2.5% PVA/DABCO mounting media (Sigma). Brain sections were 
imaged using as z-stacks using the 40x objective of a Zeiss LSM 810 confocal microscope 
(Carl Zeiss).  
Statistics 
 The appropriate statistical test was determined based on the number of 
comparisons being done. Student's t tests were used for comparison of two groups, in the 
analysis of qRT-PCR following in vivo CRISPR-mediated gene activation and Two-way 
ANOVAs were used for comparison of saline and cocaine treatment across abstinence 
time points; when appropriate, a post-hoc test followed to determine significant differences 
across multiple comparisons, in the analysis of qRT-PCR and qChIP data. One-way 
ANOVA was used for analysis of three or more experimental groups, when appropriate, a 
post-hoc test followed to determine significant differences across multiple comparisons, in 
the analysis of CRISPR-mediated gene regulation when compared to controls (qRT-PCR). 
Repeated measure two-way ANOVA was used for comparison of two groups on different 
observations, when appropriate, a post-hoc test followed to determine significant 
differences across multiple comparisons, in the analysis of cocaine self-administration and 
condition place preference. Main and interaction effects were considered significant at P 
< 0.05. P values greater than 0.05 and below 0.1 were considered trends.  Data are 
expressed as mean [+ or -] s.e.m. The Grubbs test was used when appropriate to identify 
outliers. F tests of variance were conducted on all data sets to ensure that the data 
followed a normal distribution. All experiments were carried out one to three times, and 
data replication was observed in instances of repeated experiments. Experimental sample 
sizes were determined using G*power using preliminary data. Details on each statistical 
test can be found in the source data file.  






 ANY-Maze software was used for behavioral tracking in conditioned place 
preference studies. We have used published software for data analyses. Requests can be 
sent to the corresponding author.  
Data Availability 
 RNA-Seq source data presented in Fig. 2.1 and 2 and Supplementary Fig. 2.2 and 
2.4 can be accessed through GSE141520. All data and statistics reported in main text can 
be found in the Source Data file.  
Results 
Cocaine increased Nr4a1 via histone modifications (hPTMs)  
 Several studies suggest that drug exposure increases homeostatic gene 
expression during abstinence to mitigate cocaine induced neuroadaptations (Keramati et 
al., 2017). To identify a master regulator of homeostatic gene expression, we profiled 
global transcriptomic changes in the adult mouse brain, including the NAc, VTA, and PFC, 
at early (1-day) and late (28-days) abstinence following cocaine self-administration (Fig. 
2.1A). In all cases, we compared cocaine to saline treated tissue at each time point. All 
cocaine treated mice acquired self-administration behavior (SA), measured by a greater 
number of infusions, active (cocaine-paired) spins and discrimination between the active 
and inactive (saline-paired) wheels across 21 daily sessions (Fig. 2.1B; Supplementary 
Fig. 2.1A-F). In the NAc, we found a greater number of regulated transcripts at 28-days 
(341 differentially expressed genes (DEGs)) than at 1-day (44 DEGs) of abstinence (Fig. 
2.1C, D) (Freeman et al., 2010). Alternatively, in the VTA and PFC there were a greater 
number of cocaine-regulated genes at 1-day (DEGs: VTA 3040, PFC 82) than at 28-days 
(DEGs: VTA 1571, PFC 45) of abstinence (Supplementary Fig. 2.2A-F). Nr4a1 was 
identified in the highest-ranked biological process group, cellular response to the 






(Fig. 2.1E, top). Interestingly, at 28-days of abstinence there was enrichment for the 
biological process of memory, which includes genes involved in the acquisition, 
modification and retrieval of informational stimuli (Fig. 2.1E, bottom). RNA-seq measured 
activation of Nr4a1 at 1-day but not 28-days of abstinence (Fig. 2.1F). Nr4a1 activation 
and several other DEGs were validated via qPCR in a separate cohort of animals that 
underwent the SA paradigm (Fig 2.1G; Supplementary Fig. 2.3A-D, 2.4A-D). Nr4a1 is 
activated in brain as an adaptive response to hyperexcitation, and functions as a 
transcription factor to regulate target genes necessary for synaptic reorganization 
(Jeanneteau et al., 2018; Huiping Li et al., 2016). We found no significant differences in 
the activation of Nr4a1 in the VTA or PFC at either 1- or 28-days of abstinence, suggesting 
a NAc-specific mechanism of Nr4a1-dependent transcription across abstinence. 
 To interrogate the mechanism of Nr4a1 gene activation, we measured the 
enrichment of Nr4a1 protein and the hPTMs, histone H3 lysine 27 trimethylation 
(H3K27me3) and acetylation (H3K27ac), and histone H3 lysine 4 trimethylation 
(H3K4me3) at the Nr4a1 promoter following repeated, investigator-administered cocaine 
(Fig. 2.1H). The technical ease and reduced variability of investigator administered 
cocaine relative to cocaine SA allowed us to profile transcription factor binding and 
multiple epigenetic modifications at several loci. We first validated Nr4a1-binding to the 
promoters of cocaine-activated genes in the NAc by quantitative chromatin 
immunoprecipitation (qChIP) using an Nr4a1 specific antibody (Supplementary Fig. 
2.5A). As in cocaine SA, repeated investigator administered cocaine activated Nr4a1 at 
1-day (Fig. 2.1I) and increased the enrichment of Nr4a1 at the Nr4a1 promoter (Fig. 2.1J) 
in the NAc at 1- and 28-days of abstinence. We found no differences in the repressive 
modification, H3K27me3 (Fig. 2.1K), and enrichment of the activating hPTMs, H3K27ac 






abstinence. Taken together, these findings indicated that cocaine induced transient 
activation of Nr4a1 and persistent changes in chromatin state at the Nr4a1 promoter. 
Cocaine regulated Nr4a1 target genes via hPTMs  
 To determine the mechanism of action of Nr4a1 across abstinence, we measured 
expression of known Nr4a1 target genes that were regulated by cocaine abstinence and 
are relevant in the neuroadaptive processes underlying drug-associated behavior. 
Specifically, we found that Nr4a1 bound to the promoter region of (1) casitas B-
lineage lymphoma (Cbl), an E-3 ubiquitin-ligase that regulates Nr4a1 expression via 
targeting to the proteasome (X. Li et al., 2015) (2) period circadian regulator 2, Per2, which 
is activated by cocaine in the striatum and negatively regulates cocaine sensitization and 
conditioned place preference (CPP) (McClung, 2007)  and (3) Cartpt, which is increased 
in the NAc of both humans and mice during abstinence from cocaine (Albertson et al., 
2004; Freeman et al., 2010; Hubert & Kuhar, 2008) (Supplementary Fig. 2.5A). With 
respect to cocaine-activation of these Nr4a1 target genes, RNA-seq measured transient 
activation of Cbl at 1-day of abstinence and no significant difference at 28-days of 
abstinence (Fig. 2.2A), while Per2 was activated at 1-day and repressed at 28-days of 
abstinence (Fig. 2.2A). Cartpt was activated only at 28-days of abstinence (Fig. 2.2A). 
These expression patterns were validated in a distinct cohort of mice via qPCR (Fig. 2.2B).  
 We hypothesized that Nr4a1 enrichment facilitates the recruitment of histone 
modifying enzymes at target genes to regulate long-lasting changes in transcription 
(Hedrick et al., 2017; Palumbo-Zerr et al., 2015). To quantify the association between 
Nr4a1 and histone modification, we measured the enrichment of Nr4a1 at Cartpt, a gene 
with delayed activation after 28-days of abstinence. Similar to cocaine SA, repeated 
investigator administered cocaine activated Cartpt specifically at 28-days, but not 1-day, 






2.2D). To investigate the regulatory mechanism for delayed activation of Cartpt, we 
measured hPTMs at the promoter region. At 1-day of abstinence, at which point Cartpt is 
repressed, we measured enrichment of the repressive hPTM, H3K27me3 (Fig. 2.2E), as 
well as enrichment of the activating hPTMs, H3K27ac (Fig. 2.2F) and H3K4me3 (Fig. 
2.2G). Cartpt was activated only at late abstinence (28-days), along with H3K27me3 
depletion (Fig. 2.2E) and H3K27ac enrichment (Fig. 2.2F); H3K4me3 was also enriched 
at Cartpt at this time point (Fig. 2.2G). Thus, abstinence-induced activation of Cartpt was 
associated with sustained Nr4a1 enrichment and depletion of the repressive hPTM, 
H3K27me3. Therefore, Nr4a1 may act as a master regulator of delayed cocaine-mediated 
gene activation via sustained binding at target genes.  
CRISPR regulation of Nr4a1 and target genes  
 We next applied CRISPR-activation to determine the causal relevance of Nr4a1 to 
homeostatic target gene expression during cocaine abstinence. This system consists of 2 
components: (1) a catalytically dead Cas9 protein fused to a VP64 transcriptional 
activation domain (dCas9-VP64), driven by a neuron specific promoter and (2) a single-
guide RNA (sgRNA) targeting the Nr4a1 promoter. dCas9-VP64 moderately activated 
gene expression which is advantageous in obtaining physiologically relevant Nr4a1 
activation (Matharu et al., 2019). For control experiments, dCas9-VP64 was paired with a 
control, non-targeting sgRNA (sgRNA-NT) with no homology to the mouse genome (Fig. 
2.3A). We first used Neuro2a (N2a) cells to screen a library of sgRNAs that targeted the 
Nr4a1 promoter at various locations upstream (-366, -231, -39 bps) or downstream (+82, 
+200 bps) of the transcription start site (TSS) (Fig. 2.3B). Nr4a1-sgRNA-366 and -231 
both activated Nr4a1 mRNA expression, relative to control sgRNA-NT (Fig. 2.3B). We 
also measured activation of Cartpt, as it is associated with Nr4a1 binding during cocaine 






transcriptional repressor previously validated in vivo (Thakore et al., 2018). In N2a cells, 
co-transfection of Nr4a1 sgRNAs with dCas9-KRAB did not change Nr4a1 expression 
(Fig. 2.3B).  
 To examine potential off-target effects, we conducted engineered DNA-binding 
molecule ChIP (enChIP), which allows qChIP with an antibody that recognizes dCas9 
fused to a synthetic affinity tag (AMtag) (Fujita et al., 2018). When co-transfected with 
sgRNA-231, dCas9-AMtag was enriched above input only at the sgRNA-Nr4a1 target 
region and not at a distal site -1000 bps from the Nr4a1 TSS (Fig. 2.3D). There was no 
enrichment above input when dCas9-AMtag was transfected with sgRNA-NT (Fig. 2.3D).  
 We next examined the feasibility of CRISPR-mediated Nr4a1 activation and 
repression in vivo, by co-transfection of sgRNA-Nr4a1 (sgRNA-231) and dCas9-VP64 or 
-KRAB in the NAc. In our stereotaxic transfections, expression is primarily in the core sub 
region of the NAc, with small amounts of expression in shell. In all cases, sgRNA-Nr4a1 
and sgRNA-NT were injected contralaterally, to accomplish rigorous, within-animal 
comparisons. We first confirmed neural specificity of dCas9-VP64, conferred by the 
synapsin (hSyn) promoter, via double immunohistochemical analysis using anti-Cas9 and 
anti-NeuN antibodies. We found that dCas9-VP64 colocalizes exclusively with NeuN 
positive neurons in the NAc, 24 hours post-transfection (Fig. 2.3E; Supplementary Fig. 
2.6A). By qPCR, co-transfection of sgRNA-Nr4a1 and dCas9-VP64 activated Nr4a1, 
relative to sgRNA-NT (Fig. 2.3F). Co-transfection of sgRNA-Nr4a1 with dCas9-KRAB 
repressed Nr4a1 (Fig. 2.3F). We conducted several control experiments to evaluate 
specificity of this bidirectional effect on mRNA expression. We found that dCas9-VP64 nor 
-KRAB in combination with sgRNA-NT, or dCAs9-VP64 nor sgRNA alone or Cdk5-sgRNA 
(an unrelated gene), were sufficient to regulate activation of Nr4a1 (Fig. 2.3F). We next 






transfected with dCas9-VP64 or dCas9-KRAB caused activation or repression, 
respectively, of Cartpt, relative to sgRNA-NT (Fig. 2.3G, H). We determined the time 
course of CRISPR-mediated Nr4a1 activation and found activation of Nr4a1 and Cartpt at 
4-days and 7-days, but not 14-days post transfection (Fig. 2.3I). Finally, as in cocaine SA, 
CRISPR-mediated activation of Nr4a1 depleted H3K27me3 (Fig. 2.3J) and enriched 
H3K27ac (Fig. 2.3K). There were no significant changes in H3K4me3 (Fig 2.3L). We 
conclude Nr4a1 activation coordinates the depletion of H3K27me3 and enrichment of 
H3K27ac to facilitate Cartpt activation. 
Nr4a1 bidirectionally modulated cocaine behavior 
 Having established the role of Nr4a1 in mediating gene transcription and hPTMs 
at cocaine-induced target genes, we next determined the effect of CRISPR-mediated 
Nr4a1 regulation on cocaine-induced behavior and gene expression. These effects can 
be evaluated in mouse place conditioning paradigms or self-administration. Because the 
time course of conditioned place preference (CPP) matched more precisely that of 
CRISPR-mediated Nr4a1 activation, we first examined the effects in this paradigm. Most 
drugs that are self-administered also produce CPP suggesting there are similar molecular 
substrates underlying drug-memories and drug-seeking (Bardo & Bevins, 2000). As 
shown schematically, bilateral NAc of each subject was co-transfected with dCas9-VP64 
and sgRNA-Nr4a1 or -NT (control) before CPP was conducted; the effect of Nr4a1 
repression by dCas9-KRAB was examined in a separate cohort (Fig. 2.4A).  
 Prior to cocaine conditioning, both control mice and those with activated Nr4a1 
showed no differences in their preference for the saline-paired chamber (Fig. 2.4B). 
Following conditioning, both groups of mice spent more time in the cocaine-paired 
chamber, compared to the pre-test (Fig. 2.4B), indicating that activation of Nr4a1 did not 






preference was attenuated in mice following CRISPR activation of Nr4a1, compared to 
control mice. A separate cohort receiving a higher dose of cocaine showed a similar effect, 
that is, reduced cocaine CPP following Nr4a1 activation (Fig. 2.4B). At both doses, this 
attenuation of CPP was accompanied by activation of Cartpt (Fig. 2.4C). Alternatively, 
CRISPR repression of Nr4a1 increased preference for the cocaine-paired chamber in 
mice administered a low dose of cocaine at which control mice did not form cocaine CPP 
(Fig. 2.4D). At a dose to which control mice develop a preference, Nr4a1 repression also 
increased cocaine CPP (Fig. 2.4D). Increased cocaine preference was associated with 
repression of Cartpt at both doses (Fig 2.4E). To determine if deficits in baseline locomotor 
activity could account for these effects, total distance traveled was measured and no 
significant differences between groups were found (Supplementary Fig. 2.7A-D). 
 We next investigated the role of Nr4a1 in acquisition of cocaine SA and cocaine-
seeking behavior during abstinence (Fig. 2.4J-L). In cocaine-seeking, mice freely perform 
the operant tasks in the presence of cues, but no reinforcer is given for active responses. 
CRISPR activation of Nr4a1 prior to cocaine SA had no effect on acquisition (Fig. 2.4G; 
Supplementary Fig. 2.8A-D) or cocaine-seeking at 1-day of abstinence (Fig. 2.4H; 
Supplementary Fig. 2.8E-G). Given the time course of homeostatic target gene activation 
following CRISPR activation of Nr4a1, we next activated Nr4a1 during abstinence 
following cocaine SA, to coincide with a test of cocaine-seeking in late abstinence (Fig. 
2.4I-K; Supplementary Fig. 2.9A-D). This manipulation attenuated cocaine-seeking at 
28-days of abstinence (Fig. 2.4J; Supplementary Fig. 2.9E-G), at a time point when 
Cartpt is activated by cocaine SA (See Fig. 2.2A, B). In conclusion, Nr4a1 activation is 








The majority of studies at the cellular level have focused on cocaine-induced 
adaptations at either early or late abstinence, which limits understanding of how processes 
that occur during abstinence affect subsequent behavior. In the present study, we used 
an unbiased genome wide approach to profile gene expression at both early and late 
abstinence following cocaine SA. We found that cocaine transiently activated Nr4a1, 
specifically in NAc, while key homeostatic target genes were activated at late abstinence. 
Interestingly, Nr4a1 regulates contextual fear memory via transient expression that peaks 
2 hours after learning but returns to baseline by 4 hours, long before memory retrieval at 
24 hours (Attner et al., 2007). It is not yet understood how Nr4a1 activation patterns cause 
long-term changes in neuronal function following cocaine exposure. To overcome this, we 
designed a CRISPR-Cas9 system to activate and repress Nr4a1 expression in the context 
of cocaine and control conditions. Similar to cocaine induced activation of Nr4a1, we found 
that Nr4a1 activation bidirectionally regulated Cartpt expression and associated hPTMs. 
Remarkably, activation of Nr4a1 attenuated, while repression of Nr4a1 enhanced 
behavioral responses to cocaine. In sum, we identified a mechanism of epigenetic 
regulation to combat cocaine use disorders that can be targeted pharmacologically and 
through locus specific Nr4a1 activation. 
 We hypothesized that Nr4a1 is a key mediator of homeostatic responses across 
cocaine abstinence, given that (1) Nr4a1 is highly expressed in striatal regions of 
dopaminergic output, such as the NAc (2) Nr4a1-deficient mice show increased sensitivity 
to psychostimulants measured by amphetamine-induced locomotor activity and dopamine 
metabolism (Bourhis et al., 2009; Gilbert et al., 2006; Langlois et al., 2001) and (3) 
following repeated dopamine excitation, the activation of Nr4a1 prevents the accumulation 






Jeanneteau et al., 2018; Huiping Li et al., 2016). Prior data on the regulation of Nr4a1 and 
target genes across cocaine abstinence, although scant, supports our findings. For 
example, one study has applied RNA-sequencing across cocaine abstinence(Walker et 
al., 2018), identifying Nr4a1, among other nuclear receptors, as an upstream master 
regulator of gene expression at late abstinence. An earlier study using microarray, finds 
that Nr4a1 is upregulated at 1- and 10-days of abstinence in rat NAc, following 10 days of 
cocaine SA (24 hours per day) (Freeman et al., 2010). This abstinence-induced Nr4a1 
expression was not detected by qPCR (Freeman et al., 2008, 2010); which may reflect 
differences in the mRNA quantification method. Importantly, prior studies confirm transient 
activation of Nr4a1 by psychostimulant exposure, such that an acute injection of cocaine 
(Alsio et al., 2011) or methamphetamine (McCoy et al., 2011) upregulates Nr4a1 
expression in mouse and rat NAc, respectively. Interestingly, activation of Nr4a1 following 
acute methamphetamine treatment is abrogated by prior chronic treatment (McCoy et al., 
2011), supporting the concept of long-lasting effects on the Nr4a1 promoter. Our data 
expand upon these findings, providing a potential epigenetic mechanism for stimulant 
activation of Nr4a1. Specifically, activation of Nr4a1 at 1-day of cocaine abstinence was 
accompanied by enrichment of the activating hPTM, H3K4me3. By 28-days of abstinence, 
we measured sustained enrichment of H3K27ac and H3K4me3, yet Nr4a1 was no longer 
activated above saline controls. Despite this, Nr4a1 remained enriched in the promoter of 
a key homeostatic target gene, Cartpt, in cocaine versus saline treated NAc after 28-days 
of abstinence.  
 To examine the functional relevance of Nr4a1 in the context of cocaine abstinence, 
we applied CRISPR-mediated gene regulation, to drive activation of Nr4a1 to 
physiologically relevant levels matching that of cocaine SA. Using this approach, we found 






of Cartpt. We then applied this tool to determine epigenetic mechanisms for the delayed 
activation of Cartpt only at late abstinence. Based on our data, we propose the following 
mechanism depicted in Fig. 2.5: In early abstinence, the Cartpt promoter is enriched in 
activating hPTMs, but its expression is repressed by enrichment of H3K27me3. During 
late abstinence, this repression is relieved by depletion of H3K27me3 and enrichment of 
H3K27ac and H3K4me3, via Nr4a1 binding. It is important to consider that the time course 
of target gene expression following CRISPR activation of Nr4a1 differs from that of 
cocaine SA. That is, Cartpt is only activated simultaneously with Nr4a1 activation, while in 
the context of cocaine abstinence, Cartpt is only activated at late abstinence (28-days), 
when Nr4a1 expression is no longer elevated. This suggests that Nr4a1 is sufficient for 
activation of Cartpt, but additional factors initially suppress expression during early 
abstinence. There is evidence the enrichment of H3K27me3 and H3K4me3 recruit 
nucleosome machinery important in transcription factor binding (Gao et al., 2018). In fact, 
Nr4a1 binding positively correlates with H3K27ac enrichment and creates large scale 
open chromatin regions facilitating subsequent gene activation via the recruitment of, 
p300, a histone acetyltransferase (Duren et al., 2016; Xindong Liu et al., 2019). We show 
that Nr4a1 activation depleted H3K27me3 and enriched H3K27ac facilitating activation of 
Cartpt during abstinence. Moreover, work in peripheral tissue has shown Cartpt activation 
is associated with H3K27me3 depletion and H3K27ac enrichment, which enables more 
sensitive activation upon stimulation (N. Sinha et al., 2019). These data support our 
hypothesis that Nr4a1 expression facilitates the cascade of events necessary for 
activation of repressed genes via H3K27ac enrichment and the resolution of H3K27me3 
(Gao et al., 2018).  
 We further applied CRISPR-mediated Nr4a1 activation or repression to the 






attenuate cocaine CPP, a phenomenon that was accompanied by increased activation of 
Cartpt. Alternatively, repression of Nr4a1 increased cocaine CPP, along with repression 
of Cartpt. Taken together, these findings support our hypothesis that Nr4a1 regulates 
cocaine reinforced behavior, via regulation of Cartpt, a key homeostatic target gene.  
Given that we initially identified Nr4a1 in a transcriptomic screen following cocaine SA, we 
next examined its manipulation in this paradigm (Walker et al., 2018). Activation of Nr4a1 
during abstinence was sufficient to attenuate cocaine-seeking at 28-days of abstinence, a 
time point at which Cartpt is normally activated. There are key differences between 
intraperitoneal (IP) and intravenous (IV) drug exposure paradigms, such as peak levels of 
cocaine in the brain, which could explain discrepancies in our findings (Ma et al., 1999; 
Pan et al., 1999). Specifically, the concentration of cocaine in the brain increases following 
repeated IP administration but remains constant following repeated IV administration (Ma 
et al., 1999; Pan et al., 1999).  Because we measured the same effect on Nr4a1 activation 
in both paradigms, we provide evidence that the mechanism of Nr4a1 activation is 
conserved between the two paradigms.  Nr4a1 may regulate gene expression essential in 
long-term context-dependent drug associations rather than changes directly associated 
with the pharmacological properties of cocaine. This notion is supported by the lack of 
effect of Nr4a1 activation on cocaine SA acquisition. The regulatory effects of Nr4a1 on 
cocaine-induced gene transcription and its role in attenuating cocaine-induced behaviors 
make it a promising therapeutic target in cocaine use disorder.  
 Cue-associated relapse increases in likelihood across abstinence. It is promising, 
however, that drug-induced synaptic plasticity and associated drug memories are 
reversible, as evidenced by the fact that human drug users show increased reactivity to 
drug-cues for up to 6 months but not at 1 year of abstinence (Parvaz et al., 2016). A critical 






changes in synaptic and structural plasticity in NAc, measured by a stable elevation in 
glutamate receptors and spine density, seen at 30 days of abstinence but not 1-day 
(Christian et al., 2017; Conrad et al., 2008; Wolf, 2016).  Such changes in plasticity and 
behavior dissipate by 180 days which suggests there are homeostatic mechanisms 
working to restore normal brain function (Wolf, 2016). Prior studies support the notion that 
gene expression in NAc underlies neuronal activity mediating the incubation of cocaine 
craving (Hollander & Carelli, 2007; Shaham & Hope, 2005). Our work identifies a molecular 
mechanism that reverses drug-induced pathology and is a potential inroad to therapeutic 
interventions in cocaine use disorders. Given the fact that most drug users are poly users, 
targeting a common mechanism that generalizes to other drugs is essential. While future 
experiments are needed to elucidate the long-term effects of this treatment on other drugs, 
and its role in attenuating cocaine SA, our current findings underscore the value in 
pursuing research on the mechanism of action of Nr4a1 in relapse behavior and cocaine 
use disorders in general.  
 In conclusion, our data support the role of Nr4a1 in activating Cartpt and 
suppressing cocaine-induced behavior in late abstinence. Locus-specific gene regulation 
allowed elucidation of the precise epigenetic mechanisms involved in Nr4a1 target gene 
activation, specifically the loss of repressive and gain of activating histone modifications 
at late abstinence. Finally, the availability of a small molecule agonist that crosses the 
blood-brain barrier to activate Nr4a1, in vivo, lends promise to the clinical relevance of our 









Figure 2.1. Cocaine increased Nr4a1 and changed promoter function. A. Timeline of 
cocaine self-administration (SA) (0.7 mg/kg/inf, 21 days) and abstinence (1-day and 28-
days). B. Cocaine SA mice responded significantly higher than saline self-administering 
mice (left, n=24 mice/group, two-way repeated measures ANOVA) and discriminated 
between active and inactive wheels, while saline mice responded equally (right, n=24 
mice/group, two-way repeated measures ANOVA) during 21-days of self-administration. 
*P<0.05. C. Volcano plot showing differentially expressed genes (DEGs), significantly 






1- and 28-days of abstinence. E. Gene Ontology (GO) analysis of DEGs at 1-day (Top) 
and 28-days (Bottom) of abstinence. P<0.05. F. Nr4a1 activation at 1-day of abstinence 
following cocaine SA measured by RNA-seq log2 fold change, q-value < 0.01 G. Nr4a1 
expression measured by qPCR in a biological replicate (n=6 mice/group, two-way 
ANOVA, followed by Tukey’s multiple comparisons test, P=0.0097). *P<0.05. H. Timeline 
of repeated investigator-administered (IA) cocaine (20 mg/kg; i.p.) and abstinence (1-day 
and 28-day). I. Cocaine activated Nr4a1 at 1-day (P=0.0001) but not 28-days of 
abstinence (P=0.9967), relative to saline controls (n=6-7 mice/group, two-way ANOVA, 
followed by Tukey’s multiple comparisons test). *P<0.05. J. Cocaine enriched Nr4a1 at 
the Nr4a1 promoter at 1-day (P=0.0343) and 28-days (P=0.0101) of abstinence, 
normalized to input, relative to saline controls (n=6 mice/group, two-way ANOVA, followed 
by Tukey’s multiple comparisons test). *P<0.05. K. Cocaine had no effect on H3K27me3 
enrichment at either 1-day or 28-days of abstinence, normalized to input, relative to saline 
controls (n=8 mice/group, two-way ANOVA, followed by Tukey’s multiple comparisons test 
P=0.0527) *P<0.05. L. Cocaine enriched H3K27ac at the Nr4a1 promoter at 28-days 
(P=0.0096), but not 1-day (P=0.0916) of abstinence, normalized to input, relative to saline 
controls (n=7-8 mice/group, two-way ANOVA, followed by Bonferroni’s multiple 
comparisons test). *P<0.05. M. Cocaine enriched H3K4me3 at the Nr4a1 promoter at 28-
days (P<0.0001) but not 1-day (P=0.9363) of abstinence, normalized to input, relative to 
saline controls (n=8 mice/group, two-way ANOVA, followed by Tukey’s multiple 


















Figure 2.2. Cocaine regulated Nr4a1 target genes and promoter function.  A. RNA-
seq measures activation of Cbl and Per2 following cocaine SA at 1-day of abstinence and 
Cartpt activation and Per2 repression at 28-days, log2 fold change normalized to saline 
controls, q-value < .001. B. qPCR following cocaine SA, in a biological replicate, identifies 
activation of Cbl (n=5-6 mice/group, two-way ANOVA, followed by Tukey’s multiple 
comparisons test, 1-day P=0.0099) and Per2 (n=5-6 mice/group, two-way ANOVA, 
followed by Tukey’s multiple comparisons test, 1-day P=0.0002) at 1-day of abstinence, 
no change in Cbl (P=0.1197) and repression of Per2 (P=0.046) at 28-days of abstinence, 
and Cartpt activation at 28-days (n=6 mice/group, two-way ANOVA, followed by Tukey’s 
multiple comparisons test, 28-days P=0.0112) of abstinence but not at 1-day (P=0.0934)  
of abstinence. *P<0.05. C. qPCR following repeated cocaine identifies Cartpt activation at 
28-days (n=6 mice/group, two-way ANOVA, followed by Tukey’s multiple comparisons 
test, 28-days P=0.0095 of abstinence but not at 1-day P=0.9987) of abstinence relative to 
saline controls. *P<0.05. D. Cocaine enriched Nr4a1 at the Cartpt promoter at 28-days 
(n=6 mice/group, two-way ANOVA, followed by Tukey’s multiple comparisons test, 28-
days P=0.0089) but not at 1-day of abstinence (P=0.6515), normalized to input, relative to 
saline controls. *P<0.05. E. Cocaine enriched H3K27me3 at the Cartpt promoter at 1-day 






P=0.0112) of abstinence and depleted H3K27me3 from the Cartpt promoter at 28-days 
(P=0.0381) of abstinence, normalized to input, relative to saline controls. *P<0.05. F. 
Cocaine enriched H3K27ac at the Cartpt promoter 1- and 28-days of abstinence (n=7-8 
mice/group, two-way ANOVA, followed by Tukey’s multiple comparisons test, 1-day 
P=0.0097, 28-days P=0.0461), normalized to input, relative to saline controls. *P<0.05. G. 
Cocaine enriched H3K4me3 at the Cartpt promoter at 1- and 28-days of abstinence (n=7-
8 mice/group, two-way ANOVA, followed by Tukey’s multiple comparisons test, 1-day 
P=0.0367, 28-days P=0.0297), normalized to input, relative to saline controls. *P<0.05. All 




























Figure 2.3. CRISPR regulation of Nr4a1 and target genes in vitro and in vivo. A. 
Neuronal expression of dCas9 via synapsin promoter (hSyn). Schematic of five sgRNAs 
relative to the transcription start site (TSS). B. sgRNA-231 and dCas9-VP64 activated 
Nr4a1 in N2a cells (n=6-11 mice/group, one-way ANOVA, followed by Bonferroni’s 
multiple comparisons test, NT vs. -231 P=0.0123, NT vs. -366 P=0.0148), normalized to 
GAPDH, and sgRNA-NT. *P<0.05. C. sgRNA-231 and dCas9-VP64 activated Cartpt in 
N2a cells (unpaired two-tailed t test, P=0.0411) normalized to GAPDH, and sgRNA-NT. 
*P<0.05. D. dCas9 and sgRNA-231 bind specifically at the Nr4a1 promoter (n=3 
mice/group, two-way ANOVA, followed by Tukey’s multiple comparisons test P<0.0001), 
but not at distal site (P=0.2338) normalized to input, relative to sgRNA-NT. *P<0.05. E. 
dCas9-VP64 colocalizes with NeuN+ cells in the NAc. Yellow arrow heads indicate 
NeuN+/dCas9-VP64+ cells. DAPI = Blue, dCas9 = Red, NeuN=Green, Anterior 
Commissure (AC). F. sgRNA-Nr4a1/dCas9-VP64  activated and sgRNA-Nr4a1/dCas9-
KRAB  repressed Nr4a1 in vivo (n=4-11 mice/group, one-way ANOVA, followed by 
Bonferroni’s multiple comparisons test, sgRNA-NT/dCas9-VP64 vs. sgRNA-
Nr4a1/dCas9-VP64 P=0.0039, sgRNA-NT/dCas9-KRAB vs. sgRNA-Nr4a1/dCas9-KRAB 
P=0.0483), normalized to GAPDH, and sgRNA-NT. *P<0.05 G. sgRNA-Nr4a1/dCas9-
VP64  activated Cartpt in vivo (n=8, unpaired two-tailed t test, P=0.0138), normalized to 
GAPDH, and sgRNA-NT. *P<0.05. H. sgRNA-Nr4a1/dCas9-KRAB repressed Cartpt in 
vivo (n=9-10, unpaired two-tailed t test, P=0.0033), normalized to GAPDH, and sgRNA-
NT. *P<0.05. I. dCas9-VP64 and sgRNA-Nr4a1  activated Nr4a1 and Cartpt at 4- and 7-
days but not at 14-days (Nr4a1: n=7-10 mice/group, two-way ANOVA, followed by 
Bonferroni’s multiple comparisons test, 1-day P=0.0225, 4-days P=0.0318, 14-days 
P>0.9999; Cartpt: n=7-10 mice/group, two-way ANOVA, followed by Bonferroni’s multiple 
comparisons test, 1-day P=0.0094, 4-days P=0.0359, 14-days P>0.9999), normalized to 
GAPDH, relative to sgRNA-NT. *P<0.05. J. dCas9-VP64 and sgRNA-Nr4a1 depleted 
H3K27me3 at the Cartpt promoter (n=5, unpaired two-tailed t test, P=0.0421), normalized 
to input, relative to saline controls. *P<0.05. K. dCas9-VP64 and sgRNA-Nr4a1 enriched 
H3K27ac at the Cartpt promoter (n=6, unpaired two-tailed t test, P=0.0280), normalized 
to input, relative to saline controls. *P<0.05. L. dCas9-VP64 and sgRNA-Nr4a1 caused no 
significant change in H3K4me3 at the Cartpt promoter (n=5, unpaired two-tailed t test, 
P=0.6851), normalized to input, relative to saline controls. *P<0.05. All error bars 



















Figure 4. CRISPR-mediated Nr4a1 regulation bidirectionally modulates cocaine 
behavior. A. Schematic of the cocaine conditioned place preference (CPP) paradigm and 
transfection time course. B. dCas9-VP64 and sgRNA-Nr4a1 attenuated CPP at two doses 
of cocaine (10 mg/kg, n=7 mice/group, two-way repeated measures ANOVA, followed by 
Bonferroni’s multiple comparison test, sgRNA-Nr4a1 vs -NT Pretest P>0.9999, Posttest 
P=0.0258; 20 mg/kg, n=7 mice/group, two-way repeated measures, followed by 
Bonferroni’s multiple comparison test, sgRNA-Nr4a1 vs -NT Pretest P>0.9990, Posttest 
P=0.0326), relative to sgRNA-NT. *P<0.05. C. dCas9-VP64 and sgRNA-Nr4a1 activated 
Cartpt following cocaine CPP (10 mg/kg: n=3, unpaired two-tailed t test, Nr4a1 P=0.606, 
Cartpt P=0.048; 20 mg/kg: n=7, unpaired two-tailed t test, Nr4a1 P=0.8667, Cartpt 
P=0.0112), normalized to GAPDH, and sgRNA-NT. *P<0.05. D. dCas9-KRAB and 
sgRNA-Nr4a1 enhanced CPP at two doses of cocaine (5 mg/kg: n=7 mice/group, two-way 
repeated measures ANOVA, followed by Bonferroni’s multiple comparison test, sgRNA-
Nr4a1 vs -NT Pretest P>0.9999, Posttest P=0.0057; 10 mg/kg: n=6-8 mice/group, two-
way repeated measures ANOVA, followed by Bonferroni’s multiple comparison test, 
sgRNA-NT Pretest P>0.9999, Posttest P=0.018), relative to sgRNA-NT. *P<0.05. E. 
dCas9-KRAB and sgRNA-Nr4a1 attenuated Cartpt following cocaine CPP (5 mg/kg: n=7, 
unpaired two-tailed t test, Nr4a1 P=0.724, Cartpt P<0.0001; 10 mg/kg: n=6-8, unpaired 
two-tailed t test, Nr4a1 P=0.4673, Cartpt P=0.046), normalized to GAPDH, and sgRNA-
NT. *P<0.05. F. Schematic of cocaine self-administration paradigm and transfection time 
course. G. dCas9-VP64 and sgRNA-Nr4a1 causes no significant changes in the 
acquisition of cocaine self-administration, (n=5-6 mice/group, two-way repeated measures 
ANOVA), relative to sgRNA-NT. *P<0.05. H. dCas9-VP64 and sgRNA-Nr4a1 causes no 
significant changes in cocaine-seeking at 1-day of abstinence (unpaired two-tailed t test, 
P=0.742), relative to sgRNA-NT. *P<0.05. I. Schematic of cocaine self-administration 
paradigm and transfection time course. J. There were no significant changes in the 
acquisition of cocaine self-administration, prior to Nr4a1 activation (n=6 mice/group, two-
way repeated measures ANOVA), relative to sgRNA-NT. *P<0.05. K. dCas9-VP64 and 
sgRNA-Nr4a1 attenuated cue-induced seeking behavior at 28-days of abstinence (n=6, 
unpaired two-tailed t test, P=0.009), relative to sgRNA-NT. *P<0.05. All error bars 
















Figure 2.5. Mechanism of Nr4a1 activation of homeostatic gene expression. In 
untreated mice, Cartpt is repressed. During early abstinence, Nr4a1 is activated and 
Cartpt is repressed by H3K27me3 enrichment but poised for later activation. During late 
abstinence, Nr4a1 expression returns to baseline, and Cartpt is activated by depletion of 










Supplementary Figure 2.1. Cocaine self-administration behavior RNA-Seq cohort. 
A. Cocaine self-administering mice responded significantly higher than saline self-
administering mice (n=24 mice/group, two-way repeated measures ANOVA). *P<0.05.  B. 
There were no significant differences in inactive spins (n=24 mice/group, two-way 
repeated measures ANOVA). *P<0.05.  C. 1- and 28-days cocaine self-administering mice 
infused similar amounts of drug (n=24 mice/group, two-way repeated measures ANOVA, 
followed by Bonferroni’s multiple comparisons test). *P<0.05.  D. 1- and 28-days cocaine 
self-administering mice responded similar across sessions (n=24 mice/group, two-way 
repeated measures, followed by Bonferroni’s multiple comparisons test). *P<0.05.  E. 1- 
and 28-days cocaine self-administering mice responded similar on inactive spins across 
sessions (n=24 mice/group, two-way repeated measures ANOVA, followed by 
Bonferroni’s multiple comparisons test). *P<0.05.  F. 1- and 28-days cocaine self-
administering mice discriminate between inactive and active spins across sessions (n=24 
mice/group, two-way repeated measures ANOVA, followed by Bonferroni’s multiple 











Supplementary Figure 2.2. PFC and VTA transcriptomics following 1- and 28-days 
of abstinence. A. Mice were sacrificed, and PFC collected at 1- and 28-days of 
abstinence and subjected to RNA-seq. Volcano plot showing differentially expressed 
genes (DEGs), significantly downregulated (Blue) and upregulated (red), q-value < 0.01. 
B. Comparison of DEGs at 1- and 28-days of abstinence, showing fewer. DEGs at 28-
days of abstinence compared to 1-day, with no overlapping genes. C. Gene Ontology 
(GO) analysis of DEGs at 1-day (Top) and 28-days (Bottom) of abstinence. DEGs cluster 
in GO biological process of antigen processing and presentation (1-day) and estrogen 
metabolic process (28-day) D. Mice were sacrificed and VTA collected at 1- and 28-days 
of abstinence and subjected to RNA-seq. Volcano plot showing differentially expressed 
genes (DEGs), significantly downregulated (Blue) and upregulated (red), q-value < 0.05. 
E. Comparison of DEGs at 1- and 28-days of abstinence, showing a greater number of 
DEGs at 28-days of abstinence compared to 1-day, with few overlapping genes. F. Gene 
Ontology (GO) analysis of DEGs at 1-day (Top) and 28-days (Bottom) of abstinence. 
DEGs cluster in GO biological process of cell adhesion (1-day) and nervous system 







Supplementary Figure 2.3. Behavior data of RNA-Seq replication cohort. A. 1- and 
28-days cocaine self-administering mice infused similar amounts of drug (n=24 
mice/group, two-way repeated measures ANOVA, followed by Bonferroni’s multiple 
comparisons test). *P<0.05.  B. 1- and 28-days cocaine self-administering mice 
responded similar across sessions (n=24 mice/group, two-way repeated measures, 
followed by Bonferroni’s multiple comparisons test). *P<0.05.  C. 1- and 28-days cocaine 
self-administering mice responded similar on inactive spins across sessions (n=24 
mice/group, two-way repeated measures ANOVA, followed by Bonferroni’s multiple 
comparisons test). *P<0.05. D. 1- and 28-days cocaine self-administering mice 
discriminate between inactive and active spins across sessions (n=24 mice/group, two-
way repeated measures ANOVA, followed by Bonferroni’s multiple comparisons test). All 







Supplementary Figure 2.4. qPCR validation of RNA-Seq A. DEGs at 1-day of abstinence 
following cocaine SA measured by RNA-seq log2 fold change normalized to saline 
controls, q-value < 0.01 B. Validation of DEGs at 1-day of abstinence by qPCR in a 
biological replicate following cocaine SA (n = 6, unpaired two-tailed t test, Fmo2 P=0.002, 
Ccdc141 P=0.0326, Mertk P=0.0048, Nr4a3 P=0.0009, Kirrel2 P=0.0179, *P<0.05), 
relative to saline controls (grey circles). *P<0.05. C. DEGs at 28-day of abstinence 
following cocaine SA measured by RNA-seq log2 fold change normalized to saline 
controls, q-value < 0.01 D. Validation of DEGs at 28-day of abstinence by qPCR in a 
biological replicate following cocaine SA (n = 6, unpaired two-tailed t test, E2f1 P=0.0136, 
Mark2 P=0.0163, Ndn P=0.0235, Robo  P=0.013,  *P<0.05), relative to saline controls 







Supplementary Figure 2.5. Nr4a1 binding in promoter regions of genes differentially 
expressed at 1-day and 28-days of abstinence. A. Nr4a1 was enriched at the Nr4a1, Cbl, 
Per2, and Cartpt, promoters (One-way ANOVA; Nr4a1 P=0.0114, Cbl P<0.0001, Per2 P= 
0.0031, Cartpt P=0.0188) but not at distal sites (Distal P>0.9999), normalized to percent 













Supplementary Figure 2.6. dCas9, NeuN+ and DAPI IHC in the NAc. A. dCas9-VP64 
colocalizes with NeuN+ cells in the NAc. Plasmid hemisphere (right) transfected with 
dCas9 alone and control hemisphere transfected with reagent alone. Yellow arrow heads 
indicate NeuN+/dCas9-VP64+ cells. White arrows indicate NeuN-/Cas9- cells. DAPI = 































Supplementary Figure 2.7. Total distance traveled in cocaine CPP A. There were no 
significant differences in distance traveled when comparing sgRNA-Nr4a1 to control NT 
at pretest and posttest (10 mg/kg, n=7 mice/group, two-way repeated measures ANOVA), 
*P<0.05.  B. There were no significant differences in distance traveled when comparing 
sgRNA-Nr4a1 to control NT at pretest and posttest when comparing sgRNA-Nr4a1 to 
control NT (20 mg/kg, n=7 mice/group, two-way repeated measures ANOVA, *P<0.05.  C. 
There were no significant differences in distance traveled when comparing sgRNA-Nr4a1 
to control NT at pretest and posttest (5 mg/kg, n=7 mice/group, two-way repeated 
measures ANOVA, *P<0.05.  D. There were no significant differences in distance traveled 
when comparing sgRNA-231 to control NT at pretest and posttest (10 mg/kg, n=7 













Supplementary Figure 2.8. CRISPR-mediated activation of Nr4a1 and cocaine SA A. 
No significant effect of treatment on food training prior to transfection and cocaine SA 
(n=5-6 mice/group, two-way repeated measures ANOVA, *P<0.05. B. No significant effect 
of treatment on infusions following CRISPR-mediated Nr4a1 activation (n=5-6 mice/group, 
two-way repeated measures ANOVA *P<0.05.  C. No significant effect of treatment on 
inactive nose pokes (n=5-6 mice/group, two-way repeated measures ANOVA, *P<0.05.  
D. No significant effect of treatment on the discrimination index (n=5-6 mice/group, two-
way repeated measures ANOVA, *P<0.05.  E. No significant effect of treatment on 
infusions (saline) on 1-day seeking test (n=5-6, unpaired two-tailed t test, P=0.742). 
*P<0.05. F. No significant effect of treatment on the discrimination on 1-day seeking test 
(n=5-6, unpaired two-tailed t test, P=0.717).*P<0.05.  G. No significant effect of treatment 








Supplementary Figure 2.9. CRISPR-mediated activation of Nr4a1 and cocaine 
seeking A. No significant effect of treatment on in food training prior to transfection and 
cocaine SA (n=6 mice/group, two-way repeated measures ANOVA,*P<0.05.  B. No 
significant effect of treatment on infusions during acquisition of cocaine SA (n=6 
mice/group, two-way repeated measures ANOVA, *P<0.05.  C. No significant effect of 
treatment on inactive nose pokes during acquisition of cocaine SA (n=6 mice/group, two-
way repeated measures ANOVA, *P<0.05. D. No significant effect of treatment on the 
discrimination index during acquisition of cocaine SA (n=6 mice/group, two-way repeated 
measures ANOVA, *P<0.05.  E. CRISPR-mediated Nr4a1 activation attenuated cocaine-
seeking at 28-days of abstinence measured by the number of saline infusions (n=6, 
unpaired two-tailed t test, P=0.0037). *P<0.05.  F. No significant effect of treatment on 






*P<0.05.  G. No significant effect of treatment on inactive nose pokes on 28-day seeking 
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Despite the prevalence of cocaine use disorder, there is currently no medicine available 
that prevents or reduces relapse. Using fundamental approaches, we recently discovered 
that activation of orphan nuclear receptor, Nr4a1, regulates abstinence-induced gene 
expression important in the suppression of cocaine associated memories. Nr4a1 is a 
ligand-activated transcription factor and therefore a highly attractable biological target. 
This thesis will test both a new target – Nr4a1 – and a new therapeutic approach – 
druggable transcription factors – as treatment modalities in cocaine use disorder. First, to 
validate this target we used CRISPR activation and repression tools and demonstrate the 
direct causal role of Nr4a1 in the activation of downstream target gene, Cartpt. Then using 
a small molecule activator of Nr4a1, we confirm the role of Nr4a1 in both the prevention 
and reversal of cocaine seeking behavior. We posit that Nr4a1 activated homeostatic 
mechanisms in the brain that reduces the propensity for relapse via epigenetic regulation 
of gene expression. In addition, our confirmatory research strategy provides preclinical 
evidence of small molecule activators in the activation of Nr4a1 in brain. In our final study, 
we show a direct effect of Nr4a1 in the suppression of cocaine memories and produced 











 National rates of cocaine use have risen over recent years with approximately 2.2 
million regular users reported in 2019 (Butler et al., 2017; John & Wu, 2017; Kerridge et 
al., 2019). The current standard in treatment is psychosocial intervention which is 
burdened by high dropout rates and short periods of abstinence (Kampman, 2019; Stitzer 
et al., 2010). Despite these alarming statistics, no medications have been approved for 
cocaine abuse. A core feature of cocaine use disorders is the propensity for relapse during 
abstinence (Shaham & Hope, 2005). To combat relapse, endogenous homeostatic 
mechanisms may restore and even reverse normal function to reward-related brain areas 
(Huang et al., 2011; Keramati et al., 2017). As cocaine use disorder can only be identified 
in afflicted patients, identification of a homeostatic molecular mechanism across cocaine 
abstinence has important therapeutic implications. Recently, we and others have analyzed 
gene expression across abstinence, identifying Nr4a1 as a central transcriptional regulator 
in the nucleus accumbens (NAc) (Carpenter et al., 2020; Walker et al., 2018). The family 
of nuclear receptors, Nr4a1-3, regulate drug behavior via activation of downstream, 
dopaminergic target genes. Nr4a1-3 (1) are activated in brain reward areas by cocaine 
SA and abstinence, (2) mediate drug-induced behaviors (Bourhis et al., 2009; Carpenter 
et al., 2020; Koo et al., 2015) and (3) are reduced in postmortem brains of cocaine users 
(Albertson et al., 2004; Bannon et al., 2005). Importantly, we applied rigorous target 
validation tools to fully interrogate Nr4a1 in mouse brain regions following cocaine self-
administration (SA). These included data mining and CRISPR activation to validate Nr4a1 
has a viable target gene for cocaine use disorders. Importantly, an endogenous ligand 
that binds Nr4a1 with high affinity, docosahexaenoic acid (DHA), is prominent in brain, 






Branchey et al., 2009, 2011; Vinayavekhin & Saghatelian, 2011).  This biology has 
inspired the proposed use of synthetic Nr4a1 agonists to protect against cocaine relapse.  
 We propose that activation of Nr4a1 is beneficial in treating cocaine use disorder. 
The octaketide, Cytosporone B (Csn-B), a naturally occurring Nr4a1 agonist isolated from 
Dothiorella sp HTF3, an endophytic fungus, Csn-B, has strong affinity for Nr4a1 (EC50 = 
.278 nm) and molecular modeling infers physical binding (Y. Zhan et al., 2008). The 
components of the pharmacophore necessary for Csn-B binding to Nur77 included the 
benzene ring, the phenolic hydroxyl group, and the acyl chain of the Csn-B scaffold, 
whereas the key feature for activating the biological function of Nur77 was the ester group 
(J. Liu et al., 2010). In non-malignant cells Csn-B regulates transactivational activity of 
Nr4a1 and acts as a checkpoint for normal repair processes (Egarnes et al., 2017; T. Y. 
Liu et al., 2017; Palumbo-Zerr et al., 2015; Rothe et al., 2017; Y. Zhan et al., 2008). 
Importantly, Csn-B does not exert any of these effects in Nr4a1-null cells, indicating a 
Nr4a1-dependent effect of Csn-B (Egarnes et al., 2017; T. Y. Liu et al., 2017; Palumbo-
Zerr et al., 2015; Y. Zhan et al., 2008). Various derivatives of Csn-B also induce autophagy 
and inhibit inflammation (G.-Q. Chen et al., 2019). RNAseq analysis have shown that 
treatment with specific C-DIM/NR4A1 ligands or Nr4a1 overexpression results in both 
induced and repressed gene expression (Duren et al., 2016). Thus, Nr4a1 is a ligand-
activated transcription factor and therefore a highly attractable biological target. This 
chapter will test both a new target – Nr4a1 – and a new therapeutic approach – druggable 
transcription factors – as treatment modalities in cocaine use disorder. 
Methods 
Animals 
 Adult male and female, 8-week-old C57BL/6J mice (The Jackson Laboratory) were 






(23°C) with access to food and water ad libitum. Animals were habituated to experimenter 
handling for at least 1 week before experimentation. All animals were maintained 
according to National Institutes of Health guidelines in Association for Assessment and 
Accreditation of Laboratory Animal Care.  Ethical and experimental considerations were 
approved by the Institutional Animal Care and Use Committee of The University of 
Pennsylvania. 
Cytosporone B Treatment 
Mice were group housed and habituated to the researcher for 3-days by daily handling 
sessions. Cytosporone B (Sigma-Aldrich) reconstituted with DMSO was freshly dissolved 
in 0.9% saline and injected i.p. (10 mg/kg)(Egarnes et al., 2017; Y. Zhan et al., 2008). 
Mice were either treated with single or repeated injections (twice-daily injections for 4 
days). Control mice were injected with DMSO diluted in saline (0.9% saline). The final 
concentration of DMSO was no more than 1%. 
Conditioned place preference  
 Mice were placed in a two-sided conditioning chamber (Ugo Basile) for 20 min to 
assess innate pretest preferences. Mice were then conditioned for 2-days to associate 
cocaine with their non-preferred side. Mice were injected in the morning with cocaine and 
in the afternoon with saline (i.p., 10 mg/kg), then restricted to their preferred chambers 
and non-preferred, respectively, for 30 min. On day 4, mice were placed in the chamber 
with free access to both sides for a 20 min post-test session to assess conditioned place 
preference. ANY-Maze (version 4.99) software was used to analyze time and total 
distance traveled. NAc tissue was collected 4 hours following the post-test session. 
Cocaine preference for all testing sessions was calculated as time spent in the cocaine-
paired chamber minus time spent in the saline-paired chamber and is reported as a 






the average cocaine preference score of the cocaine-treated group was significantly 
higher than the preference score at baseline (Burgdorf et al., 2017). Csn-B was 
administered twice daily for 4 days prior to the pretest or acutely 6 hours before the post-
test.  
Single Sample RNA extraction and Chromatin Immunoprecipitation (S3EQ) 
S3EQ was conducted on NAc 1.2 mm bilateral punches dissected as described above (1 
mouse/sample), 6 hours following acute administration and 1-day and 4-days following 
repeated administration. Tissue was homogenized in cell lysis buffer (10mM Tris Hcl pH 
8.1, 10mM NaCl, 3mM MgCl2, 0.5% Np-40). Low speed centrifugation (1000xg) separated 
the cytosol (supernatant) from the nuclei (pellet). RNA was isolated from the supernatant 
using the RNeasy Mini Kit (Qiagen) according to the manufacturer instructions. RNA 
concentration and integrity were determined using a Nanodrop spectrophotometer 
(Nanodrop Technologies, Wilmington, DE) and the RNA NanoChip on the Bioanalyzer 
(Agilent), respectively. All RNA samples were of good quality (RIN above 8) and purity 
(1.9 +/- 0.1). cDNA was synthesized from RNA (100ng) using the iScript cDNA Synthesis 
Kit (Life Technologies). Quantitative real-time PCR (qRT-PCR) was conducted on the 
QuantStudio 7 Flex Real-Time PCR System (ThermoFisher). Ct values of the 
experimental group to control using the ΔΔCt method (Livak & Schmittgen, 2001). Primer 
sequences can be found in Supplementary Table 1.  
 Nuclei were mildly fixed in 1% formaldehyde for 6 minutes and the reaction was 
terminated with glycine and pelleted by centrifugation (5500xg). Fixed nuclei were 
resuspended in nuclear isolation buffer (50mM Tris pH 8.1, 5mM EDTA, 1% SDS) and 
chromatin was sheared using a diogenode bioruptor XL at high sonication intensity. For 
histone modification enrichment, chromatin was sheered for 30 min (30 s on/30 s off) and 






chromatin was incubated overnight with H3K27me3 (EMD Millipore 07-449) previously 
bound to magnetic beads (Dynabeads M-280, Life Technologies): The Dynabeads were 
washed twice each with 1 ml of Low Salt Wash Buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 
2 mM EDTA, 1% TritonX-100, 0.1% SDS), High Salt Wash Buffer (20 mM Tris, pH 8.0, 
500 mM NaCl, 2 mM EDTA, 1% TritonX-100, 0.1% SDS), and TE Buffer (10 mM Tris, pH 
8.0, 1 mM EDTA). After reverse cross-linking and DNA purification (Qiagen Spin Column), 
primers were designed to amplify regions ~150-200 within gene promoter regions. 
Results 
Csn-B activated Nr4a1 and attenuated cocaine behavior 
 Given our findings that Nr4a1 activation attenuated cocaine CPP and cocaine-
seeking following abstinence, we investigated the therapeutic potential of its 
pharmacological activation. Although an endogenous ligand for Nr4a1 has not been 
identified, the naturally occurring small molecule Cytosporone-B (Csn-B) induces activity 
and subsequent transcription of Nr4a1 in vivo (Y. Zhan et al., 2008). Indeed, both acute 
(6 hrs) and repeated (8 injections total/2x per day for 4 days; 1- and 4-days post injection) 
systemic administration of Csn-B activated Nr4a1 in the NAc (Fig. 3.1A, B). Furthermore, 
acute administration of Csn-B activated Cartpt but repeated administration had no effect 
on Cartpt activation at 1-, but not 4-days following repeated Csn-B administration (Fig. 
3.1C). Acute administration of Csn-B enriched H3K27me3 and H3K4me3, but not 
H3K27ac at the Cartpt promoter (Fig. 3.1D-F). There were no changes in the enrichment 
of H3K27me3, H3K4me3 or H3K27ac following repeated Csn-B administration (Fig. 3.1D-
F). Finally, we conducted cocaine CPP following repeated injections of Csn-B and found 
attenuated cocaine-preference (Fig. 3.1G, H), accompanied by increased Nr4a1 and 
Cartpt activation, compared to DMSO-injected controls (Fig. 3.1I). As expected, an acute 






Cartpt (Fig. 3.1J-L). There was no difference in total distance traveled between groups, a 
measure a baseline locomotor activity (Supplementary Fig. 2.2E-H). Taken together, Csn-
B administration was sufficient to activate Nr4a1 in the NAc and enhanced homeostatic 
gene expression via epigenetic mechanisms and attenuate cocaine CPP. 
Discussion 
 Our results indicate the preclinical efficacy of Csn-B, a small-molecule agonist of 
Nr4a1, in activating Nr4a1 in NAc, attenuating cocaine behavioral responses, and 
enhancing homeostatic gene transcription. This result is consistent with our previous 
studies showing that Nr4a2 is critical in the suppression of cocaine memories using 
CRISPRa (Carpenter et al., 2020). We found that Cartpt activation is associated with 
increased enrichment of H3K27me3 and H3K4me3 following acute of administration of 
Csn-B. In contrast, we found no changes in Cartpt activation or hPTMs following repeated 
Csn-B treatment, which suggests that changes in H3K27me3 and H3K4me3 after acute 
administration are early events indirectly involved in gene activation. It is important to note 
that we have not tested the effect of Csn-B on delayed activation of Cartpt at later time 
points which may explain the absence of changes in gene expression and hPTMs 
following repeated Csn-B administration. Despite these inconsistencies, we found that 
both acute and repeated systemic administration of Csn-B attenuated cocaine CPP and 
activated Cartpt. This psychostimulant specific effect suggests cocaine and Nr4a1 induce 
synergistic effects on cocaine activation of Cartpt.  
 In addition to Csn-B, several exogenous ligands have been shown to be effective 
in regulating Nr4a1 genomic and non-genomic functions. Of these, Csn-B derived analogs 
have been developed as a novel group of potent and effective cancer agents.  N-pentyl 2-
[3,5-dihydroxy-2-(1-nonanoyl)-phenyl] acetate (PDNPA) targets the LBD of Nr4a1, 






Li et al., 2015).  1-(3,4,5-trihydroxyphenyl)-nonan-1-one (THPN), another Csn-B 
derivative, inhibits melanoma growth via and autophagic mechanism (W. Wang et al., 
2014). Whereas, another derivative Ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)-phenyl] 
acetate (TMPA) suppresses the phosphorylation of adenosine 5′-monophosphate-
activated protein kinase α (AMPKα) and thus efficacious for the treatment of metabolic 
disorders (Yan-yan Zhan et al., 2012). Importantly, PDNPA THPN, and TMPA do not 
function in Nr4a1 null mice (L. Li et al., 2015; W. Wang et al., 2014; L. Wu & Chen, 2018; 
Y. Zhan et al., 2008; Yan-yan Zhan et al., 2012). Collectively, data suggest Csn-B 
derivatives regulate Nr4a1 translocation from the nucleus to the mitochondria which 
suggest these molecules have both genomic functions and non-genomic functions (L. Wu 
& Chen, 2018). Cytoplasmic Nr4a1 is associated with apoptosis whereas nuclear 
localization is associated with a pro survival phenotype in cancer cells (Safe & Karki, 
2020). More broadly, however, there is a lack of research on the function of Nr4a1 
pharmacological activators in non-cancer cells, although it is clear that under similar 
conditions, Csn-B and derivatives, do not induce apoptosis in non-cancer cells (Safe & 
Karki, 2020).   
 Another set of molecularly distinct compounds known collectively as C-DIMs 
agonize or antagonize Nr4a1 depending on the exact molecule and cell-type. C-DIMs are 
analogs based on a metabolic product in the GI tract of the natural compound indole-3-
carbinole (I3C) (Schwartz & Ginsberg, 2002; S. Wang et al., 2016). Through luciferase 
activation assays and BIAcore binding studies, it has been demonstrated that some C-
DIMs bind with high affinity to Nr4a1. Most Nr4a1 studies are in cancer where the 
compounds act as inverse agonist and block Nr4a1-dependent pro-oncogenic responses 
(Lee et al., 2010; Lee and Jin, et al., 2014). In contrast, they act as agonists in muscle 






treatment induces activation, repression or no change of downstream Nr4a1 target gene 
expression depending on the cell-type (Duren et al., 2016; Syng-Ook Lee et al., 2009). 
Future studies will be necessary to determine the cell-type specificity of Nr4a1 activation 
and potential non-specific effects. 
 Outside the brain, Nr4a1 is detected at varying high levels in the adrenal cortex, 
lungs, prostate, ovaries, and testes (Su et al., 2004). In line with this fact, the general 
consensus is that Nr4a1 plays a role in cellular proliferation, apoptosis and fuel utilization 
important in the maintenance of homeostasis across tissue (Bridi et al., 2017; 
Mohankumar et al., 2018; Safe et al., 2016; C.-S. Wu et al., 2018). It is reasonable to 
presume that downstream expression of Nr4a1 target genes and physiological responses 
are dictated by cellular phenotype. Thus, cell-type specific chromatin architecture may 
regulate Nr4a1 binding and target gene activation (Arvey et al., 2012; Keilwagen et al., 
2019; Marstrand & Storey, 2014).  For example, Nr4a1 plays a critical role in T-cell 
differentiation and has been studied for over 30 years (Kurakula et al., 2014). Global loss 
of Nr4a1 activation mediates T-cell exhaustion via the enrichment of H3K27ac and 
activation of tolerance related gene expression  (J. Chen et al., 2019; Xindong Liu et al., 
2019). Thus, in this context, Nr4a1 activation is detrimental to immune function and 
caution must be taken when evaluating systemic activation of Nr4a1. Therefore 
concentration dependent effects must be considered when using global KO and viral 
mediated over expression strategies that induce Nr4a1 outside of the physiological range 
(J. Chen et al., 2019; Xindong Liu et al., 2019). Using stable neuronal cell lines with graded 
Nr4a1 gene expression and transcriptome profiling assays, data shows that Nr4a1 
expression results in concentration dependent effects on target gene expression (Duren 
et al., 2016; M. M. Johnson et al., 2011). Nr4a1 recruits histone modifying enzymes to 






example, the compound tamoxifen is an ER inverse agonist in breast cancer while it is an 
agonist in other tissues via the recruitment of cell-type specific transcriptional 
regualtors(Alramadhan et al., 2016; Xian Liu & Shi, 2015). Thus, gene regulatory 
strategies that modulate gene expression within the physiological range may show 
profound differences in cell function 1,2. To parse these interactions and potential toxicities 
associated with systemic Nr4a1 activation, it will be essential to define Nr4a1 function in 
a tissue and cell type specific manner using physiological relevant levels of gene 
modulation.   
 Based on our findings illustrating the pre-clinical efficacy of Csn-B in activating 
Nr4a1 expression and suppressing cocaine conditioned place preference, we propose 
that pharmacological activation of Nr4a1 can be used to as a novel pharmacotherapy for 
cocaine use disorders. Although the safety profile of systemic Nr4a1 activation should be 








Figure 3.1. Csn-B activated Nr4a1 and attenuated cocaine behavior. A. Timeline of 
Csn-B administration (10mg/kg) acute and repeated (2x daily, 4 days). B. Nr4a1 was 
activated after acute and repeated Csn-B treatment (n=5 mice/group; two-way ANOVA, 
followed by Bonferroni’s multiple comparisons test, 6hrs P=0.028, 1-day P=0.0174, 4-days 
P=0.0168), normalized to GAPDH, relative to DMSO controls. *P<0.05. C. Csn-B 






(two-way ANOVA, followed by Tukey’s multiple comparisons test, 6hrs P=0.0307, 1-day 
P>0.9999; 4-day P=0.0978), normalized to GAPDH, relative to DMSO controls. *P<0.05. 
D. Acute Csn-B administration enriched H3K27me3 at the Cartpt promoter (n=6 
mice/group; two-way ANOVA, followed by Tukey’s multiple comparisons test, 6hrs 
P=0.0276), normalized to input, relative to DMSO controls. *P<0.05. E. There were no 
significant change in H3K27ac enrichment following acute and repeated Csn-B 
administration (n=6 mice/group; two-way ANOVA, followed by Tukey’s multiple 
comparisons test, 6hrs P=0.0276), normalized to input, relative to DMSO controls. 
*P<0.05 F. Acute Csn-B administration enriched H3K4me3 at the Cartpt promoter (n=6 
mice/group; two-way ANOVA, followed by Tukey’s multiple comparisons test, 6hrs 
P=0.033), normalized to input, relative to DMSO controls. *P<0.05. G. Schematic of 
cocaine conditioned place preference (CPP) paradigm and Csn-B administration time 
course. H. Repeated Csn-B administration (green circles) attenuated cocaine CPP (n=7 
mice/group, two-way repeated measures ANOVA), relative to DMSO control. *P<0.05. I. 
Repeated Csn-B administration activated Nr4a1 and Cartpt following cocaine CPP (n=7-
8, unpaired two-tailed t test, Nr4a1 P=0.0157, Cartpt P=0.005), normalized to GAPDH, 
relative to DMSO. *P<0.05. J. Schematic of cocaine conditioned place preference (CPP) 
paradigm and Csn-B administration time course. K. Acute Csn-B administration inhibited 
cocaine CPP (n=7 mice/group, two-way repeated measures ANOVA) relative to DMSO 
control. *P<0.05. L. Acute Csn-B administration activated Nr4a1 and Cartpt following 
cocaine CPP (n=7, unpaired two-tailed t test, Nr4a1 P=0.0404, Cartpt P=0.0075), 




















Supplementary Figure 3.1 Total distance traveled. There were no significant 
differences in distance traveled when comparing Csn-B to control DMSO at pretest and 
posttest (repeated Csn-B, n=9 mice/group, two-way repeated measures ANOVA, 
*P<0.05. F. There were no significant differences in distance traveled when comparing 
Csn-B to control DMSO at pretest and posttest (10 mg/kg, n=8 mice/group, two-way 
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Histone post-translational modifications (HPTMs) regulate neuronal gene expression via 
chromatin accessibility and transcription factor recruitment. Yet, current protocols for 
global hPTM profiling lack resolution at low cell numbers recovered from a single mouse. 
Consequently, correlating cell type specific epigenetic regulation to behavioral phenotypes 
remains elusive. Here, we combined several burgeoning techniques, including INTACT, 
CUT&RUN and CRISPRa, to interrogate transcriptomic and epigenetic features of striatal 
MSNs subtypes, D1 or A2a. First, we confirmed consistent expression of cell type specific 
markers in isolated nuclei. Second, A2a-specific Nr4a1 CRISPRa activated CArtpt 
expression similar to bulk CRISPRa. Then, using integrative analyses of epigenomic 
profiles, we quantified hPTM enrichment associated with cell type specific gene 
expression. Taken together, our approach enables the dissection of cell type specific gene 








 Epigenetic regulation in the heterogenous brain remains challenging to decipher. 
Bulk tissue analysis quantifies the  weighted proportion of cell type specific changes, which 
impedes the interpretability of causal relationships between epigenetic modifications, 
regulation of gene expression and behavior (Feng et al., 2014; Gajewski et al., 2019; 
Lepack et al., 2020; Werner et al., 2019). Cell type specific RNA-seq has proven to be 
valuable for the deconvolution of bulk tissue RNA-seq data sets but cell type specific 
epigenomic profiling in brain is only emerging (Armand et al., 2021; Zhu et al., 2020, 2021). 
Fortunately, recent advances in technology have facilitated cell type specific epigenetic 
profiling without the requirement of single cell biology (Agrawal et al., 2019; Avila Cobos 
et al., 2020; Lawler et al., 2020; Mo et al., 2015). Data support the notion that pathogenic 
epigenetic phenotypes result from cell type specific abnormalities (Y. Kim et al., 2018; Nott 
et al., 2019; R. H. Reynolds et al., 2019; N. G. Skene et al., 2018). A given cell type may 
be one of many types affected by a common pathology, or intrinsic factors perturb the 
function of a single type leading to dysfunction. For example, in Parkinson’s disease, 
studies show disease neuropathology is associated with global dysfunction across several 
different cell types, including MSNs (R. H. Reynolds et al., 2019). In contrast, genomic loci 
implicated in schizophrenia map specifically to MSNs rather than interneurons, astrocytes, 
or glia (Mendizabal et al., 2019; N. G. Skene et al., 2018). In fact, many of the 
schizophrenia related genes are targets of anti-psychotic medications (Y. Kim et al., 2018; 
N. G. Skene et al., 2018). Cell type specific analysis allows for more accurate prediction 
of therapeutic strategies.  
 In the striatum, D1 and A2a-MSNs have complimentary, opposing, or restricted 
roles in motivated behavior (R. Chandra et al., 2015; Ramesh Chandra et al., 2017; Engeln 






make up 75-80% of the neuronal population but only 20-30% of the total cell population 
(Ernst et al., 2014). D1-MSNs project to the ventral pallidum, globus pallidum internal, 
ventral tegmental area (VTA), and substantia nigra, whereas A2a-MSNs project to ventral 
pallidum (Smith et al., 2013). Cell type specific gene expression further defines these 
subpopulations, such that pharmacological activation of D1-MSNs promote motivated 
behaviors and pharmacological activation of A2a-MSNs generally inhibit this behavior 
(Kupchik et al., 2015; Smith et al., 2013). Conversely, depending on the temporality of 
optogenetic stimulation, activation of A2a-MSNs enhances motivation to obtain drug (Cole 
et al., 2018; Soares-Cunha et al., 2016, 2020). We show Nr4a1 activation in non-specific 
neuronal populations attenuated cocaine reward and Nr4a1 repression enhanced reward 
(Carpenter et al., 2020). Although these findings give some insight into the functional 
relevance of Nr4a1 in cocaine mediated behavior, they do not provide insight into the 
circuit or cell type responsible for the observed behavioral changes. Further investigations 
are required for the elucidation of specific pathways involved in the casual mechanisms of 
sustained transcription and the validation of key genetic targets for the treatment of brain 
disorders.  
 Chromatin immunoprecipitation (ChIP) sequencing has been widely used to profile 
transcription factor binding and histone modifications in specific neuronal cell populations 
but several technical limitations impede its widespread use (Kidder et al., 2011; Y. Kim et 
al., 2018; Ian Maze et al., 2014; Nott et al., 2019; R. H. Reynolds et al., 2019; N. G. Skene 
et al., 2018). 1.) ChIP-seq requires a large number of cells that may not be readily 
accessible. At low cell numbers, the reliability and sensitivity of detecting small changes 
is greatly diminished (Kidder et al., 2011; Ian Maze et al., 2014). This drives investigators 
to pool cells across subjects, which hinders downstream correlation to individual animal 






by the isolation technique (Emmert-Buck et al., 1996; Lawler et al., 2020; Mo et al., 2015; 
Sugino et al., 2006). Fluorescence activated cell sorting (FACS) facilitates isolation of 
sufficient cell numbers but cellular stress contributes to increased background signal 
related to shearing of DNA (P. J. Skene & Henikoff, 2017). To compensate for high 
background signal, data is normalized to input chromatin, requiring greater sequencing 
costs. 3.) Formaldehyde fixation required for many ChIP protocols introduces false 
positive interactions and reduces the efficiency of immunoprecipitation by masking protein 
epitopes (Baranello et al., 2016; Jain et al., 2015; Meyer & Liu, 2014). ChIP can be 
conducted without cross-linking, but problems still remain, such as insufficient binding 
efficiency (P. J. Skene & Henikoff, 2017). To overcome these limitations, we utilized affinity 
purification by INTACT (isolation of nuclei tagged in specific cell types) and target 
digestion by ‘Cleavage Under Targets and Release Using Nuclease’ (CUT&RUN) to 
generate robust epigenomic profiling data at a fraction of the read depth required by ChIP-
Seq.  
Preliminary data support the hypothesis that Nr4a1 activates persistent gene 
expression across cocaine abstinence via deenrichment of the repressive histone 
modification, H3K27me3 (Carpenter et al., 2020). Because Nr4a1 regulates cell type 
specific functions and many cell types express Nr4a1, including both A2a and D1-MSNs 
s, additional data are needed to directly connect the homeostatic function of Nr4a1 and 
the observed suppression of cocaine seeking. The central hypothesis of Chapter 4 is that 
cocaine-induced Nr4a1 target gene regulation in direct (D1-expressing) or indirect 
pathway (A2A-expressing) MSNs plays a functional role in cocaine-mediated behavior. 
Here we present a robust method for the isolation, characterization and manipulation of 
cell type specific gene expression in neurons. First, we isolated D1+ and A2a+ nuclei of 






type specific gene expression patterns, we profiled both repressive and activating histone 
modifications, H3K27me3 and H3K4me3, respectively. Recent data suggest that these 
marks are important regulators of poised transcription and may persistently regulate 
activity dependent gene expression (Bernstein et al., 2006; Margaritis & Holstege, 2008; 
Voigt et al., 2013). We used cell type specific Nr4a1 CRISPRa to determine the sufficiency 
of each MSN subtype in suppressing of cocaine reward behavior following activation of 
Nr4a1 expression. (Figure 4.1). Using this approach, we overcame previous limitations in 
identifying cell type specific gene expression changes and behavioral consequences.  
Methods 
Animals  
R26-CAG-LSL-Sun1-sfGFP knock-in mouse were crossed with A2a-Cre and D1-Cre mice 
to generate Sun1-sfGFP;A2a-Cre and Sun1-sfGFP;D1-Cre mouse lines. Mice were 
housed on a 12-h light-dark cycle at constant temperature (23°C) with access to food and 
water ad libitum. Mice were sacrificed between the ages of 8-12 weeks, brains were 
dissected in ice-cold homogenization buffer (0.25M sucrose, 25mM KCl, 5mM MgCl2, 
20mM Tricine-KOH), snap frozen on dry ice. All animals were maintained according to 
National Institutes of Health guidelines in Association for Assessment and Accreditation 
of Laboratory Animal Care. Ethical and experimental considerations were approved by the 
Institutional Animal Care and Use Committee of The University of Pennsylvania. 
INTACT 
INTACT was conducted as previously described with minor modifications (Mo et al., 2015). 
Briefly, frozen bilateral striatum of mouse was homogenized in 1.2 ml buffer HB 
supplemented with 1mM DTT, 0.15mM spermine, 0.5mM spermidine, and EDTA-free 






In qPCR experiments, RNasin Plus RNase Inhibitor (Promega N2611) was added to the 
antibody and bead buffers. Then 5% IGEPAL-630 solution was added to obtain .3%, and 
further homogenized with the tight pestle (7 strokes). The sample was then mixed with 
50% iodixanol density medium (Sigma D1556), to obtain 25% iodixanol. Samples are 
underlayed with a gradient of 2.5 mL 30% and 1.33 mL 40% iodixanol, and centrifuged at 
13,000rpm for 18 minutes in a swinging bucket centrifuge at 4°C. Nuclei were collected 
and precleared with 20 uL Protein G Dynabeads (Life Technologies 10003D) for 15 
minutes. Beads were removed with a magnet, and nuclei were incubated with 10 μL of 0.2 
mg/mL rabbit monoclonal anti-GFP antibody (Life Technologies G10362) for 30 minutes. 
60 μL of Dynabeads were added, and the mixture was incubated for an additional 20 
minutes. To increase yield, the bead-nuclei mixture was placed on a magnet for 30 
seconds to 1 minute, completely resuspended by inversion, and placed back on the 
magnet 6-7 times. Bead-bound nuclei were then washed 3 x 800 uL with wash buffer. All 
steps were placed on ice or in the cold room, and all incubations were carried out using 
an end-to-end rotator. When purifying RNA following INTACT. 
Immunohistochemistry  
Sun1-GFP; A2a-Cre and Sun1-GFP; D1-Cre mice were anesthetized with 
ketamine/xylazine and perfused with 4% paraformaldehyde (PFA). Brains were rapidly 
extracted and stored in 4% PFA overnight for fixation. Brains were then transferred to 15% 
sucrose for 24 hours and then stored in 30% sucrose until sectioning. Then brains were 
sectioned at 40 μm using a cryostat. Sections were blocked for 90 minutes at room 
temperature with 10% Normal Donkey Serum and 0.2% Triton X-100 in PBS. Sections 
were then incubated with 0.2% Triton X-100 in PBS with the following antibodies overnight 
at 4°C: rabbit anti-D1 (1:500, Bioss USA, BSM-52920R) or rabbit anti-A2a (1:200, Fisher 






215). Sections were then washed three times with PBS and incubated at room 
temperature in the dark for two hours with secondary antibodies for fluorescent labeling: 
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 
Plus 555 (Fisher Scientific, A32794) and Donkey anti-Goat IgG (H+L) Cross-Adsorbed 
Secondary Antibody, Alexa Fluor 488 (Fisher Scientific, A-11055). After the first hour of 
incubation, 0.5 µg/mL of DAPI (dihydrochloride, Invitrogen, D1306) was directly added into 
the secondary antibody solution. Sections were then washed three times with PBS and 
then mounted on glass slides using ProLong™ Gold Antifade Mountant (Invitrogen, 
P36930). Images were taken using a Zeiss LSM 810 Confocal Microscope.  
Cell Counting 
For cell counting that produced INTACT specificity and yield, aliquots were taken following 
nuclei isolation and affinity bead-bound pull downs. Nuclei from isolation (i.e., before the 
addition of antibody and Protein G beads) and bead-bound nuclei were stained with DAPI 
(30uM) and 10ul of sample was added to a hemocytometer. Images were acquired using 
a Leica Fluorescence Microscope. The numbers of DAPI+/GFP+ and DAPI+/GFP- nuclei 
were counted from 4-8 squares of a hemocytometer and averaged. Counts were then 
scaled up based on aliquot volumes. To calculate the specificity INTACT, DAPI+/GFP+ 
and DAPI+/GFP- nuclei from bead-bound nuclei were used. To calculate the INTACT 
yield, the total number of nuclei and the % of DAPI+/GFP+ nuclei from nuclei isolation, 
and the total number of bead-bound nuclei after INTACT purification were used. 
For cell counts following Immunohistochemistry, raw images were uploaded to ImageJ 
and cell counting was conducted using ImageJ’s Multipoint Tool. Following counting 
Adobe Photoshop was then used to adjust brightness, contrast, and levels in individual 







All RNA samples were of good quality (RIN above 8) and purity (1.9 +/- 0.1). cDNA was 
synthesized from RNA (100ng) using the iScript cDNA Synthesis Kit (Life Technologies). 
Quantitative real-time PCR (qRT-PCR) was conducted on the QuantStudio 7 Flex Real-
Time PCR System (ThermoFisher). Ct values of the experimental group to control using 
the ΔΔCt method (Livak & Schmittgen, 2001).  
CUT&RUN 
Bead bound nuclei following INTACT are washed 2X with Digitonin Buffer (20 mM HEPES, 
pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 1x Roche (CPI-mini, 1tab/10mL), 0.00055% 
Digitonin). Next, bead bound nuclei were incubated in antibody buffer (50 ul digitonin 
Buffer, .5 ul antibody, 2 mM EDTA) with either H3K27me3, H3K27me3 or IgG antibodies 
(Thermo MA5-11198, Epicyphr 13-0041, Epicyphr 13-0042) for 2 hrs at 4°C on an end-to-
end rotator. Following incubation, bead-bound nuclei were washed 2X with Digitonin 
Buffer, and .5 ul MNAse (20x CUTANA™ pAG-MNase, 15-1116) was added and 
incubated for 30 min at 4°C. Bead-bound nuclei were washed 2X with Digitonin Buffer and 
1 μL 100 mM CaCl2 was added to samples and incubated at 4°C for 2hr. The reaction 
was stopped with 33 ul Stop Buffer (68 ul of 5M NaCl, 40 ul of 0.5M EDTA, 40 ul of 4mM 
EGTA) and incubation 10 min at 37ºC in thermocycler. 1 µl of 10% (wt/vol) SDS (to a final 
concentration of 0.1%) and 1.5 µl of proteinase K (20 mg/ml) was added to each sample 
and incubated 20 min at 50 ºC. Samples are mixed with 100 µL phenol-chloroform-
isoamyl, followed by centrifugation for 5 min (13,000g). Samples are decanted into phase 
lock tubes and centrifuged at RT 5 min (16,000g). An equivalent volume of chloroform 
(100 ul) was added to initial sample volume, tubes were inverted 10x and then centrifuged 
for 5 min (16,000g). Remove top liquid phase by pipetting to a fresh tube containing 2 ul 
2mg/ml glycogen (diluted 1:10 from 20 mg/mL glycogen stock). Add 500 ul of ice cold 






15 min, 4 ºC (16,000 g). Pour off liquid and drain on paper towel and rinsed with 1 mL 
100% ethanol and centrifuge 1 min 4 ºC (16,000 g). Finally, samples are air dried (10-15 
min) and Dissolved in 1/10 diluted TE. 33. Using the entire purified CUT&RUN-enriched 
DNA, prepare Illumina library using the NEBNext® UltraTM II Library Prep Kit for Illumina 
per manufacturer's instructions, except that DNA clean-up is performed with 1.1X Ampure 
beads. All CUT&RUN libraries were paired end sequenced (40 bases x 2) on a Nextseq 
500. 
CUT&RUN Data Analysis 
Base call (BCL) files were demultiplexed and converted into FASTQ files using bcl2fastq2 
(version v2.20.0.422) with default parameters. Next, raw paired-end reads were mapped 
to the mm10 reference genome using bowtie2 (version 2.1.0)(Langmead & Salzberg, 
2012) with options: -q --local --no-mixed --no-unal --dovetail --phred33. Using local 
alignment mode makes removal of adapter sequences unnecessary. Then, we used 
Picard (version: 2.23.4) (Broad Institute;GitHub Repository., 2019) to check whether the 
insert size distribution is consistent with the library fragment size obtained from 
Bioanaylzer. Properly mapped reads were selected and further filtered by mapping quality 
score >= 20 using samtools (version 0.1.19, samtools view -q 20 -f 0x2) (Heng Li et al., 
2009) for downstream analyses. Read alignments were converted into bigwig files and 
visualized in IGV 2.8.10. 
Correlation between INTACT/CUT&RUN and ChIP-seq data 
To evaluate reproducibility and specificity of the INTACT/CUT&RUN data, we calculated 
pairwise Spearman’s correlation coefficients among INTACT/CUT&RUN replicates, 
Nucleus accumbens (NAc) H3K27me3 chromatin immunoprecipitation sequencing (ChIP-
seq) data from (Feng et al., 2014), and excitatory pyramidal neuron H3K27me3 ChIP-seq 






INTACT/CUT&RUN data and NAc H3K27me3 ChIP-seq data using samtools: samtools 
view -s fraction. The whole Excitatory pyramidal neuron H3K27me3 ChIP-seq data were 
used due to low sequencing depth from those datasets. To calculated Spearman’s 
correlation coefficient, we first computed with read coverages for the entire genome in 10-
kb bins using deepTools (Ramírez et al., 2016) with command: multiBamSummary –-
binSize 10000. Then, Spearman’s correlation coefficients were calculated and visualized 
by plotCorrelation function of deepTools with parameters: --corMethod spearman --
skipZeros. 
CUT&RUN Density plot 
We obtained A2a and D1 differentially expressed genes from published transcriptome of 
D1- and A2a-MSNs purified by the RiboTag affinity approach (Kronman et al., 2019). 
Then, we computed H3K27me3 signal distribution around transcription start sites (-1 kb 
to +1 kb) of A2a and D1 differentially expressed genes using deepTools: computeMatrix 
reference-point –referencePoint TSS -a 1000 -b 1000. The signal distribution is visualized 
by plotProfile function of deepTools. We also quantified H3K27me3 signal (reads per kilo 
base per million mapped reads, RPKM) for differentially expressed genes (-3 kb to + 3kb 
of gene body) using custom Python scripts. 
CUT&RUN Peak calling 
H3K27me3 peaks were called using callpeak command of macs2 (version 2.2.7.1) (Yong 
Zhang et al., 2008) with parameters: -f BAMPE -g mm -B --broad --keep-dup all -p 1e-5. 
Cell type Specific CRISPR activation    
 Cell type-specific expression of CRISPR activation tools is achieved through the 
incorporation of a loxP-stop (33polyA signal)-loxP (LSL) sequence, rendering expression 
inducible by Cre recombinase, which can be is transgenically induced in D1- or A2a- CRE 






stereotaxic coordinates: +1.6 (anterior/posterior), +1.5 (medial/lateral), and −4.4 
(dorsal/ventral) at an angle of 10° from the midline (relative to Bregma). In-vivo 
transfection were conducted using the transfection reagent Jet-PEI (Polyplus 
transfection), prepared according to manufacturer’s instructions. 12.5 μl DNA plasmid (1.0 
μg/uL) was diluted in 12.5 μl of 10% sterile glucose and added to diluted Jet-PEI, mixed 
by pipetting and incubated at room temperature (RT) for 15 min. A total of 1.5 μl of Jet-
PEI/Plasmid solution was delivered NAc at a rate of 0.2 l per minute, followed by 5 min 
of rest. Following surgery, mice were allowed to recover for 4-7 days and closely monitored 
for distress 
Cocaine conditioned place preference 
 Cocaine CPP was conducted as previously described (Carpenter et al., 2020). 
Mice were placed in a two-sided conditioning chamber (Ugo Basile) for 20 min to assess 
innate pretest preferences. Mice were then conditioned for 2-days to associate cocaine 
with their non-preferred side. Mice were injected in the morning with cocaine and in the 
afternoon with saline (i.p., 5, 10 or 20 mg/kg), then restricted to their preferred chambers 
and non-preferred, respectively, for 30 min. On day 4, mice were placed in the chamber 
with free access to both sides for a 20 min post-test session to assess conditioned place 
preference. ANY-Maze (version 4.99) software was used to analyze time and total 
distance traveled. NAc tissue was collected within 4 hours immediately following the post-
test session. Cocaine preference for all testing sessions was calculated as time spent in 
the cocaine-paired chamber minus time spent in the saline-paired chamber and is reported 
as a preference score (in seconds). Mice were defined as having acquired cocaine CPP 
when the average cocaine preference score of the cocaine-treated group was significantly 







Isolation of specific cell types for genomic and epigenomic profiling 
We employed INTACT to isolate A2a+ and D1+ nuclei at sufficient number and quality to  
measure MSN-specific increases in Nr4a1 mRNA expression following cocaine exposure 
(Figure 4.1). To generate a mouse line for affinity purification of striatal A2a+ and D1+ 
nuclei, we crossed the established SUN1-GFP-Myc mouse line, containing a tagged 
SUN1 mouse protein under the control of a loxP-3x polyA-loxP transcriptional roadblock, 
with A2a- or D1-Cre mouse lines (Figure 4.2A). A2a-Cre; or D1-Cre; SUN1-GFP mice are 
healthy, fertile and display no phenotypic abnormalities. Double immunohistochemistry of 
GFP and A2a or D1 shows expression of nuclear SUN1-GFP only in the target cell type 
(Figure 4.2A). Using INTACT, we isolated A2a+ or D1+ nuclei with an anti-GFP antibody, 
as well as GFP- nuclei (supernatant) from the whole striatum of single mouse (Figure 
4.2B). Fluorescence microscopy and manual quantification showed a sufficient number of 
nuclei (20-25,0000) were recovered to perform CUT&RUN from a single striatum (Figure 
4.2C) (Hainer et al., 2019; Hainer & Fazzio, 2019; N. Liu et al., 2018; P. J. Skene et al., 
2018; P. J. Skene & Henikoff, 2017). To validate the purity of the isolated nuclei, we 
quantified the expression of genes with known A2a- and D1-specific expression using 
qPCR (Kronman et al., 2019; Lobo et al., 2006; Smith et al., 2013). To quantify the 
expression data, we compared expression in A2a+ MSN nuclei to bulk (SUN1-GFP-) 
nuclei, which consisted of D1+ MSN nuclei and nuclei of other cell types. D1+ nuclei were 
compared to bulk tissue which consisted of A2a+ nuclei and nuclei of other cell types. As 
expected, A2a-specific genes were enriched and D1-specific genes were depleted in 
purified A2a+ nuclei (Figure 4.2D). Next, we quantified expression of Nr4a1 and its 
downstream target gene, Cartpt, in A2a+ and D1+ nuclei. There was no cell type specific 






4.2D). Cartpt enrichment specifically in A2a+ MSNs is consistent with published single-
cell sequencing data in the striatum (Gokce et al., 2016). We next confirmed that D1-
specific genes are enriched and A2a-specific genes are depleted in purified D1+ nuclei 
(Figure 4.2E). Nr4a1 expression was depleted and Cartpt showed no difference in 
expression in D1+ purified nuclei (Figure 4.2E). Taken together, these data confirm that 
INTACT is sufficient to enrich A2a+ and D1+ nuclei, validating well-established and novel 
cell type specific gene expression, including that of Nr4a1 and Cartpt.  
Epigenomic profiling using INTACT followed by CUT&RUN is robust and 
reproducible. 
 
Next, we used CUT&RUN to profile H3K27me3 and H3K4me3 enrichment in isolated MSN 
nuclei from the striatum of a single mouse (Figure 4.3A). To illustrate the cost 
effectiveness of CUT&RUN relative to ChIP-seq we downsampled the total number of 
reads to 10 million reads per sample and compared our results to published data (Feng et 
al., 2014; Mo et al., 2015). Correlation matrices comparing CUT&RUN replicates to 
published bulk ChIP-seq and excitatory neuron ChIP-seq were computed with read 
coverages for the entire genome in 10-kb bins (Feng et al., 2014; Mo et al., 2015). Data 
showed H3K27me3 CUT&RUN replicates are more similar to bulk striatal ChIP-Seq than 
to control IgG CUT&RUN and Camk2a-specific ChIP-Seq (Figure 4.3B). In addition, A2a+ 
H3K27me3 mean read density across gene regions, +/- 5 kb from transcription start site 
(TSS) and transcription end site (TES), shows similar patterns to bulk striatal ChIP-Seq 
(Figure 4.3C). To measure the repressive capacity of H3K27me3 in A2a+ purified nuclei,  
we quantified Reads Per Kilobase of transcript, per Million mapped reads (RPKM) at A2a- 
and D1-specific genes derived from the Ribo-Tag approach (Kronman et al., 2019). 
H3K27me3 was enriched at D1-specific genes in A2a+ purified nuclei, but not in nuclei 






peaks in A2a+ nuclei were using MACS2 and compared peak loci to a published cell type-
specific gene list (Kronman et al., 2019). H3K27me3 peaks were found at a greater 
percentage of D1-specific genes than A2a-specific genes, while K4me3 peaks were found 
at a greater percentage of A2a-specific genes than D1-specific (Figure 4.3E). Taken 
together, CUT&RUN generated robust epigenomic profiling data that can delineate 
regulatory features in specific neuronal populations. 
Nr4a1 activation in A2a+ nuclei 
 Having developed a method to quantify the abundance of transcripts and hPTMs  
in specific cell types, we next determined the effect of CRISPR-mediated Nr4a1 activation 
on cocaine-induced behavior and gene expression. This system consists of a catalytically 
dead Cas9 protein fused to a VP64 transcriptional activation domain (dCas9-VP64) and a 
single-guide RNA (sgRNA) targeting the Nr4a1 promoter. Cell type specificity is achieved 
by the incorporation of a loxP-stop (33polyA signal)-loxP (LSL) sequence, rendering 
expression inducible by Cre recombinase expressed in A2a-Cre or D1-Cre mice (Figure 
4.4A). By qPCR, we confirmed cell type specificity of Nr4a1 activation in A2a+ purified 
nuclei (SUN1-GFP+) and bulk nuclei (SUN1-GFP-). Intra-NAc expression of Nr4a1-gRNA 
and flx-dCas9-VP64 activated Nr4a1, relative to NT-sgRNA control (Figure 4.4B). Nr4a1 
downstream target gene, Cartpt, was similarly activated specifically in A2a+ nuclei (Figure 
4.4B). As expected, no difference in Nr4a1 or Cartpt expression was observed in bulk, 
SUN1-GFP- nuclei. (Figure 4.4B). Next, to rule out artifacts in purification due to the 
transfection of CRISPRa, we quantified cell type specific markers via qPCR. A2a and D1 
were enriched and depleted, respectively in A2a+ purified nuclei when compared to bulk 
nuclei (SUN1-) and no difference was observed between gRNA-Nr4a1 or gRNA-NT + flx-






in manipulating and quantifying cell type specific epigenomic and transcriptomic features 
to correlate epigenetic modifications to individual differences in behavior.  
 Prior data supports the notion that Nr4a1 activation suppresses cocaine mediated 
behavior, however, the pathways responsible for these observed changes have yet to be 
determined. We next measured the effect of CRISPR-mediated Nr4a1 activation on 
cocaine-induced behavior. As shown schematically, mice were treated with bilateral NAc 
co-transfected of Nr4a1-sgRNA or NT-sgRNA and flx-dCas9-VP64 and given 4-days of 
rest prior to cocaine CPP (Figure 4.4D). Mice treated with either NT- or Nr4a1- CRISPRa 
showed similar preference for the saline-paired chamber (Figure 4.4E). Following cocaine 
conditioning, control mice spent more time in the cocaine-paired chamber, compared to 
the pre-test (Figure 4.4E). In contrast, activation of Nr4a1 perturbed the ability of mice to 
form a preference for cocaine (Figure 4.4E). To determine if the observed effects were 
due to deficits in baseline locomotor activity, we measured total distance traveled in the 
pre-test and no significant differences were found between treatment groups (Figure 
4.4F). Taken together, Nr4a1 activation in A2a-MSNs is sufficient to suppress cocaine 
mediated behavior.  
Discussion 
 This study integrates methodologies including INTACT, CUT&RUN and CRISPR-
mediated gene regulation to describe cell type specific neuronal processes. In 
combination, we have developed methodology to determine the contribution of epigenetic 
modifications to the regulation of gene expression mediating individual differences in 
motivated behavior. We isolated A2a+ and D1+ nuclei using INTACT from a single mouse 
striatum for downstream transcriptomic and epigenomic analysis. While some 
investigations have applied FACS to INTACT and other transgenic lines to isolate MSNs, 






genes (Kolodziejczyk et al., 2015; Lacar et al., 2016; Poulin et al., 2016; Fernandez-Albert 
et al., 2019; Hu et al., 2017; Y. E. Wu et al., 2017) . Using qPCR and CUT&RUN we 
confirmed the specificity of our isolation technique and showed that H3K27me3 was 
enriched at developmentally defined, cell type specific genes. Then we elucidated the 
pathway responsible for Nr4a1 mediated suppression of cocaine CPP. Specifically, Nr4a1 
CRISPRa in A2a+ neurons activated Nr4a1 expression, its downstream homeostatic 
target genes, such as, Cartpt and attenuated cocaine CPP. In addition, Nr4a1 CRISPRa 
enriched H3K27ac and depleted H3K27me3 at the Cartpt promotor. Our data adds to the 
growing body of literature describing epigenetic regulation of activity dependent 
expression critical for neuronal function and behavior.  
 One intriguing epigenetic mechanism of long-lasting cocaine-mediated gene 
expression involves bivalent chromatin, which marks genes that are repressed but poised 
for immediate activation due to the simultaneous enrichment of repressive and activating 
hPTMs (Damez-Werno et al., 2012; Feng et al., 2014; Margaritis & Holstege, 2008). 
During differentiation, bivalent chromatin is resolved to ensure long-lasting expression or 
repression of cell- and tissue-specific gene expression. Widespread resolution of bivalent 
chromatin to active chromatin may explain overall increases in gene activation following 
cocaine exposure, as well as stable gene regulation across long periods of abstinence  
(Carpenter et al., 2020; Damez-Werno et al., 2012; Freeman et al., 2008, 2010; Walker et 
al., 2018). To quantify chromatin bivalency in neurons, we will generate a mutual 
exclusivity index for H3K4me3 and H3K27me3, using our cell type specific hPTM profiles, 
to determine the ratio of combinatorial histone modifications and associated gene 
expression. Overall gene activation can correlated with an increase in the mutual 
exclusivity of these two modifications, driven by the depletion of H3K27me3, in regions 






data suggest that Cartpt is bivalent at baseline, and its cocaine activation is mediated by 
the specific loss of H3K27me3. In sum, combinatorial cell type specific histone 
modification enrichment profiles can more readily decipher gene expression patterns. Our 
lab now plans to use this approach to quantify epigenetic regulation of gene expression 
induced by volitional cocaine seeking in mouse NAc. 
 Persistent changes in gene expression mediate neuronal plasticity including long-
term potentiation (LTP) and long term depression (LTD), serving as important substrates 
of learning and memory (Smith et al., 2013). During prolonged abstinence both A2a and 
D1 expressing neurons show long-lasting deficits in LTD in NAc, in addition to reduced 
expression of N-methyl-D-aspartate receptor-dependent (NMDAR) synaptic plasticity 
associated genes (Kasanetz et al., 2010; Scofield et al., 2016).  Nr4a1 activation regulates 
a subset of these genes, such as Polo-like kinase 2 (PLK2) and ras homolog gene family, 
member A, (RhoA) leading to spine loss without concomitant changes in excitatory 
transmission (Y. Chen et al., 2014). Conversely, chronic cocaine results in abnormal 
increases in dendritic spine density in NAc, at early and late abstinence (Smith et al., 
2013). Conflicting data suggest that cocaine induces dendritic spine formation 
preferentially occurs on D1-MSNs or on both A2a+ and D1-MSNs  (Dobi et al., 2011; J. Li 
et al., 2012). One possible mechanism mediating MSN-subtype specific increases in spine 
density may be the relative enrichment of Nr4a1 +.  Consistent with this hypothesis, we 
found decreased Nr4a1 in D1+ nuclei but no difference in Nr4a1 in A2a+ nuclei, relative 
to respective bulk nuclei. Enrichment of Nr4a1 in A2a+ nuclei has been observed by other 
investigators (Lobo et al., 2006; Savell et al., 2020).  D1-MSN specific baseline and activity 
dependent Nr4a1 abundance may underlie the susceptibility of D1-MSNs to cocaine 
induced neuroadaptations (Smith et al., 2013). Further we show simultaneous exogenous 






unknown if Nr4a1-dependent transcription in D1-MSNs contributes to cocaine CPP 
(Carpenter et al., 2020; Y. Chen et al., 2014; Jeanneteau et al., 2018). Future studies will 
delineate the contribution of Nr4a1 in cell type specific target gene activation and behavior.  
 Taken together, we identified cell type specific mechanisms in NAc, that when 
activated, suppress cocaine mediate behaviors. Studies such as this will improve the 
understanding of precise epigenetic mechanisms by which individual genes “remember” 
prior drug exposure. In the age of precision medicine, targeting cell type specific pathways 










Figure 4.1. Approach to determine cell type specific mechanisms of persistent gene 
expression across abstinence. Sun1-GFP-tagged nuclei are isolated from specific cell 
types (INTACT) in a single reward brain area of a single mouse. Then we applied 
CUT&RUN (cleavage under targets and release using nuclease sequencing) + RNA-Seq 
to profile global Nr4a1 or H3K4me3 and H3K27me3 enrichment. To move beyond 








Figure 4.2 INTACT validation in indirect (A2a+) and direct (D1+) pathway NAc MSNs. 
(A, B) Double immunohistochemistry with anti-GFP + anti-A2a or anti-D1 showed SUN1-
GFP in nuclear envelope colocalized specifically with the genetically targeted cell type 
(top), but not the non-targeted cell type (bottom). (B) Schematic of INTACT from double 
transgenic mice followed by qPCR of D1+ (n=8) or A2a+ (n=3-6) nuclei. Supernatant 
(SUP) served as bulk MSN control. (C) Representative quantification and imaging of 
isolated nuclei following INTACT. (D) Enrichment of A2a and Cartpt mRNA, and depletion 
of D1 mRNA in A2a+ MSNs. (E) Enrichment of D1 mRNA and depletion of Nr4a1 and A2a 










Figure 4.3. H3K27me3 and H3K4me3 CUT&RUN in A2a+ MSNs. (A) One A2a-Cre; 
LS1L-Sun1-GFP mouse striatum (2x2.0mm punch/mouse) was subjected to 
INTACT/H3K27me3 CUT&RUN and sequenced on NextSeq500. Peaks were generated 
using MACS2. (B) Spearman correlation calculated between A2a+ replicates and 
published datasets of H3K27me3 ChIP-Seq from whole NAc (NAc R1/2) (Feng et al., 
2014) and from CamK2a+ excitatory forebrain neurons (CamK2a R1/2) (Mo et al., 2015). 
A2a+ H3K27me3 peaks more closely correlated with bulk NAc MSNs than with forebrain 
excitatory neurons. Value in box center depicts correlation value (C) Density plots of 
H3K27me3 in A2a+ MSNs were more similar to that from bulk NAc than from CamK2a+ 
neurons. (D). At A2a and D1- specific genes, the H3K27me3 signal (Reads Per Kilobase 
Million, RPKM) is calculated for gene body +/- 3kb. Differentially expressed genes were 
derived from published data (Kronman et al., 2019). Welch Two Sample t-test. IgG 
p=0.315, A2a R1 p=0.060, A2a R2 p=0.0003, A2a R1 p=0.0002 (E) H3K27me3 and 
H3K4me3 peaks at A2a and D1-specefic genes. Fischer exact test H3K27me3+ vs D1+  
p = 0.0456; H3K27me3+ vs A2a+  p = 1; H3K27me3+ vs D1+  p = 0.0025 H3K27me3+ vs 










Figure 4.4. Nr4a1 CRISPR activation in A2a+ MSNs attenuated cocaine conditioned 
place preference. (A) Schematic of CRISPRa transfection in NAc. Tissue was collected 
and qPCR was performed following INTACT from both A2a+, Sun1-GFP+ nuclei (IP) and 
supernatant (Sup). (B) Nr4a1 and Cartpt were activated relative to NT-sgRNA, only in 
A2a+, IP’d nuclei. (C) Enrichment of A2a in IP and D1 in Sup. 2-way ANOVA, Bonferroni 
multiple comparisons test, p > 0.05. (D) Timeline and schematic of CPP study. (E) Nr4a1 
CRISPRa in A2a+ cells reduced time spent in the cocaine-paired side. (F) Total distance 
















 Despite the prevalence of cocaine use disorder, there is currently no medicine 
available that prevents relapse. Psychosocial treatments for cocaine use disorders suffer 
from high dropout rates and short periods of abstinence (Kampman, 2019; Stitzer et al., 
2010). In recent years, there have been several failed clinical trials investigating the 
efficacy of dopamine agonists and modulators of inhibitory synaptic transmission as 
treatments for cocaine use disorder (Kampman, 2019). In addition, poor adherence in 
cocaine users has not been addressed and thus novel medications should prioritize long-
lasting, sustained release formulations that prevent relapse during prolonged abstinence 
(Galloway et al., 2005; Goonoo et al., 2014; Jarvis et al., 2017). This dissertation explored 
novel mechanisms of homeostatic regulation that occur during abstinence with a focus on 
developing novel therapies for reducing relapse.   
 Our lab discovered that activation of Nr4a1 suppresses cocaine reward behavior. 
In Chapter 2, we developed the novel approach of druggable transcription factors as a 
treatment modality in cocaine use disorder, using Nr4a1 as the therapeutic target. We 
focused on Nr4a1 for several reasons: 1.) Nr4a1 plays an integral role in neuroprotection 
in response to hyperexcitation (Y. Chen et al., 2014; Jeanneteau et al., 2018; Walker et 
al., 2018). 2.) Nr4a ligands enhance learning and memory (Chatterjee et al., 2020; Hawk 
et al., 2012) and 3.) protect against Parkinson’s disease (De Miranda et al., 2013, 2015; 
Montarolo et al., 2016). To validate this target in cocaine use disorder, we designed tools 
for the regulation of Nr4a1 and characterized Nr4a1 function in cocaine reward behavior 
(Carpenter et al., 2020). Specifically, we show that Nr4a1 activation attenuated, while 






decrease the acquisition of self-administration when compared to control mice, 
highlighting a low abuse liability of Nr4a1 activation (Carpenter et al., 2020). The absence 
of Nr4a1 effects on the acquisition of drug taking provides evidence that  mechanisms of 
drug-seeking differ when drug is onboard versus during abstinence (Bossert et al., 2013; 
Edwards & Koob, 2013). In addition, we show that important downstream Nr4a1 targets, 
such as Cartpt, were associated with Nr4a1 activation and reduced cocaine-mediated 
behaviors (Carpenter et al., 2020). Future work should continue to assess off-target effects 
of Nr4a1 activation, such as anhedonia, learning and stress.   
 DHA is an endogenous ligand that binds Nr4a1-3 with high affinity, is prominent in 
brain, and lowered in the blood and correlated with increased relapse risk in cocaine users 
(Buydens-Branchey et al., 2009, 2011; Vinayavekhin & Saghatelian, 2011). These 
findings are consistent will loss of Nr4a1-3 protein levels observed in the striatum of 
withdrawn human cocaine users (Albertson et al., 2004; Bannon et al., 2005; W.-X. Tang 
et al., 2003). Loss of Nr4a1-3 protein and ligand may impede critical components of self-
regulation during abstinence. This biology has inspired the proposed use of synthetic 
Nr4a1 agonists to protect against relapse in the addicted patient. To support this, we found 
systemic administration of Nr4a1 ligand, Csn-B, repressed cocaine CPP (Carpenter et al., 
2020). Similarly, the CDIM class of Nr4a1 agonists mitigate dopamine dysfunction (De 
Miranda et al., 2013, 2015). However, CsnB and CDIM are highly hydrophobic, have short 
circulation half-lives (<30 min), and cause off-target toxicity which limits their dosing. Thus, 
optimization efforts centered on improving the pharmacokinetic profile of Csn-B and 
CDIMs will further the therapeutic potential of Nr4a1 as a target in the treatment of cocaine 
use disorder. The goal of this future work is to develop nanoparticle (NP)-based drug 
delivery approaches with unparalleled flexibility to modify fundamental drug properties 






on the knowledge created in Chapter 3 we plan to yield a safe, efficacious compound with 
sufficient pre-clinical data to support clinical research.  
 Important to these efforts is consideration of target cell types and brain regions, 
especially given widespread expression of Nr4a1 mRNA and protein (Saucedo-Cardenas 
& Conneely, 1996; Xiao et al., 1996). Nr4a1 binding is cell type specific and many cell 
types express Nr4a1, including MSNs (A2a+ and D1), macrophages and astrocytes (Y. 
Zhang et al., 2014; Ye Zhang et al., 2016). It cannot be assumed that cocaine induced 
Nr4a1 and Cartpt activation occurs only in neurons, as observed in Chapter 2 and 3. 
Recent single nuclei RNA-seq analysis confirmed that cocaine activates Nr4a1 primarily 
in A2a and D1-MSNs, relative to saline, but the relative difference between cell types was 
not assessed (Savell et al., 2020). In agreement with neuronal-specific cocaine induced 
Nr4a1, we found that neuron specific Nr4a1 activation attenuated cocaine CPP and 
seeking after cocaine IVSA plus abstinence (Carpenter et al., 2020). In Chapter 4, we 
addressed the possibility of cell type specific differences in Nr4a1 function. We show that 
activation of Nr4a1 specifically in A2a+ MSNs enhanced the expression of Cartpt and 
attenuated cocaine CPP. The similar results observed between neuron- and A2a- specific 
Nr4a1 activation provides evidence that Nr4a1 expression attenuates cocaine CPP when 
activated in A2a+ MSNs prior to cocaine exposure. Further research may reveal 
differences in Nr4a1 function across MSNs, given the often-opposing roles of D1+ and 
A2a+ MSNs in response to cocaine (Kravitz et al., 2012).  
Cell type specific activation of Nr4a1 in D1-MSNs  
 Selective optogenetic stimulation of D1-MSNs reinforces cocaine seeking while 
stimulation of A2A--MSNs causes drug aversion (Kravitz et al., 2012). However, the role 
of cell type specific transcription factor function is not as well studied. For example, 






treatment reflects Egr3 overexpression in D1-MSNs and downregulation in A2a-MSNs (R. 
Chandra et al., 2015). Behaviorally, Erg3 overexpression in D1 or A2a-MSNs enhanced 
or repressed cocaine CPP, respectively (R. Chandra et al., 2015). These findings 
underscore the importance of determining the effect of Nr4a1 activation in both subtypes. 
Regulation of key Nr4a1 target genes using multiplexed sgRNAs 
 We hypothesized that Nr4a1 enrichment facilitates the recruitment of histone 
modifying enzymes at target genes to regulate long-lasting changes in transcription 
(Hedrick et al., 2017; Palumbo-Zerr et al., 2015). To test this, we measured the enrichment 
of Nr4a1 at Cartpt, a gene with delayed activation only after 28-days of cocaine 
abstinence. Our fundamental research on the mechanism of Nr4a1 gene regulation 
provides a druggable link to downstream effectors, such as Cartpt, involved in the 
homeostatic response to cocaine exposure in both humans (Albertson et al., 2004) and 
animals (Hubert & Kuhar, 2008; Jason N Jaworski et al., 2008; Shieh, 2003) . Prior data 
on Cartpt supports our supposition of its role in the homeostatic response to cocaine 
stimulation. First, postmortem brains of human cocaine users show increased CARTPT 
mRNA (Albertson et al., 2004). Second, intra-NAc injection of Cart, the peptide encoded 
by Cartpt, only in the presence of psychostimulants, increases dopamine metabolism, and 
attenuated cocaine locomotor sensitization and SA (Hubert & Kuhar, 2008; Jason N 
Jaworski et al., 2008; Shieh, 2003). Indeed, intra-NAc injection of Cart directly inhibits 
locomotor activity associated with the intra-Nac injection of dopamine (Jason N. Jaworski 
et al., 2003). In this context, Cart functions to reduce levels of dopamine in the synapse, 
thereby mitigating the effects of dopamine toxicity (Shieh, 2003). We postulate that in 
addition to Cartpt, Nr4a1 regulates a network of gene expression changes which 






individual and multiple downstream genes, future studies will target these genes for 
activation, in parallel, using multiplexed sgRNAs (Savell et al., 2020).  
Bivalent chromatin and persistent gene expression  
 Beyond hPTM regulation of the binary states of active and repressed gene 
expression, genes also exist in a ‘poised’ state, in which they are silent but poised for 
immediate action. Poised genes exist in a ‘bivalent’ chromatin state - simultaneously 
enriched in H3K4me3, a mark of active genes, and H3K27me3, a repressive hPTM 
(Bernstein et al., 2006; Gao et al., 2018; Larson et al., 2019). While bivalent chromatin 
largely marks developmental and lineage-specific genes (Harikumar & Meshorer, 2015), 
this state has been observed in a number of scenarios, including in the adult mammalian 
brain, and is highly dynamic (Larson et al., 2019; Minoux et al., 2017). H3K27me3 and 
H3K4me3 co-occupancy is associated with functional priming events that regulate delayed 
changes in gene expression (Hawkins et al., 2010; Larson et al., 2019; Marco et al., 2020; 
Minoux et al., 2017). However, data is sparse on the role of bivalent chromatin in response 
to environmental stimuli (Marco et al., 2020). Immediate early genes such as Fos and 
Nr4a1 are known to be developmentally regulated genes silenced to ensure robust 
activation upon stimulation (Boyer et al., 2006; Madabhushi et al., 2015; Miller et al., 2018; 
Thomas et al., 2016). This precise regulation is critical for the dynamic changes observed 
in neuronal plasticity and behavior (Madabhushi et al., 2015).  
 Chronic cocaine administration increased PolI binding at the Fosb promoter in 
NAc, indicating that PolI primes Fosb for fast transcription upon cocaine re-exposure. 
Such priming is facilitated by changes in H3K4me3 and H3K27me3 enrichment at the 
promoter region of Fosb (Damez-Werno et al., 2012). Drug challenge induced H3K4me3 
depletion and H3K27me3 enrichment at promoter regions of select genes in the striatum. 






expression; future studies should aim to use novel techniques to address the question of 
bivalency and changes in transcription without changes in steady state mRNA levels. 
Prior high-throughput sequencing studies of brain reward regions have focused on 
the binary states of gene activation and repression. A comprehensive view of chromatin 
regulation in NAc following repeated cocaine injections found that cocaine regulates global 
gene expression correlated with differential enrichment of H3K4me1, H3K4me3, 
H3K9me2, H3K9me3, H3K27me3, H3K36me3 and PolII (Feng et al., 2014). More 
specifically, repeated cocaine administration decreases H3K9me3 enrichment at specific 
genomic repeats, indicating global patterns of genomic destabilization (I. Maze et al., 
2011). Cocaine also directly affects expression and activity of histone modifying enzymes, 
such as sirtuin 1 (SIRT1), which is depleted in mouse NAc following investigator-
administered cocaine, resulting in H4K16ac enrichment and gene activation (Ferguson et 
al., 2013, 2015). The induction of SIRT1 in NAc causes deacetylation and activation of the 
majority of downstream SIRT1 targets (Ferguson et al., 2015). These studies point to the 
key role of activating (H3K9/14Ac, H3K27ac) and repressive (H3K4me1, H3K4me3, 
H3K9me2, H3K9me3, H3K27me3) hPTMs as the underlying mechanism of the 
widespread gene activation following cocaine administration, but they are limited to 
measuring changes due to non-contingent drug exposure.  
Mitigating off-target effects of Nr4a1 activation  
 We propose that activation of Nr4a1 is beneficial in treating cocaine use disorder. 
This hypothesis is based on several rigorous methods of target identification and 
validation: (1) bioinformatic data mining (2) target modulation with CRISPRa/i and (3) 
target modulation with agonist, Csn-B (Carpenter et al., 2020). To further develop Nr4a1 
activators we plan to perform an extensive panel of in vitro adsorption, distribution,  






physicochemical studies for Csn-B, including measures of microsome stability, CYP 
induction and inhibition, solubility, permeability in MDCK or Caco-2 cells, and full 
pharmacokinetics (PK), including brain and plasma analysis in mouse. However, CsnB 
and CDIM12 are highly hydrophobic, limited by insufficient dosing, and prone to significant 
off-target toxicity. To overcome these limitations, one could use nanoparticle (NP)-based 
Nr4a1 agonist delivery approaches to develop long-acting drugs for cocaine use disorder. 
Because treatment of psychiatric disease often suffers from noncompliance, it is essential 
to develop long-acting therapeutic approaches (Galloway et al., 2005; Goonoo et al., 2014; 
Hulse, 2013). NP delivery can be used to modify fundamental drug properties such as 
solubility, targeting, circulation time, and release characteristics (Febvay et al., 2010; 
Makadia & Siegel, 2011; L. Zhang et al., 2008). This strategy involves development of 
novel formulations, empirically optimized for bioactivity, targeting, circulation time, and 
release characteristics, to allow a weekly or monthly dosing in clinical studies.  
 The most widely studied in vitro model for Nr4a1 activation is cancer cell-based 
cytotoxicity screening (Hedrick et al., 2017; Safe et al., 2016; Safe & Karki, 2020; Y. Zhan 
et al., 2008). Although gene activity reporter systems are more appropriate for high 
throughput assays, current methodologies are unable to distinguish between off target 
and ligand dependent effects. Traditionally, genetic constructs containing the NRBE 
upstream of the luciferase gene is transfected in cells to measure Nr4a1 transcriptional 
activity (Mohankumar et al., 2020). However, in vivo the probability of transcription factor 
binding is heavily influenced by the local chromatin environment (B. Li et al., 2007). To 
detect in vivo nuances that might indicate desirable cell type specific effects, we have 
developed a mid-throughput method for the identification of safe lead compounds using 
transcription factor and epigenomic profiling in mouse NAc neurons. Given the potential 






measure Nr4a1-DNA interactions to identify genes associated with drug function. Using 
integrative analysis of endogenous binding characteristics at several doses we hope to 
better inform small molecule drug discovery strategies.  
Opiate induced activation of Nr4a target genes 
Adaptive changes in cellular and synaptic function after prolonged opiate exposure 
and withdrawal is well documented (Koo et al., 2015; Sanchez et al., 2016). For example, 
consistent with our studies of the NAc, others have observed increased expression of 
Nr4a2, Cartpt, Th and Dat in the VTA during opiate withdrawal (Carpenter et al., 2020; 
García-Pérez et al., 2016; Spijker et al., 2004). These changes showed a high degree of 
co-localization with TH+ neurons in the VTA suggesting that Nr4a2 is associated with 
withdrawal induced alterations of dopaminergic neuron activity (García-Pérez et al., 2016). 
Human studies provide neurological evidence that abnormal expression of Nr4a2 in heroin 
abusers is exacerbated by age (Horvath et al., 2007). In addition, gene expression 
changes following adult opioid exposure in mice is correlated with epigenetic changes, 
including loss of histone H3K9ac, H3K9me3 and H3K27me3 (Authement et al., 2016; Koo 
et al., 2015). In the VTA, morphine exposure increases HDAC activity in dopamine 
neurons and reduces H3K9ac genome-wide (Authement et al., 2016). These changes 
were associated with greater disinhibition of dopaminergic neurons, which can be restored 
via increased histone acetylation (Authement et al., 2016). Systemic administration of 
HDAC inhibitors (HDACi) facilitates extinction of morphine CPP, blocks priming-induced 
reinstatement and attenuates sensitization (Jing et al., 2011; R. Wang et al., 2010). 
Opioid-induced withdrawal is also associated with Ezh2 (enhancer of zester homolog 2) 
expression, which catalyzes H3K27me3 (X. Wu et al., 2018). Virally-mediated 
overexpression of Ezh2 in the VTA repressed genes for dopaminergic neuron survival and 






function was broadly implicated in drug use disorders across different brain regions. We 
proposed that prolonged exposure to oxycodone during adolescence increases the 
sensitivity to morphine later in adulthood via the suppression of Nr4a mediated gene 
expression. A detailed description of these findings can be found in the Appendix 
(Carpenter et al., 2020b). 
Concluding Remarks  
 Developing effective treatments for cocaine use disorder requires a shift in 
approach. In this dissertation, we provide evidence that Nr4a1 is one possible target and 
provide a pipeline for pre-clinical validation of future targets. In addition, we describe a 
method for the isolation, characterization and manipulation of specific neuronal cell types 
to rigorously validate the Nr4a1 mechanism of activation. This rigorous validation strategy 
can potentially “derisk” potential targets via the identification of off target effects. 
Importantly, we have built on a body of growing literature on the potential uses of Nr4a1 
activators in brain diseases. Altogether, elucidating the epigenetic processes that shape 
cocaine memories has emphasized the role of abstinence, rather than drug taking, as a 
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 Prescription opioid misuse is a major public health concern among children and 
adolescents in the USA (Birnbaum et al., 2011). Opioids are the most commonly abused 
drugs and are the fastest growing drug problem among adolescents (Manchikanti & Singh, 
2008). In humans and animals, adolescence is a particularly sensitive period associated 
with an increased response to drugs of abuse (Clark et al., 1998; Doremus-Fitzwater et 
al., 2010; Spear, 2000). Our previous studies indicate that oxycodone exposure during 
adolescence increases morphine reward in adulthood (Sanchez et al., 2016). How early 
drug exposure mediates long-term changes in the brain and behavior is not known, but 
epigenetic regulation is a likely mechanism. To address this question, we exposed mice 
to oxycodone or saline during adolescence and examined epigenetic modifications at 
genes associated with dopamine activity during adulthood at early and late withdrawal, in 
the ventral tegmental area (VTA). We then compared these to alterations in the VTA of 
adult-treated mice following an equivalent duration of exposure and withdrawal to 
determine if the effects of oxycodone are age-dependent. We observed persistence of 
adolescent-like gene expression following adolescent oxycodone exposure relative to 
age-matched saline exposed controls, although dopamine related gene expression was 
transiently activated at 1-day of withdrawal. Following prolonged withdrawal enrichment 
of the repressive histone mark, H3K27me3, was maintained, consistent with inhibition of 
gene regulation following adolescent exposure. In contrast, mice exposed to oxycodone 
as adults showed loss of the repressive mark and increased gene expression following 
28-days of withdrawal following oxycodone exposure. Together our findings provide 
evidence that adolescent oxycodone exposure has long-term epigenetic consequences in 








The impact of prescription opioid abuse continues to be a serious public health 
problem. Nonmedical use of prescription opioids remains the number one cause of drug 
overdose (Center for Behavioral Health Statistics and Quality, 2019). Current estimates 
indicate that 10.3 million people in the United States abuse prescription opioids, including 
700 thousands afflicted individuals between the ages of 12 and 17 (Center for Behavioral 
Health Statistics and Quality, 2019). Use of prescription opioids, such as oxycodone, 
increased the propensity to initiate heroin use in adulthood (Center for Behavioral Health 
Statistics and Quality, 2019; Cerdá et al., 2015). In humans and mouse, the association 
between adolescent opioid use and the propensity to initiate adult heroin use has been 
well documented (Cerdá et al., 2015; Niikura et al., 2013; Sanchez et al., 2016; Yong 
Zhang et al., 2016). This underscores the importance of efforts to identify molecular 
mechanisms that contribute to the transition from prescription opioid to heroin use (Cerdá 
et al., 2015; Sanchez et al., 2016). 
Adolescence is defined by age-specific behavioral characteristics associated with 
the transition from childhood to adulthood (Spear, 2000). Neurobiological correlates to 
human adolescence, such as synaptic pruning and reductions in dopamine receptor 
expression, are conserved across the mammalian species. Compared to adult, adolescent 
dopamine neurons in the ventral tegmental area (VTA) fire at higher rates and release 
larger pools of dopamine in the NAc, which facilitate the development of drug taking in 
mice (Caudle et al., 2007; Stamford, 1989). Enhanced dopaminergic neuron activity during 
adolescence results in increased levels of dopamine in the NAc, relative to adult (Philpot 
et al., 2009). A similar trend is observed in the expression of dopamine receptors 1 and 2 
(D1 and D2)  (Thorpe et al., 2020). These data indicate that molecular adaptions 






environmental stimuli, particularly in the mesolimbic dopamine system (Morrison et al., 
2014; Spear, 2000). However, knowledge regarding the molecular mechanisms that 
regulate functional changes in the VTA during adolescence remains limited and requires 
further investigation. 
Adolescent structural and molecular remodeling contributes to enhanced drug 
sensitivity and reward (F. Naneix et al., 2012). µ-opioid receptor agonists such as 
oxycodone and morphine, disinhibit dopamine neurons in the VTA, thereby increasing 
levels of dopamine in the nucleus accumbens (NAc) (Di Chiara & Imperato, 1988). 
Compared to the transient dopamine release caused by morphine, oxycodone has a 
greater potential to promote drug seeking given its long-lasting effect on dopamine release 
(Vander Weele et al., 2014). We previously demonstrated that oxycodone exposure during 
adolescence enhances rewarding properties of opioids later in life (Sanchez et al., 2016). 
The effects of oxycodone exposure differ between adolescents and adults, including 
enhanced striatal dopamine release (Yong Zhang et al., 2009) and oxycodone conditioned 
place preference (CPP) (Niikura et al., 2013), and attenuated self-administration in 
adolescent mice (Yong Zhang et al., 2009). In fact, prolonged exposure to oxycodone 
during adolescence enhances both behavioral responses to opioids in adulthood and 
alters gene expression (Sanchez et al., 2016; Yong Zhang et al., 2014, 2016). These data 
suggest that the effects of adolescent oxycodone exposure on the mesolimbic reward 
pathway persist well into adulthood. This long-lasting phenotype led us to hypothesize that 
adolescent oxycodone exposure induces a persistent adolescent-like state in gene 
expression and behavior (Sanchez et al., 2016). 
There is increasing evidence that epigenetic mechanisms mediate the influence of 
drugs on the CNS and are likely involved in the pathology of drug abuse. Epigenetic 






However, epigenetic regulation during adolescence is understudied and may underlie the 
behavioral responses to drugs of abuse. Histone H3 lysine 27 trimethylation (H3K27me3) 
is a well-studied epigenetic modification that is associated with gene repression (Wever 
et al., 2019). We hypothesized that H3K27me3 regulates drug induced gene expression 
during adolescence and early adulthood, given its critical role in the maintenance of 
dopaminergic neurons in the VTA (Wever et al., 2019). Given that H3K27me3 is regulated 
following opioid exposure, its abundance is associated with important gene expression 
changes related to drug behavior. 
In mouse models, adolescence spans approximately from post-natal day (PND) 
28-42, followed by a considerable “gray zone” approaching adulthood (PND 60+) (Spear, 
2000; Thorpe et al., 2020). Therefore, we examined gene expression and the enrichment 
of H3K27me3 at several target genes during adulthood (PND56, PND84, and PND112) 
relative to the naive adolescent brain at PND 28. In addition, we exposed mice to 
oxycodone (or saline) during adolescence or early adulthood and examined epigenetic 
modifications at genes associated with the dopamine transmission during adulthood at 1- 
and 28-days of withdrawal (Cass et al., 2013; Sanchez et al., 2016). Adolescent mice were 
exposed to oxycodone from PND28-56 to ensure coverage of the entire period in which 
neurobehavioral discontinuities from younger and older mice are evident (Spear, 2000; 
Thorpe et al., 2020). We utilized two controls to distinguish alterations in normal 
development from those that occur as a result of withdrawal: (1) all oxycodone groups 
were compared to the naive adolescent brain (PND28) to define developmentally 
regulated gene expression changes; (2) oxycodone exposed mice were compared to 
saline exposed, age-matched controls to define effects of withdrawal and age of exposure. 
We hypothesized that genes associated with the development of dopamine neurons 






nuclear receptor subfamily 4 group A member 2 (Nr4a2), and its downstream target genes, 
cocaine and amphetamine related transcript (Cartpt), tyrosine hydroxylase (Th) and the 
dopamine transporter (DAT), would be particularly prone to long-lasting alterations 
following oxycodone exposure. In sum, we identified an epigenetic mechanism specific to 
adolescent oxycodone exposure that is associated with the inhibition of withdrawal-
induced gene expression. 
Methods 
Animals 
C57Bl/6NTac mice (Taconic, Hudson, New York) were bred in house at the University of 
Pennsylvania for a minimum of two generations to eliminate the potential effects of 
shipping. Male offspring, used in experiments, were grouped housed (3-5/cage) with ad 
libitum access to food and water under a 12h light cycle. All procedures were approved 
by the University of Pennsylvania Animal Care and Use Committee and in compliance 
with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. 
Surgery 
All surgical procedures were conducted using aseptic techniques under 1-3% 
isoflurane/oxygen vapor. Osmotic minipumps (model 1004; Alzet, Cupertino, CA) were 
inserted subcutaneously at either PND 28 or 56 during adolescence or early adulthood, 
respectively. Minipumps were placed parallel to the thoracic vertebrae with the flow 
moderator directed away from the wound. Minipumps chronically delivered either 
oxycodone (oxycodone HCl, Spectrum Chemical, New Brunswick, NJ) dissolved in 0.9 % 
saline at a dosage of 3 mg/kg/day for 28 days, or saline only for saline control mice. Mice 
were surgerized at different developmental timepoints to measure the effects of 






days of oxycodone or saline exposure, minipumps were surgically removed from all 
groups. 
Tissue collection  
To obtain sufficient numbers of mice in all treatment groups, tissues  were collected from 
4 different cohorts of mice. Every cohort included mice in each of the following treatment 
groups; adolescent saline exposure, adolescent oxycodone exposure, adult saline 
exposure and adult oxycodone exposure.  Mice were weaned at PND21 at which time 
individual littermates (average # of litters per cohort: n = 5-6) were randomly assigned to 
each of the 9 groups; and every group contained mice from each cohort. Tissue was 
collected at PND28 in naïve mice or after 1- or 28-days following oxycodone/saline 
exposure. Mice were euthanized by cervical dislocation and brains were rapidly removed 
and placed in ice-cold phosphate buffered saline with protease inhibitor cocktail (Roche 
cOmplete Protease inhibitor). One-millimeter-thick sections of the ventral tegmental area 
were prepared using a cold tissue matrix and regions were bilaterally micro-dissected with 
a 1.2-mm diameter micro-punch (Harris). Tissue was immediately frozen in liquid nitrogen 
and stored at -80oC for downstream analysis. During tissue processing, all samples were 
coded and randomized to reduce experimenter bias and batch effects. 
Single Sample RNA extraction and Chromatin Immunoprecipitation (S3EQ) 
S3EQ was conducted on VTA 1.2 mm bilateral punches dissected as described above (1 
mouse/sample), 24 hours after minipump removal or withdrawal. Tissue was 
homogenized in cell lysis buffer (10mM Tris Hcl pH 8.1, 10mM NaCl, 3mM MgCl2, 0.5% 
Np-40). Low speed centrifugation (1000xg) separated the cytosol (supernatant) from the 
nuclei (pellet). RNA was isolated from the supernatant using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer instructions. RNA concentration and integrity were 






DE) and the RNA NanoChip on the Bioanalyzer (Agilent), respectively. All RNA samples 
were of good quality (RIN above 8) and purity (1.9 +/- 0.1). cDNA was synthesized from 
RNA (100ng) using the iScript cDNA Synthesis Kit (Life Technologies). Quantitative real-
time PCR (qRT-PCR) was conducted on the QuantStudio 7 Flex Real-Time PCR System 
(ThermoFisher). Ct values of the experimental group to control using the ΔΔCt method 
(Livak & Schmittgen, 2001). Primer sequences can be found in Supplementary Table 1.  
Nuclei were mildly fixed in 1% formaldehyde for 6 minutes and the reaction was terminated 
with glycine and pelleted by centrifugation (5500xg). Fixed nuclei were resuspended in 
nuclear isolation buffer (50mM Tris pH 8.1, 5mM EDTA, 1% SDS) and chromatin was 
sheared using a diogenode bioruptor XL at high sonication intensity. For histone 
modification enrichment, chromatin was sheered for 30 min (30 s on/30 s off) and fragment 
size was verified at 150–300 bps with an Agilent 2100 bioanalyzer. Sheared chromatin 
was incubated overnight with H3K27me3 (EMD Millipore 07-449) previously bound to 
magnetic beads (Dynabeads M-280, Life Technologies): The Dynabeads were washed 
twice each with 1 ml of Low Salt Wash Buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 2 mM 
EDTA, 1% TritonX-100, 0.1% SDS), High Salt Wash Buffer (20 mM Tris, pH 8.0, 500 mM 
NaCl, 2 mM EDTA, 1% TritonX-100, 0.1% SDS), and TE Buffer (10 mM Tris, pH 8.0, 1 mM 
EDTA). After reverse cross-linking and DNA purification (Qiagen Spin Column), primers 
were designed to amplify regions ~150-200 within gene promoter regions. 
Statistics  
The appropriate statistical test was determined based on the number of comparisons 
being conducted. We utilized two controls to distinguish alterations in normal development 
from those that occur as a result of withdrawal: (experiment 1 & 2) all oxycodone groups 
were compared to the naive adolescent brain (PND28) to define developmentally 






compared to saline exposed, age-matched controls to define effects of withdrawal and 
age of exposure. For experiment 1 (Appx. 2), multiple two-tailed student ttest were used 
to compared saline exposed mice at developmental timepoints relative to naïve mice at 
PND28; we then adjusted the p value using the Two-stage Benjamini, Krieger, & Yekutieli 
FDR procedure to account for the multiple comparisons being made. For experiment 2 
(Appx. 3, 4 and 5), multiple two-tailed student ttest were used to compare naïve mice 
relative to oxycodone exposed mice at 1- and 28-days of withdrawal; we then adjusted the 
p value using the Two-stage Benjamini, Krieger, & Yekutieli FDR procedure to account for 
the multiple comparisons being made. The Two-stage Benjamini, Krieger, & Yekutieli FDR 
procedure has been shown to have greater power to detect true positives, while still 
controlling the proportion of type I errors at a specified level (5%) (Benjamini & Hochberg, 
1995). All seven comparisons to naive control mice (PND28) were used to adjust the p 
value and account for multiple testing in experiments 1 and 2 (Supplementary Appx. 2). 
For experiment 3 (Appx. 6, 7 and 8), two-way ANOVAs compared saline exposed mice 
relative to age-matched oxycodone exposed mice at 1- day or 28-days of withdrawal; 
when appropriate, a Holm-Sidak’s post-hoc test followed to determine significant 
differences across multiple comparisons. Main and interaction effects were considered 
significant at P < 0.05. P-values greater than 0.05 and below 0.1 were considered trends. 
Data are expressed as mean [+ or −] s.e.m. The Grubbs’ test was used when appropriate 
to identify outliers. F-tests of variance were conducted on all data sets to ensure that the 
data followed a normal distribution. 
Results 
Developmental expression of genes involved in dopamine transmission 
To examine molecular changes associated with the dopamine transmission across 






Nr4a2 encoding the nuclear receptor NURR1 (Nuclear receptor related-1 protein) known 
to be important in dopamine neuron development and neuroprotection in the context of 
opiate exposure (Volakakis et al., 2010), (2) Cartpt, encoding the “cocaine and 
amphetamine regulated transcript’ which is a neuropeptide activated acutely by morphine 
in sensitized and naive animals (Spijker et al., 2004), (3) Th, encoding tyrosine 
hydroxylase, the rate limiting enzyme in catecholamine biosynthesis, which is activated by 
chronic morphine in the VTA and regulates dopamine release during morphine CPP (Koo 
et al., 2015; Liang et al., 2012) and (4) Dat, (Slc6a3) , which encodes the dopamine 
transporter that negatively modulates morphine reward (Spielewoy et al., 2000). Gene 
expression was determined from the onset of adolescence (PND 28) to adulthood (PND 
112). Nr4a2 and Cartpt were both significantly upregulated at PND 84 (Appx. 2B, C), while 
Dat was downregulated at PND 112 (Appx. 2D). There were no significant changes in Th 
expression across the developmental time points examined (Appx. 2E).  
To interrogate the mechanism by which gene expression is altered across 
postnatal development, we measured the enrichment of the repressive histone 
modification, H3K27me3, at promoter regions. In agreement with the upregulation of 
Nr4a2 and Cartpt (Appx. 2B, C), H3K27me3 was significantly depleted at these genes at 
PND 84 (Appx. 2F, G). In addition, the H3K27me3 mark was reduced at the Cartpt 
promoter on PND 56 (Appx. 2G). The repression of Dat was associated with enrichment 
of H3K27me3 at its promoter on PND 112 (Appx. 2D, H). There were no significant 
changes in H3K27me3 modified histones at the Th promoter (Appx. 2I) in line with the 
absence of a corresponding changes in gene expression (Appx. 2E). Taken together, 
these findings indicate that key genes in dopamine transmission are associated with 






Adolescent oxycodone exposure alters expression of key genes in dopamine 
transmission 
 
 To determine the effects of adolescent oxycodone exposure on gene expression 
and epigenetic modifications at key genes in the dopamine system, we exposed 
adolescent mice (PND28-56) to oxycodone and measured gene expression and 
H3K27me3 enrichment in the VTA after 1- and 28-days of withdrawal (Appx. 3A). All 
comparisons were made relative to the onset of adolescence (PND 28) to detect 
deviations from normal development 22. Adolescent oxycodone exposure dramatically 
activated Nr4a2 expression at 1- and 28-days of withdrawal (Appx. 3B). There were no 
changes in Cartpt expression at either 1- or 28-days relative to the naïve adolescent brain 
(PND28; Appx. 3C). Dat was transiently activated at 1-day but not at 28-days of withdrawal 
(Appx. 3D). There were no significant changes in Th expression (Appx. 3E). 
 We next examined the abundance of the H3K27me3 mark at the relevant 
promoters during withdrawal. We found that although Nr4a2 expression was activated at 
both 1- and 28-days of withdrawal (Appx. 3B), the repressive H3K27me3 was depleted 
only at 28-days of withdrawal, suggesting that another mechanism must be responsible 
for its acute regulation at 1-day of withdrawal (Appx. 3F). Consistent with the lack of 
changes in Cartpt mRNA levels following adolescent oxycodone exposure (Appx. 3C), we 
found no changes in H3K27me3 enrichment (Appx. 3G). The H3K27me3 mark was 
increased at the Dat promoter at 28-days of withdrawal (Appx. 3H), when gene expression 
returned to baseline (Appx. 3D). In contrast, loss of the H3K27me3 modification at the Th 
promotor (Appx. 3I) corresponded with increased gene expression at 1-day of withdrawal 
(Appx. 3E). These data suggest that adolescent oxycodone exposure disrupts normal 







Adult oxycodone exposure alters expression of key genes in dopamine 
transmission differently than adolescent treatment 
 
 To determine if oxycodone-induced changes in gene expression and histone 
modifications were contingent on exposure during adolescence, we treated adult mice 
(PND56-84) with oxycodone and measured mRNA and H3K27me3 following withdrawal 
in the VTA (Appx. 4A). All comparisons were made relative to the onset of adolescence 
(PND 28) to detect deviations from normal development. Adult oxycodone exposure 
activated Nr4a2 expression at 1- and 28-days of withdrawal (Appx. 4A, B). In contrast to 
the findings in adolescent exposure, we found Cartpt expression was activated specifically 
at 1- and 28-days of withdrawal (Appx. 4C). Dat and Th expression did not differ at either 
withdrawal time point relative to the naïve adolescent brain (PND28; Appx. 4D, E).  
Next, we measured H3K27me3 enrichment at promotor regions following adult 
oxycodone exposure. H3K27me3 was depleted at Nr4a2 at 28-days and Cartpt at 1- and 
28-days of withdrawal (Appx. 4F, G), which corresponded with increased gene expression 
at these time points (Appx. 3B, C). We found no significant change in H3K27me3 
enrichment at the Dat promoter when compared to the naïve brain (PND28, Appx. 4H). At 
Th we found a reduction of H3K27me3 at 28-days of withdrawal (Appx. 4I). In conclusion, 
adult oxycodone exposure prolonged the increased gene expression of Nr4a2 and Cartpt, 
relative to normal development (Appx. 5B, C), which is associated with the abundance of 
the repressive H3K27me3 mark at gene promoters. 
Adolescent oxycodone exposure causes gene expression changes at 1-day of 
withdrawal.  
To determine the age-dependent effects of drug exposure in the VTA, we 
compared adolescent and adult oxycodone exposed mice relative to age-matched, saline 






following 28-days of oxycodone exposure followed by 1-day of withdrawal (Appx. 6B, D, 
E). Specifically, only adolescent oxycodone exposure activated Nr4a2, Dat and Th 
expression when compared to saline age-matched controls (PND56). There was no 
change in the expression of these genes following adult oxycodone exposure relative to 
saline age-matched controls (PND84). Cartpt mRNA levels were unchanged following 
exposure paradigm (Appx. 6C). Unexpectedly, we did not find any changes in the 
abundance of H3K27me3 at the promotor regions of Nr4a2, Cartpt, Dat, or Th by any of 
the treatments (Appx. 6F-I), suggesting that alternative mechanisms of regulation are 
responsible for the observed gene expression patterns in adult mice exposed to 
oxycodone during adolescence.  
Adult oxycodone exposure causes gene expression changes after 28-days of 
withdrawal. 
 
 To interrogate long-term effects of adolescent and adult oxycodone exposure we 
examined the abundance of H3K27me3 and gene expression in the VTA at 28-days of 
withdrawal following four weeks of opioid treatment (Appx. 7A). We found an age x drug 
effect following oxycodone exposure at 28-days of withdrawal (Appx. 7B-E). Specifically, 
adult oxycodone exposure activated Nr4a2, Cartpt, Dat, and Th expression when 
compared to saline age-matched controls (Appx. 7B-E). Remarkably, at the same time 
point no changes in steady-state mRNA levels were observed if oxycodone was given to 
adolescent mice (Appx. 7B-E). We then measured corresponding changes in H3K27me3 
abundance and found adult exposure reduced and adolescent exposure increased the 
repressive mark H3K27me3 at selected genes after 28-days of withdrawal (Appx. 7F-I). 
Specifically, adult oxycodone exposure depleted H3K27me3 modified histones at Nr4a2, 
Cartpt, Dat, and Th promoters which corresponded to changes in gene expression (see 






Cartpt and Dat promoters when compared saline age-matched controls (PND84, Appx. 
7G, H). These data suggest adult oxycodone exposure induces long-term changes in 
H3K27me3, whereas adolescent oxycodone exposure abrogates dopamine related gene 
expression via the maintenance of H3K27me3.  
Discussion  
 Epidemiological data shows prescription opioid abuse in adolescence causes 
heroin use in adulthood (Cerdá et al., 2015). To investigate the gene regulatory 
mechanisms underlying this transition, we exposed either adolescent or adult mice to 
oxycodone and examined epigenetic modifications at genes associated with dopamine 
transmission following 1- or 28- days of withdrawal. Using this approach, we identified 
adolescence-specific gene regulation that may render this developmental phase 
particularly sensitive to oxycodone exposure. The subtle distinction between naïve mice 
at PND28 controls and age-matched controls in our study allows one to concluded that 
oxycodone does not alter normal development of dopamine related gene expression, per 
se, but rather inhibits abstinence related expression via oxycodone induced epigenetic 
modifications following adolescent exposure. Specifically, increased gene expression of 
Nr4a2 and its downstream target gene, Cartpt, was associated with reduced H3K27me3 
at PND84. At PND112 the expression of Nr4a2 and Cartpt returned to levels observed at 
PND28, and Dat expression declined below baseline (Volz et al., 2008). We examined 
gene expression during oxycodone exposure relative to PND28 to examine abnormalities 
in normal development. Both adolescent and adult oxycodone exposure activated Nr4a2 
expression during 1- or 28- days of withdrawal, relative to PND28. The expression pattern 
of Cartpt relative to PND28 was specific to adult exposure.  
By comparing oxycodone exposed mice to age-matched, saline exposed mice, we 






We discovered epigenetic changes specific to adult oxycodone exposure, such as 
depleted H3K27me3 and increased expression of Cartpt. Adolescent oxycodone 
exposure led to increased Th and Dat expression at 1-day of withdrawal relative to age-
matched controls, while adult oxycodone exposure resulted in activation of these genes 
at 28-days of withdrawal relative to age-matched controls. We defined age and length of 
withdrawal-dependent gene regulation, in which dopamine related gene expression is 
transient following adolescent oxycodone exposure and delayed following adult 
oxycodone exposure. We further identified developmental differences in a putative 
underlying epigenetic mechanism. Adult, but not adolescent, oxycodone exposure led to 
loss of H3K27me3 at dopamine related genes at 28-days of withdrawal. We hypothesize 
that the failure of adolescent oxycodone exposure to induce prolonged dopamine related 
gene expression may underlie developmental differences in the risk of transition to heroin 
us following oxycodone use (Sanchez et al., 2016). Specifically, Nr4a2 and its downstream 
target, Cartpt, function to repress drug sensitivity via homeostatic control of dopaminergic 
signaling (Carpenter et al., 2020; Koo et al., 2015; Rakovska et al., 2017), and we find that 
Cartpt activation is lost specifically during adolescent oxycodone exposure and withdrawal 
(Appx. 8).  
The relative immaturity of the dopamine system during adolescence leads to 
enhanced behavioral responses to drug exposure (Cass et al., 2013; Feltmann et al., 
2018; Natividad et al., 2012; Palmisano & Pandey, 2017). Innervation of dopamine 
neurons and striatal dopamine levels gradually increased across adolescence, and then 
decline throughout adulthood (Rothmond et al., 2012; Willing et al., 2017). Our current 
study provides further evidence that adolescence is a specific developmental period with 
respect to epigenetic modifications at genes associated with dopamine transmission 






exposure by examining gene expression following adult and adolescent oxycodone 
exposure across development, relative to both naïve and age-matched controls. Our work 
is consistent with reports of declining levels of Nr4a2 (Kwapis et al., 2019) and Dat (Volz 
et al., 2008) during normal aging in the VTA. To our knowledge, we are the first to report 
age-dependent changes in Cartpt expression. Importantly, we found that at 1-day of 
withdrawal following adolescent exposure, expression of Nr4a2 and Dat were greater than 
that in adult at PND56, compared to PND28, although we cannot completely exclude 
effects of intracranial surgery on dopamine related gene expression. During adolescence, 
mice have larger pools of releasable dopamine and self-administer less oxycodone than 
adults, which is associated with an enhanced response to oxycodone (Stamford, 1989; 
Yong Zhang et al., 2009). This conclusion is further supported by enhanced opioid 
(oxycodone and morphine) CPP following adolescent self-administration and 
subcutaneous oxycodone (Sanchez et al., 2016; Yong Zhang et al., 2016). Interestingly, 
adolescent increased in oxycodone CPP relative to adult, has only been observed at lower 
doses, suggesting a leftward shift in the dose response curve following adolescence 
exposure (Yong Zhang et al., 2016). We suppose that adolescent oxycodone exposure 
results in persistence of increased dopamine release and opioid sensitivity that is 
maintained beyond adolescence (Stamford, 1989). In regard to adult oxycodone 
exposure, the increased expression of Cartpt and Dat may reflect a greater capacity for 
dopamine uptake (Rakovska et al., 2017; Sanchez et al., 2016; Shieh, 2003). Taken 
together, we identified a putative epigenetic mechanism by which withdrawal following 
adolescent oxycodone exposure leads to persistent adolescent dopamine related gene 
expression into adulthood.  
Similar to the enhanced drug-induced behavioral responses observed during 






adolescents than adults (Sanchez et al., 2016). For example, adolescent ethanol self-
administration attenuates dopamine D2 receptor (D2) expression and histone H3 
acetylation at 1-day of withdrawal in the NAc (Pascual et al., 2009). These changes do 
not occur after adult exposure until 28-days of withdrawal (Feltmann et al., 2018; 
Palmisano & Pandey, 2017). Furthermore, inhibition of histone deacetylation attenuates 
adolescent specific increases in ethanol self-administration (Jeanblanc et al., 2017). 
These data suggest that alcohol-induced gene expression is developmentally regulated. 
Our study was the first to explore gene expression in the VTA across development and 
withdrawal from oxycodone. We found that H3K27me3 depletion is only associated with 
increased gene expression at 28-days of withdrawal or adulthood (PND112). This 
suggests that H3K27me3 plays a key role in delayed gene activation following drug 
exposure. We focused specifically on how these changes were associated with long term 
neuroadaptations in response to drug reward. Increased expression of Cartpt following 
adult oxycodone exposure may be related to its role in homeostatic control of dopamine 
signaling in adulthood. We found a reduction in H3K27me3, which was associated with 
increased Cartpt expression at PND84, but both H3K27me3 abundance and Cartpt 
expression return to baseline at PND112 (Appx. 2C). Cartpt was activated in the 
oxycodone exposed adult brain at 1- and 28-days of withdrawal (PND 84 and 112), when 
compared to both the naïve brain (PND28; Appx. 4C) and age-matched controls (PND112; 
Appx. 7C). Cartpt was not activated at 1-day or 28-days of withdrawal following adolescent 
exposure (Appx. 7C). Rather, Cartpt, expression was suppressed, and H3K27me3 
enrichment was maintained when compared to both the naïve brain (PND28; Appx. 3C) 
and age-matched controls (PND56; Appx. 7C, G). This finding is significant given that 
Cartpt functions in vivo to reduced levels of dopamine in response to morphine  . 






reward pathway, and leads to long-term changes in behavior and gene expression . In the 
context of development and drug exposure, we discovered specific stages of gene 
expression which are defined by long-lasting changes in the abundance of the repressive 
chromatin modification, H3K27me3, at key dopamine related genes. This work lays the 
groundwork to examine the functional relevance of the H3K27me3 using novel strategies 
of locus specific epigenetic editing with virally expressed CRISPR/Cas9 fusion enzymes. 
Future work will interrogate additional epigenetic mechanisms of gene activation that 










Appendix 1. Study Design. Nine tissue sets of VTA were collected at the indicated times 
and processed within-subject for qChIP and qPCR. To examine adolescent gene 
expression, we compared dopamine related gene expression at PND 56, 84, and 112 (see 
Appx. 2). To distinguish between epigenetic effects of oxycodone treatment and normal 
development of gene expression, we normalized gene expression to the naïve adolescent 
mice following adolescent and adult oxycodone exposure at 1 and 28 days of withdrawal 
(WD) (see Appx. 3 and 4). To determine epigenetic effects of oxycodone exposure at 1 
and 28 days of WD, we normalized oxycodone exposed mice to age-matched saline 









Appendix 2. Epigenetic modifications at dopamine related genes across 
developmental time points in the VTA. A.) Timeline of developmental time points. B.) 
Nr4a2 is activated at PND 84, (Students two-tailed ttest; PND 84, p=0.029, adjusted p = 
0.012). C.) Cartpt is activated at PND 84 (Students two-tailed ttest; PND 84, p=0.013, 
adjusted p = 0.019). D.) Dat is repressed at PND 112 (Students two-tailed ttest; PND 112, 
p=0.015, adjusted p = 0.047). E.) No significant changes in Th. F.) H3K27me3 is depleted 
at the Nr4a2 promotor at PND 84 (Students two-tailed ttest; PND 84, p=0.012, adjusted p 
= 0.017). G.) H3K27me3 is depleted at the Cartpt promotor at PND 56 and 84 (Students 
two-tailed ttest; PND 56, p=0.001, adjusted p = 0.005; PND 84, p=0.002, adjusted p = 
0.005).  H.) H3K27me3 is enriched at the Dat promotor at PND 112 (Students two-tailed 
ttest; PND 112, p=0.006, adjusted p = 0.040).  I.) H3K27me3 is depleted at the Th 
promotor at PND 56 (Students two-tailed ttest; p=0.029, adjusted p = 0.012).  All data 
normalized to GAPDH relative to PND28. n = 5 - 12 mice per group. Error bars represent 









Appendix 3. Adolescent oxycodone exposure alters dopamine related gene 
expression in the VTA A.) Timeline of adolescent oxycodone exposure and subsequent 
periods of oxycodone withdrawal (WD). B.) Adolescent oxycodone activated Nr4a2 at 1- 
and 28-days (Students two-tailed ttest; 1-day, p=0.01, adjusted p = 0.007, 28-days, 
p=0.001, adjusted p = 0.001). C.) No significant changes in Cartpt. D.) Adolescent 
oxycodone activated Dat at 1-day (Students two-tailed ttest; 28-days, p=0.004, adjusted 
p = 0.025). E.) No significant changes in Th expression.  F.) H3K27me3 is depleted at the 
Nr4a2 promoter at 28-days (Students two-tailed ttest; 28-days, p=0.003, adjusted p = 
0.007). G.) No significant changes in H3K27me3 enrichment at the Cartpt promoter 
(Students two-tailed ttest; p=0.029, adjusted p = 0.012). H.) H3K27me3 is enriched at the 
Dat promoter at 28-days (Students two-tailed ttest; 28-days, p=0.015, adjusted p = 0.049). 
I.) H3K27me3 is depleted from the Th promoter at 1-day (Students two-tailed ttest; 1-day, 
p=0.012, adjusted p = 0.03). All data normalized to GAPDH relative to drug naïve 
adolescent brain (PND28). n = 5 - 7 mice per group Error bars represent S.E.M. *p<.05 










Appendix 4. Adult oxycodone exposure alters dopamine related gene expression in 
the VTA A.) Timeline of adult oxycodone exposure and subsequent periods of oxycodone 
withdrawal (WD). B.) Adult oxycodone activated Nr4a2 at 1- and 28-days (Students two-
tailed ttest; 1-day, p=0.014, adjusted p = 0.007, 28-days, p=0.001, adjusted p = 0.001). 
C.) Adult oxycodone activated Cartpt at 28-days (Students two-tailed ttest; 1-day, 
p=0.014, adjusted p = 0.019, 28-days, p=0.003, adjusted p = 0.001). D.) No significant 
changes in Dat expression. E.) No significant changes in Th expression. F.) H3K27me3 
is depleted at the Nr4a2 promoter at 28-days (Students two-tailed ttest; 28-days, p=0.001, 
adjusted p = 0.005). G.) H3K27me3 is depleted at the Cartpt promoter at 1-day and 28-
days (Students two-tailed ttest; 1-day p=0.036, adjusted p = 0.038, 28-days, p=0.003, 
adjusted p = 0.005). H.) No significant changes in H3K27me3 enrichment at the Dat 
promoter (Students two-tailed ttest; p=0.029, adjusted p = 0.012). I.) H3K27me3 is 
depleted at the Th promoter at 28-days (Students two-tailed ttest; 28-days, p=0.008, 
adjusted p = 0.03). All data normalized to GAPDH relative to naïve adolescent brain 
(PND28). n = 5 – 7 mice per group. Error bars represent S.E.M. *p<.05 relative to naïve 










Appendix 5. Compendium of results following adolescent and oxycodone exposure 
relative to the naïve adolescent brain (PND28) Schematic depicts Appendix 1-3 results 
for development (Top bar) and exposure paradigm (Adolescent or Adult; Bottom two bars). 
Heatmaps represent the percentage difference relative to PND28 naïve mice. A.) Nr4a2 
is activated at PND84 during development. Adolescent and adult oxycodone exposure 
activated Nr4a2 at both 1-day and 28-days of abstinence. B.) Cartpt is activated at PND84 
during development. Adolescent oxycodone exposure blunts developmental increased in 
Cartpt expression at PND84, while adult exposure activated Cartpt expression at PND112. 
C.) Dat is repressed at PND112 during development. Adolescent oxycodone exposure 
activated Dat expression at PND56. D.) Adolescent oxycodone exposure activated Th 
expression at PND56. All data is calculated by subtracting treatment fold change values 










Appendix 6. Adolescent oxycodone exposure regulates gene expression at 1-day 
of withdrawal in the VTA A.) Timeline of oxycodone withdrawal (WD) and tissue 
collection. B.) Adolescent oxycodone exposure activated Nr4a2 (Two-way ANOVA, n=6 
per group, Interaction: F (1,20) = 22.98, p=0.0001; Drug: F1,20 = 18.21, p=0.0004; Age of 
Exposure F (1,20) = 18.21, p=0.0004; followed by Sidak’s multiple comparisons test, 
Adolescent Saline vs. Oxycodone, p<0.0001; Adult Saline vs. Oxycodone, p=0.999). C.) 
No significant difference in Cartpt expression following adolescent or adult oxycodone 
exposure (Two-way ANOVA, n=6 per group Interaction: F1,20 = 0.371, p=0.549; Drug: F1,20 
= 0.371, p=0.549; Age of Exposure F1,20 = 0.011, p=0.917). D.) Dat is activated following 
adolescent oxycodone exposure (Two-way ANOVA, Interaction: F1,19 = 8.010, p=0.017; 
Drug: F1,19 = 4.175, p=0.052; Age of Exposure : F1,19 = 8.010, p=0.0176; followed by 
Sidak’s multiple comparisons test, Adolescent Saline vs. Oxycodone, p=0.004; Adult 
Saline vs. Oxycodone, p=0.834). E.) Th is activated following adolescent oxycodone 
exposure when compared to saline. (Two-way ANOVA, Interaction: F1,19 = 7.499, 
p=0.0131; Drug: : F1,19 = 7.097, p=0.015; Age of Exposure : F1,19 = 7.498, p=0.013; followed 
by Sidak’s multiple comparisons test, Adolescent Saline vs. Oxycodone, p=0.002; Adult 
Saline vs. Oxycodone, p=0.834). F.) No significant difference in H3K27me3 enrichment at 
the Nr4a2 promoter following adolescent or adult oxycodone exposure (Two-way ANOVA, 






0.616, p=0.447). G.) No significant difference in H3K27me3 enrichment at the Cartpt 
promoter following adolescent or adult oxycodone exposure (Two-way ANOVA, 
Interaction: F1,20 = 0.111, p=0.741; Drug: F1,20 = 0.111, p=0.741; Age of Exposure F1,20 = 
0.410, p=0.523). H.) No significant difference in H3K27me3 enrichment at the Dat 
promoter following adolescent or adult oxycodone exposure (Two-way ANOVA, 
Interaction: F1,17 = 0.067, p=0.7978; Drug: F1,17 = 0.028, p=0.884; Age of Exposure F1,17 = 
0.410, p=0.7971). I.) No significant difference in H3K27me3 enrichment at the Th promoter 
following adolescent or adult oxycodone exposure (Two-way ANOVA, Interaction: F1,19 = 
1.340, p=0.7184; Drug: F1,19 = 0.444, p=0.5130; Age of Exposure: F1,19 = 0.1340, 
p=0.7184). All data normalized to GAPDH relative to saline age-matched controls. n = 5-










Appendix 7. Adult oxycodone exposure regulates gene expression at 28-days of 
withdrawal in the VTA A.) Timeline of oxycodone withdrawal (WD) and tissue collection. 
B.) Nr4a2 is activated following adult oxycodone exposure when compared to saline. 
(Two-way ANOVA, Interaction: F1,17 = 5.468, p=0.0318; Drug: F1,17 = 12.94, p=0.002; Age 
of Exposure F1,17 = 5.470, p=0.0318; followed by Sidak’s multiple comparisons test, 
Adolescent Saline vs. Oxycodone, p=0.7949; Adult Saline vs. Oxycodone, p=0.004). C.) 
Cartpt is activated following adult oxycodone exposure (Two-way ANOVA, Interaction: 
F1,18 = 5.221, p=0.035; Drug: F1,18 = 7.085, p=0.016; Age of Exposure F1,18 = 5.221, 
p=0.035; followed by Sidak’s multiple comparisons test, Adolescent Saline vs. 
Oxycodone, p=0.994; Adult Saline vs. Oxycodone, p=0.009). D.) Dat is activated following 
adult oxycodone exposure (Two-way ANOVA, Interaction: F1,18 = 8.290, p=0.010; Drug: 
F1,18 = 6.310, p=0.021; Age of Exposure F1,18 = 8.332, p=0.009; followed by Sidak’s multiple 
comparisons test, Adolescent Saline vs. Oxycodone, p=0.994; Adult Saline vs. 
Oxycodone, p=0.007). E.) Adult oxycodone exposure activated Th when compared to 
saline (Two-way ANOVA, Interaction: F1,17 = 5.938, p=0.0261; Drug: F1,17 = 5.186, 
p=0.036; Age of Exposure F1,17 = 5.258, p=0.049; followed by Sidak’s multiple 
comparisons test, Adolescent Saline vs. Oxycodone, p=0.9918; Adult Saline vs. 






promoter (Two-way ANOVA, Interaction: F1,18 = 5.286, p=0.0337; Drug: F1,18 = 2.292, 
p=0.147; Age of Exposure F1,18 = 5.286, p=0.0337; followed by Sidak’s multiple 
comparisons test, Adolescent Saline vs. Oxycodone, p=0.809; Adult Saline vs. 
Oxycodone, p=0.039). G.) Adolescent oxycodone exposure enriched H3K27me3 and 
adult oxycodone exposure depleted H3K27me3 (Two-way ANOVA, Interaction: F1,18 = 
13.57, p=0.001; Drug: F1,18 = 0.3661, p=0.5527; Age of Exposure F1,18 = 13.57, p=0.001; 
followed by Sidak’s multiple comparisons test, Adolescent Saline vs. Oxycodone, 
p=0.0143; Adult Saline vs. Oxycodone, p=0.0430). H.) Adolescent oxycodone exposure 
enriched H3K27me3 when compared to saline (Two-way ANOVA, Interaction: F1,17 = 
13.91, p=0.001; Drug: F1,17 = 1.839, p=0.193; Age of Exposure F1,17 = 13.91, p=0.001; 
followed by Sidak’s multiple comparisons test, Adolescent Saline vs. Oxycodone, 
p=0.003; Adult Saline vs. Oxycodone, p=0.12). I.) Adult oxycodone exposure depletes 
H3K27me3 at the Th promoter (Two-way ANOVA, Interaction: F1,17 = 4.901, p=0.0261; 
Drug: F1,17 = 3.074, p=0.097; Age of Exposure F1,17 = 4.906, p=0.040; followed by Sidak’s 
multiple comparisons test, Adolescent Saline vs. Oxycodone, p=0.932; Adult Saline vs. 
Oxycodone, p=0.003). All data normalized to GAPDH relative to saline age-matched 








Appendix 8. Cartpt expression during development and following oxycodone 
exposure A.) During development activation of Cartpt is associated with de-enrichment 
of H3K27me3 at PND84. H3K27me3 is de-enriched at PND56, relative to PND28. B.) 
Adult oxycodone exposure activated Cartpt and H3K27me3 is de-enriched at 28-days of 
abstinence, relative to PND28 and age-matched controls. There is no difference in Cartpt 
expression following adolescent exposure, however, H3K27me3 is enriched at 28-days of 










Supplementary Appendix 1. Surgery does not affect epigenetic modifications at 
dopamine related genes across developmental time points in the VTA. Timeline of 
developmental time points following surgery. B.) Nr4a2 is activated at PND 84 despite the 
age of surgery (One-way ANOVA F = 4.500, p=0.026, followed by Dunnett’s multiple 
comparisons test, PND 28 vs. Adolescent 28D saline (A 28D Sal), p=0.044; PND 28 vs. 
Adult 1D saline (D 1D Sal), p=0.045). C.) Cartpt is activated at PND 84 despite the age of 
surgery (One-way ANOVA F = 7.040, p=0.007, followed by Dunnett’s multiple 
comparisons test, PND 28 vs. A 28D Sal, p=0.006; PND 28 vs. D 1D Sal, p=0.038). D.) 
No significant changes in Dat.  E.) No significant changes in Th. F.) H3K27me3 is depleted 
at the Nr4a2 promotor at PND 84 (One-way ANOVA F = 7.040, p=0.007, followed by 
Dunnett’s multiple comparisons test, PND 28 vs. A 28D Sal, p=0.042; PND 28 vs. D 1D 
Sal, p=0.066). G.) H3K27me3 is depleted at the Cartpt promotor at PND 84 (One-way 
ANOVA F = 5.061, p=0.022, followed by Dunnett’s multiple comparisons test, PND 28 vs. 
A 28D Sal, p=0.049; PND 28 vs. D 1D Sal, p=0.023). H.) No significant changes in Dat. 
I.) No significant changes in Th.  All data normalized to GAPDH relative to PND28. n = 5 








Supplementary Appendix 2. Two-stage Benjamini, Krieger, & Yekutieli FDR 
procedure to adjust for multiple comparison testing. Multiple comparison adjustments 
to account for the seven independent comparisons made relative to the naive PND 28 
brain. P values were generated using two-tailed ttest (black dots). q values (red dots, 
adjusted p value) were generated using the p values and the two-stage Benjamini, Krieger, 
& Yekutieli FDR procedure. Each of the seven comparisons for gene expression (A-D) 
and H3K27me3 enrichment (E-H) are represented for Nr4a2, Cartpt, Dat, and Th. A q 
value was considered significance level of 5% (black dashed line). Adolescent 1D (A-1D), 
Adolescent 28D (A-28D), Adult 1D (D-1D), Adult 28D (D-28D), Postnatal Day 56 (PND 
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